


**CUMULATIVE
SUPPLEMENT 4**
April 2025



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

45th EDITION

Department of Health and Human Services

Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

45th EDITION

**Cumulative Supplement 4
April 2025**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	ix
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi

DRUG PRODUCT LISTS

Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Products Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

45th EDITION

**CUMULATIVE SUPPLEMENT 4
April 2025**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug

Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
MYLAN INSTITUTIONAL LLC (MYLAN INSTITUTIONAL)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN TECHNOLOGIES INC (MYLAN TECHNOLOGIES)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	App'l No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	–
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	–	RS

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors;

as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2024</u>	<u>MAR 2025</u>	<u>JUN 2025</u>	<u>SEP 2025</u>	<u>DEC 2025</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	23856 2772 (11.8%)	23679 2740 (11.6%)			
MULTISOURCE	20814 (88.2%)	20939 (88.4%)			
THERAPEUTICALLY EQUIVALENT	20741 (87.9%)	20826 (88%)			
NOT THERAPEUTICALLY EQUIVALENT	73 (0.3%)	113 (0.5%)			
EXCEPTIONS ⁴	47 (0.2%)	47 (0.2%)			
NEW MOLECULAR ENTITIES APPROVED	43	13			
NUMBER OF APPLICANTS	1197	1209			

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

>A>	AB	HETERO LABS LTD V	EQ 600MG BASE;300MG	A205412	001	Apr 16, 2025	Apr NEWA
-----	----	-------------------	---------------------	---------	-----	--------------	----------

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

@	TEVA PHARMS USA	250MG
@		500MG

A208432	001	Oct 31, 2018	Mar DISC
A210726	001	Jan 26, 2023	Mar DISC

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

AB		GLENMARK PHARMS LTD	333MG
----	--	---------------------	-------

A202229	001	Jul 16, 2013	Mar CMFD
---------	-----	--------------	----------

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

AP1		ASPIRO	1GM/100ML (10MG/ML)
AP	+	B BRAUN MEDICAL INC	500MG/50ML (10MG/ML)
AP2	+		1GM/100ML (10MG/ML)
AP1		BAXTER HLTHCARE CORP	1GM/100ML (10MG/ML)
AP1		EUGIA PHARMA	1GM/100ML (10MG/ML)
AP		GLAND	500MG/50ML (10MG/ML)
AP2			1GM/100ML (10MG/ML)
AP1		HIKMA	1GM/100ML (10MG/ML)
AP1		INFORLIFE	1GM/100ML (10MG/ML)
AP1		MYLAN	1GM/100ML (10MG/ML)
AP1	!	SANDOZ	1GM/100ML (10MG/ML)
AP1		WOCKHARDT BIO AG	1GM/100ML (10MG/ML)

A216617	001	Jul 27, 2022	Mar CTEC
N204957	001	Feb 18, 2021	Mar CFTG
N204957	002	Feb 18, 2021	Mar CFTG
A214331	001	Sep 17, 2021	Mar CTEC
A210969	001	Oct 21, 2020	Mar CTEC
A219215	001	Apr 02, 2025	Mar NFTG
A219215	002	Apr 02, 2025	Mar NFTG
A202605	001	Jun 13, 2016	Mar CTEC
A215403	001	May 03, 2023	Mar CTEC
A213255	001	Aug 07, 2020	Mar CTEC
A204052	001	Mar 22, 2016	Mar CTEC
A205746	001	Apr 18, 2023	Mar CTEC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@	CHARTWELL	120MG/5ML;12MG/5ML
!	GENUS LIFESCIENCES	120MG/5ML;12MG/5ML
@	XTTRIUM LABS INC	120MG/5ML;12MG/5ML

A089450	001	Oct 27, 1992	Feb DISC
A087508	001		Feb CTEC
A087006	001		Feb CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	!	CHARTWELL	325MG/15ML;7.5MG/15ML
		WES PHARMA INC	325MG/15ML;7.5MG/15ML

A040482	001	Sep 25, 2003	Feb DISC
A211023	001	Mar 08, 2019	Feb CHRS

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

		@	CHARTWELL	300MG;5MG
		@		300MG;7.5MG
		@		300MG;10MG
		@		325MG;7.5MG
		@	RHODES PHARMS	300MG;5MG
		@		300MG;7.5MG
		@		300MG;10MG
AA	!		SPECGX LLC	300MG;5MG
AA	!			300MG;7.5MG
AA	!			300MG;10MG

A040658	001	Jan 19, 2006	Feb DISC
A040658	002	Mar 24, 2006	Feb DISC
A040658	003	Jun 23, 2004	Feb DISC
A040432	001	Jan 22, 2003	Feb DISC
A207808	001	Mar 30, 2018	Jan DISC
A207808	002	Mar 30, 2018	Jan DISC
A207808	003	Mar 30, 2018	Jan DISC
A206718	001	Mar 31, 2017	Feb CHRS
A206718	002	Mar 31, 2017	Feb CHRS
A206718	003	Mar 31, 2017	Feb CHRS

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

>D>	AA	NOSTRUM LABS INC	325MG/5ML;5MG/5ML
>A>	AA	SANKALP LIFECARE	325MG/5ML;5MG/5ML

A201448	001	Aug 26, 2021	Apr CAHN
A201448	001	Aug 26, 2021	Apr CAHN

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

@	CHARTWELL	325MG;5MG
@		325MG;7.5MG
@		325MG;10MG

A207834	001	Aug 15, 2019	Feb DISC
A207834	002	Aug 15, 2019	Feb DISC
A207834	003	Aug 15, 2019	Feb DISC

ACETAZOLAMIDETABLET; ORAL
DIAMOX

+ @ TEVA BRANDED PHARM	125MG	N008943	001		Feb CAHN
+ @	250MG	N008943	002		Feb CAHN

ACETYLCYSTEINESOLUTION; INHALATION, ORAL
ACETYLCYSTEINE

AN	CONBA USA	10%	A214177	001	Mar 14, 2025	Mar NEWA
AN		20%	A214177	002	Mar 14, 2025	Mar NEWA
AN	SOMERSET THERAPS LLC	10%	A219194	001	Feb 12, 2025	Jan NEWA
AN		20%	A219194	002	Feb 12, 2025	Jan NEWA

ACITRETINCAPSULE; ORAL
ACITRETIN

>A>	@ MYLAN	17.5MG	A203707	001	Sep 10, 2015	Apr CAHN
>A>	@	22.5MG	A203707	002	Sep 10, 2015	Apr CAHN
>D>	@ NORVIUM BIOSCIENCE	17.5MG	A203707	001	Sep 10, 2015	Apr CAHN
>D>	@	22.5MG	A203707	002	Sep 10, 2015	Apr CAHN

ACYCLOVIRCREAM; TOPICAL
ACYCLOVIR

>A>	AB	CIPLA	5%	A212981	001	May 02, 2025	Apr NEWA
	BX	ZYDUS LIFESCIENCES	5%	A206770	001	Feb 28, 2023	Mar CTEC

OINTMENT; TOPICAL
ACYCLOVIR

	@ APOTEX	5%	A210774	001	Sep 06, 2019	Jan DISC
	@ CHARTWELL MOLECULAR	5%	A206437	001	Jul 31, 2017	Feb CAHN
BX	CIPLA	5%	A211794	001	Jan 18, 2019	Mar CTEC

ACYCLOVIR SODIUMINJECTABLE; INJECTION
ACYCLOVIR SODIUM

@ FRESSENIUS KABI USA	EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	Feb DISC
-----------------------	-----------------	---------	-----	--------------	----------

ALBUTEROL SULFATEAEROSOL, METERED; INHALATION
ALBUTEROL SULFATE

AB2	PADAGIS US	EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Mar CMFD
	POWDER, METERED; INHALATION					
	PROAIR DIGIHALER					
	+ @ TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Feb CAHN
	PROAIR RESPICLICK					
	+! TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015	Feb CAHN
	SOLUTION; INHALATION					
	ALBUTEROL SULFATE					
AN	RITEDOSE CORP	EQ 0.5% BASE	A218386	001	Mar 12, 2025	Feb NEWA
	SYRUP; ORAL					
	ALBUTEROL SULFATE					
	@ COSETTE	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Jan DISC

ALENDRONATE SODIUMTABLET; ORAL
ALENDRONATE SODIUM

@ APOTEX	EQ 5MG BASE	A077982	001	Aug 04, 2008	Mar DISC
@	EQ 10MG BASE	A077982	002	Aug 04, 2008	Mar DISC
@	EQ 35MG BASE	A077982	003	Aug 04, 2008	Mar DISC
@	EQ 70MG BASE	A077982	004	Aug 04, 2008	Mar DISC

ALLOPURINOLTABLET; ORAL
ALLOPURINOL

>A>	AB	AUROBINDO PHARMA LTD	100MG	A215091	001	Apr 14, 2025	Apr NEWA
>A>	AB		300MG	A215091	002	Apr 14, 2025	Apr NEWA

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

@ APOTEX INC 0.25MG
 @ 0.5MG
 @ 1MG
 @ 2MG

A077741 001 Jan 19, 2007 Mar DISC
 A077741 002 Jan 19, 2007 Mar DISC
 A077741 003 Jan 19, 2007 Mar DISC
 A077741 004 Jan 19, 2007 Mar DISC

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ APOTEX INC 0.5MG
 @ 1MG
 @ 2MG
 @ 3MG

A078449 001 Nov 12, 2008 Mar DISC
 A078449 004 Dec 23, 2015 Mar DISC
 A078449 002 Nov 12, 2008 Mar DISC
 A078449 003 Nov 12, 2008 Mar DISC

ALPROSTADIL

SUPPOSITORY; URETHRAL

MUSE

+ @ VIATRIS 0.125MG
 + @ 0.25MG
 + @ 0.5MG
 + @ 1MG

N020700 001 Nov 19, 1996 Feb CAHN
 N020700 002 Nov 19, 1996 Feb CAHN
 N020700 003 Nov 19, 1996 Feb CAHN
 N020700 004 Nov 19, 1996 Feb CAHN

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

@ BAJAJ 50MG/5ML

A075819 001 Sep 11, 2002 Mar CAHN

AMCINONIDE

LOTION; TOPICAL

AMCINONIDE

! SOLUBIOMIX 0.1%

A076329 001 Nov 06, 2002 Feb CAHN

AMINOCAPROIC ACID

SOLUTION; ORAL

AMINOCAPROIC ACID

AA AJENAT PHARMS 0.25GM/ML

A213825 001 Apr 08, 2021 Jan CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

BX RUBICON 10MG
 BX 25MG
 BX 50MG
 BX 75MG
 BX 100MG
 BX 150MG

A215376 001 May 01, 2023 Mar CTEC
 A215376 002 May 01, 2023 Mar CTEC
 A215376 003 May 01, 2023 Mar CTEC
 A215376 004 May 01, 2023 Mar CTEC
 A215376 005 May 01, 2023 Mar CTEC
 A215376 006 May 01, 2023 Mar CTEC

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

>D> AB MICRO LABS EQ 12.5MG BASE; 5MG
 >A> @ EQ 12.5MG BASE; 5MG
 >D> AB EQ 25MG BASE; 10MG
 >A> @ EQ 25MG BASE; 10MG
 >D> AB MYLAN PHARMS INC EQ 12.5MG BASE; 5MG
 >A> EQ 12.5MG BASE; 5MG
 >D> AB ! EQ 25MG BASE; 10MG
 >A> ! EQ 25MG BASE; 10MG

A211925 001 Feb 02, 2022 Apr DISC
 A211925 001 Feb 02, 2022 Apr DISC
 A211925 002 Feb 02, 2022 Apr DISC
 A211925 002 Feb 02, 2022 Apr DISC
 A071297 002 Dec 10, 1986 Apr CTEC
 A071297 002 Dec 10, 1986 Apr CTEC
 A071297 001 Dec 10, 1986 Apr CTEC
 A071297 001 Dec 10, 1986 Apr CTEC

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB APDM PHARMS EQ 2.5MG BASE; EQ 10MG BASE
 AB EQ 2.5MG BASE; EQ 20MG BASE
 AB EQ 2.5MG BASE; EQ 40MG BASE
 AB EQ 5MG BASE; EQ 10MG BASE
 AB EQ 5MG BASE; EQ 20MG BASE
 AB EQ 5MG BASE; EQ 40MG BASE
 AB EQ 5MG BASE; EQ 80MG BASE
 AB EQ 10MG BASE; EQ 10MG BASE
 AB EQ 10MG BASE; EQ 20MG BASE

A207762 001 Jan 11, 2019 Feb CAHN
 A207762 002 Jan 11, 2019 Feb CAHN
 A207762 003 Jan 11, 2019 Feb CAHN
 A207762 004 Jan 11, 2019 Feb CAHN
 A207762 005 Jan 11, 2019 Feb CAHN
 A207762 006 Jan 11, 2019 Feb CAHN
 A207762 007 Jan 11, 2019 Feb CAHN
 A207762 008 Jan 11, 2019 Feb CAHN
 A207762 009 Jan 11, 2019 Feb CAHN

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Feb CAHN
AB		EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Feb CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

>A>	@ CHARTWELL RX	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010	Apr CAHN
>A>	@	EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010	Apr CAHN
>A>	@	EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010	Apr CAHN
>A>	@	EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010	Apr CAHN
>A>	@	EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010	Apr CAHN
>A>	@	EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010	Apr CAHN
>D>	@ STRIDES PHARMA	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010	Apr CAHN
>D>	@	EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010	Apr CAHN
>D>	@	EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010	Apr CAHN
>D>	@	EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010	Apr CAHN
>D>	@	EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010	Apr CAHN
>D>	@	EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010	Apr CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	HETERO LABS LTD V	EQ 5MG BASE;20MG	A209591	001	Feb 14, 2025	Feb NEWA
AB		EQ 5MG BASE;40MG	A209591	002	Feb 14, 2025	Feb NEWA
AB		EQ 10MG BASE;20MG	A209591	003	Feb 14, 2025	Feb NEWA
AB		EQ 10MG BASE;40MG	A209591	004	Feb 14, 2025	Feb NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	SOFIE	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Mar CAHN
----	-------	------------------------------------	---------	-----	--------------	----------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	CEDIPROF INC	1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul 05, 2022	Jan CMFD
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul 05, 2022	Jan CMFD
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul 05, 2022	Jan CMFD
AB		5MG;5MG;5MG;5MG	A210754	004	Jul 05, 2022	Jan CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul 05, 2022	Jan CMFD

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

@ RHODES PHARMS	5MG	A213852	001	Sep 07, 2021	Jan DISC
@	10MG	A213852	002	Sep 07, 2021	Jan DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

@ HIKMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Mar DISC
@	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Mar DISC

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

ANAGRELIDE HYDROCHLORIDE

@ BARR LABS	EQ 0.5MG BASE	A076530	001	Apr 18, 2005	Mar CAHN
@	EQ 1MG BASE	A076530	002	Apr 18, 2005	Mar CAHN

APALUTAMIDE

TABLET;ORAL

APALUTAMIDE

AB	ZYDUS	60MG	A217113	001	Mar 17, 2025	Mar NFTG
AB	ERLEADA					
AB	+ JANSSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Mar CFTG

APIXABAN

>A>	FOR SUSPENSION;ORAL						
>A>	ELIQUIS SPRINKLE						
>A>	+! BRISTOL	0.15MG	N220073	001	Apr 17, 2025	Apr	NEWA
	TABLET;ORAL						
	APIXABAN						
>D> AB	HETERO LABS LTD V	2.5MG	A210066	001	Nov 21, 2023	Apr	DISC
>A>	@	2.5MG	A210066	001	Nov 21, 2023	Apr	DISC
>D> AB		5MG	A210066	002	Nov 21, 2023	Apr	DISC
>A>	@	5MG	A210066	002	Nov 21, 2023	Apr	DISC
AB	IMPAX	2.5MG	A209810	001	Feb 14, 2025	Feb	NEWA
AB		5MG	A209810	002	Feb 14, 2025	Feb	NEWA
AB	MACLEODS PHARMS LTD	2.5MG	A210067	001	Feb 27, 2025	Feb	NEWA
AB		5MG	A210067	002	Feb 27, 2025	Feb	NEWA
>A>	TABLET, FOR SUSPENSION;ORAL						
>A>	ELIQUIS						
>A>	+! BRISTOL MYERS SQUIBB	0.5MG	N202155	003	Apr 17, 2025	Apr	NEWA

APOMORPHINE HYDROCHLORIDE

SOLUTION;SUBCUTANEOUS
ONAPGO

+! MDD US	98MG/20ML (4.9MG/ML)	N214056	001	Feb 03, 2025	Feb	NEWA
-----------	----------------------	---------	-----	--------------	-----	------

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION
ARFORMOTEROL TARTRATE

AN	AUCTA	EQ 0.015MG BASE/2ML	A218380	001	Feb 03, 2025	Jan	NEWA
AN	MICRO LABS	EQ 0.015MG BASE/2ML	A218555	001	Mar 07, 2025	Feb	NEWA
>A> AN	SABA ILAC SANAYI	EQ 0.015MG BASE/2ML	A218429	001	Apr 25, 2025	Apr	NEWA

ARGATROBAN

INJECTABLE;INTRAVENOUS
ARGATROBAN IN SODIUM CHLORIDE

AP	+! PLANO PHARMS	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	Mar	CAHN
----	-----------------	----------------------	---------	-----	--------------	-----	------

ARIPIPIRAZOLE

FILM;ORAL
MEZOIFY

>A>	+ CMG PHARM CO LTD	5MG	N211448	001	Apr 15, 2025	Apr	NEWA
>A>	+!	10MG	N211448	002	Apr 15, 2025	Apr	NEWA
>A>	+	15MG	N211448	003	Apr 15, 2025	Apr	NEWA

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ABILIFY MAINTENA KIT

+	OTSUKA PHARM CO LTD	300MG/VIAL	N202971	001	Feb 28, 2013	Jan	CTEC
+!		400MG/VIAL	N202971	002	Feb 28, 2013	Jan	CTEC

ARIPIPIRAZOLE

@ MYLAN	300MG/VIAL	A216608	001	Dec 03, 2024	Jan	DISC
@	400MG/VIAL	A216608	002	Dec 03, 2024	Jan	DISC

SOLUTION;ORAL

ARIPIPIRAZOLE

AA	VISTAPHARM LLC	1MG/ML	A212870	001	Dec 26, 2019	Jan	CAHN
----	----------------	--------	---------	-----	--------------	-----	------

ARMODAFINIL

TABLET;ORAL
NUVIGIL

AB	+ NUVO PHARMS	50MG	N021875	001	Jun 15, 2007	Jan	CAHN
	+ @	100MG	N021875	002	Mar 26, 2009	Jan	CAHN
AB	+	150MG	N021875	003	Jun 15, 2007	Jan	CAHN
AB	+	200MG	N021875	005	Mar 26, 2009	Jan	CAHN
AB	+!	250MG	N021875	004	Jun 15, 2007	Jan	CAHN

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

>D> AB	@ SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Mar	DISC
>A>		EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr	DISC
>A>	@	EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr	DISC
>D> AB		EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr	DISC
>A>	@	EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr	DISC
>D> AB		EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr	DISC
>A>	@	EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr	DISC

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

@ APOTEX

750MG/5ML

A209750 001 Oct 11, 2017 Mar DISC

>A> ATRASENTAN HYDROCHLORIDE

>A> TABLET;ORAL

>A> VANRAFIA

>A> +! NOVARTIS EQ 0.75MG BASE

N219208 001 Apr 02, 2025 Apr NEWA

AVIBACTAM SODIUM; AZTREONAM

POWDER;INTRAVENOUS

EMBLAVEO

+! ABBVIE

EQ 0.5GM BASE/VIAL;1.5GM/VIAL

N217906 001 Feb 07, 2025 Feb NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

ASTEPRO

>D> + @ NORVIUM BIOSCIENCE 0.137MG/SPRAY

N022203 001 Oct 15, 2008 Apr CAHN

+ @ 0.137MG/SPRAY

N022203 001 Oct 15, 2008 Jan CAHN

>D> @ 0.2055MG/SPRAY

N022203 002 Aug 31, 2009 Apr CAHN

@ 0.2055MG/SPRAY

N022203 002 Aug 31, 2009 Jan CAHN

>A> + @ VIATRIS 0.137MG/SPRAY

N022203 001 Oct 15, 2008 Apr CAHN

>A> @ 0.2055MG/SPRAY

N022203 002 Aug 31, 2009 Apr CAHN

AZELASTINE HYDROCHLORIDE

@ BIONPHARMA

0.137MG/SPRAY

A090176 001 Jul 28, 2015 Jan DISC

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB TEVA PHARMS USA INC 0.137MG/SPRAY;0.05MG/SPRAY

A208436 001 Apr 08, 2025 Mar NEWA

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE

AB ALKEM LABS LTD EQ 40MG MEDOXOMIL;12.5MG

A217490 001 Jan 21, 2025 Jan NFTG

AB EQ 40MG MEDOXOMIL;25MG

A217490 002 Jan 21, 2025 Jan NFTG

EDARBYCLOR

AB + AZURITY EQ 40MG MEDOXOMIL;12.5MG

N202331 001 Dec 20, 2011 Jan CFTG

AB +! EQ 40MG MEDOXOMIL;25MG

N202331 002 Dec 20, 2011 Jan CFTG

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB CHARTWELL RX EQ 100MG BASE/5ML

A065488 001 May 15, 2015 Feb CMFD

AB EQ 200MG BASE/5ML

A065488 002 May 15, 2015 Feb CMFD

AB ZHEJIANG POLY PHARM EQ 100MG BASE/5ML

A217036 001 Jul 27, 2023 Mar CAHN

AB EQ 200MG BASE/5ML

A217036 002 Jul 27, 2023 Mar CAHN

>D> ZITHROMAX

>D> +! PFIZER EQ 1GM BASE/PACKET

N050693 001 Sep 28, 1994 Apr DISC

>A> + @ EQ 1GM BASE/PACKET

N050693 001 Sep 28, 1994 Apr DISC

INJECTABLE;INJECTION

AZITHROMYCIN

>D> AP HOSPIRA EQ 500MG BASE/VIAL

A065511 001 Jun 26, 2009 Apr DISC

>A> @ EQ 500MG BASE/VIAL

A065511 001 Jun 26, 2009 Apr DISC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

LUMI-SPORYN

AT + CASPER PHARMA LLC 400 UNITS/GM;EQ 3.5MG
BASE/GM;10,000 UNITS/GM

N050417 001 Feb CPOT

BACLOFEN

TABLET;ORAL

BACLOFEN

AB APPCO 5MG

A090334 003 Jan 31, 2025 Jan NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL						
BALSALAZIDE DISODIUM						
AB	CARNEGIE	750MG	A219422	001	Apr 03, 2025	Mar NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION						
QVAR 40						
	+ @ TEVA BRANDED PHARM	0.04MG/INH	N020911	002	Sep 15, 2000	Mar CAHN
QVAR 80						
	+ @ TEVA BRANDED PHARM	0.08MG/INH	N020911	001	Sep 15, 2000	Mar CAHN
AEROSOL, METERED;NASAL						
QNASL						
	+ TEVA BRANDED PHARM	0.04MG/ACTUATION	N202813	002	Dec 17, 2014	Feb CAHN
	+!	0.08MG/ACTUATION	N202813	001	Mar 23, 2012	Feb CAHN

BENZTROPINE MESYLATE

TABLET;ORAL						
BENZTROPINE MESYLATE						
AA	QUAGEN	0.5MG	A212694	001	Feb 11, 2025	Jan NEWA
AA		1MG	A212694	002	Feb 11, 2025	Jan NEWA
AA		2MG	A212694	003	Feb 11, 2025	Jan NEWA

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED;TOPICAL						
BETAMETHASONE DIPROPIONATE						
	@ CHARTWELL MOLECULAR	EQ 0.05% BASE	A076603	001	Jan 23, 2004	Feb CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

SUSPENSION;TOPICAL						
CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE						
	@ PADAGIS ISRAEL	0.064%;0.005%	A212367	001	Sep 11, 2020	Jan DISC

BEXAROTENE

CAPSULE;ORAL						
BEXAROTENE						
	@ CIPLA	75MG	A210352	001	Dec 10, 2024	Jan DISC

BICALUTAMIDE

TABLET;ORAL						
BICALUTAMIDE						
	@ APOTEX	50MG	A200274	001	May 21, 2015	Mar DISC

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC						
BIMATOPROST						
AB	MANKIND PHARMA	0.01%	A218196	001	Mar 17, 2025	Mar NFTG
LUMIGAN						
AB	+! ABBVIE	0.01%	N022184	001	Aug 31, 2010	Mar CFTG

BISOPROLOL FUMARATE

TABLET;ORAL						
BISOPROLOL FUMARATE						
	RUBICON	2.5MG	A075643	003	Mar 07, 2025	Mar NEWA
>A> AB	UNIQUE PHARM	5MG	A219044	001	Apr 16, 2025	Apr NEWA
>A> AB		10MG	A219044	002	Apr 16, 2025	Apr NEWA
ZEBETA						
>A>	+ @ TEVA BRANDED PHARM	5MG	N019982	002	Jul 31, 1992	Apr CAHN
>A>	+ @	10MG	N019982	001	Jul 31, 1992	Apr CAHN
>D>	+ @ TEVA WOMENS	5MG	N019982	002	Jul 31, 1992	Apr CAHN
>D>	+ @	10MG	N019982	001	Jul 31, 1992	Apr CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL						
ZIAC						
>D> AB	+ TEVA BRANDED PHARM	2.5MG;6.25MG	N020186	003	Mar 26, 1993	Apr CAHN
>A> AB	+	2.5MG;6.25MG	N020186	003	Mar 26, 1993	Apr CAHN
>D> AB	+	5MG;6.25MG	N020186	001	Mar 26, 1993	Apr CAHN
>A> AB	+	5MG;6.25MG	N020186	001	Mar 26, 1993	Apr CAHN
>D> AB	+!	10MG;6.25MG	N020186	002	Mar 26, 1993	Apr CAHN
>A> AB	+!	10MG;6.25MG	N020186	002	Mar 26, 1993	Apr CAHN

BOSENTANTABLET, FOR SUSPENSION; ORAL
BOSENTAN

AB	NATCO PHARMA LTD	32MG	A213154	001	Feb 05, 2025	Jan NFTG
AB	TRACLEER					
AB	+! ACTELION	32MG	N209279	001	Sep 05, 2017	Jan CFTG

BREXANOLONESOLUTION; INTRAVENOUS
ZULRESSO

+	@ SAGE THERAP	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019	Jan DISC
---	---------------	---------------------	---------	-----	--------------	----------

BREXPIPIRAZOLE

TABLET; ORAL

BREXPIPIRAZOLE

AB	ALEMBIC	0.25MG	A213683	001	Jan 13, 2025	Jan NEWA
AB		0.5MG	A213683	002	Jan 13, 2025	Jan NEWA
AB		1MG	A213683	003	Jan 13, 2025	Jan NEWA
AB		2MG	A213683	004	Jan 13, 2025	Jan NEWA
AB		3MG	A213683	005	Jan 13, 2025	Jan NEWA
AB		4MG	A213683	006	Jan 13, 2025	Jan NEWA
	@ APOTEX	0.25MG	A213731	001	Feb 24, 2025	Mar DISC
AB		0.25MG	A213731	001	Feb 24, 2025	Feb NEWA
	@	0.5MG	A213731	002	Feb 24, 2025	Mar DISC
AB		0.5MG	A213731	002	Feb 24, 2025	Feb NEWA
	@	1MG	A213731	003	Feb 24, 2025	Mar DISC
AB		1MG	A213731	003	Feb 24, 2025	Feb NEWA
	@	2MG	A213731	004	Feb 24, 2025	Mar DISC
AB		2MG	A213731	004	Feb 24, 2025	Feb NEWA
	@	3MG	A213731	005	Feb 24, 2025	Mar DISC
AB		3MG	A213731	005	Feb 24, 2025	Feb NEWA
	REXULTI					
AB	+ OTSUKA	0.25MG	N205422	001	Jul 10, 2015	Jan CTEC
AB	+	0.5MG	N205422	002	Jul 10, 2015	Jan CTEC
AB	+	1MG	N205422	003	Jul 10, 2015	Jan CTEC
AB	+!	2MG	N205422	004	Jul 10, 2015	Jan CTEC
AB	+	3MG	N205422	005	Jul 10, 2015	Jan CTEC
AB	+	4MG	N205422	006	Jul 10, 2015	Jan CTEC

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

	@ AMNEAL	0.2%;EQ 0.5% BASE	A217288	001	Dec 30, 2024	Jan DISC
AB	CAPLIN	0.2%;EQ 0.5% BASE	A219093	001	Feb 25, 2025	Feb NEWA

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMFED-DM

AA	+ XTTRIUM LABS INC	2MG/5ML; 10MG/5ML; 30MG/5ML	A088811	001	Jun 07, 1985	Feb CAHN
----	--------------------	-----------------------------	---------	-----	--------------	----------

BUDESONIDE

SUSPENSION; INHALATION

BUDESONIDE

	@ SANDOZ	0.25MG/2ML	A201966	003	Sep 27, 2013	Feb DISC
	@	0.5MG/2ML	A201966	002	Sep 27, 2013	Feb DISC
	@	1MG/2ML	A201966	001	Sep 27, 2013	Feb DISC

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP	ASPIRO	0.25MG/ML	A218746	001	Feb 27, 2025	Feb NEWA
	TABLET; ORAL					
	BUMETANIDE					
AB	MANKIND PHARMA	0.5MG	A219291	001	Apr 03, 2025	Mar NEWA
AB		1MG	A219291	002	Apr 03, 2025	Mar NEWA
AB		2MG	A219291	003	Apr 03, 2025	Mar NEWA

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE;INJECTION
BUPRENORPHINE HYDROCHLORIDE

AP	SOMERSET THERAPS LLC	EQ 0.3MG BASE/ML	A219302	001	Jan 30, 2025	Jan NEWA
----	----------------------	------------------	---------	-----	--------------	----------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	DIFGEN PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A212756	003	Feb 13, 2025	Feb NEWA
AB		EQ 4MG BASE;EQ 1MG BASE	A212756	004	Feb 13, 2025	Feb NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

>A>	AB1	IPCA LABS LTD	100MG	A207874	001	May 02, 2025	Apr NEWA
>A>	AB1		150MG	A207874	002	May 02, 2025	Apr NEWA
>A>	AB1		200MG	A207874	003	May 02, 2025	Apr NEWA
		@ SUN PHARM	150MG	A200216	001	Nov 30, 2020	Feb DISC
		@	300MG	A203650	001	Dec 31, 2020	Feb DISC

BUSPIRONE HYDROCHLORIDE

CAPSULE;ORAL
BUSPIRONE HYDROCHLORIDE

	EPIC PHARMA LLC	7.5MG	A218628	001	Mar 13, 2025	Feb NEWA
		10MG	A218628	002	Mar 13, 2025	Feb NEWA
		15MG	A218628	003	Mar 13, 2025	Feb NEWA

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

>D>	AB	!	ACCORD HLTHCARE	15MG	A202557	004	Dec 30, 2014	Apr CHRS
>A>	AB			15MG	A202557	004	Dec 30, 2014	Apr CHRS
	BX		EPIC PHARMA LLC	5MG	A208972	001	Apr 16, 2019	Mar CTEC
	BX			7.5MG	A208972	002	Apr 16, 2019	Mar CTEC
	BX			10MG	A208972	003	Apr 16, 2019	Mar CTEC
	BX			15MG	A208972	004	Apr 16, 2019	Mar CTEC
	BX			30MG	A208972	005	Apr 16, 2019	Mar CTEC
	BX		INVENTIA HLTHCARE	5MG	A209696	001	May 03, 2018	Mar CTEC
	BX			7.5MG	A209696	002	May 03, 2018	Mar CTEC
	BX			10MG	A209696	003	May 03, 2018	Mar CTEC
	BX			15MG	A209696	004	May 03, 2018	Mar CTEC
	BX			30MG	A209696	005	May 03, 2018	Mar CTEC
>D>	AB		UNICHEM	15MG	A210907	003	Nov 14, 2019	Apr CHRS
>A>	AB	!		15MG	A210907	003	Nov 14, 2019	Apr CHRS

BUSULFAN

INJECTABLE;INJECTION
BUSULFAN

	@ APOTEX	6MG/ML	A210448	001	May 07, 2019	Jan DISC
--	----------	--------	---------	-----	--------------	----------

CAFFEINE CITRATE

SOLUTION;ORAL
CAFFEINE CITRATE

	@ SUN PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090357	001	Sep 30, 2009	Feb DISC
--	-------------	------------------------------------	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+	@ VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Feb CAHN
---	-----------------------	---	---------	-----	--------------	----------

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

@	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Feb CAHN
---	---------------------	--	---------	-----	--------------	----------

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+	! VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Feb CAHN
---	-----------------------	---	---------	-----	--------------	----------

INJECTABLE; INJECTION

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER							
+ @	VANTIVE US HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Feb	CAHN
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER							
+!	VANTIVE US HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Feb	CAHN
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER							
+!	VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Feb	CAHN
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER							
+!	VANTIVE US HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Feb	CAHN
PRISMASOL BGK 4/0 IN PLASTIC CONTAINER							
@	VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Feb	CAHN
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER							
+!	VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Feb	CAHN
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER							
+!	VANTIVE US HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Feb	CAHN
PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER							
@	VANTIVE US HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Feb	CAHN
PRISMASOL BK 0/0 IN PLASTIC CONTAINER							
@	VANTIVE US HLTHCARE	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Feb	CAHN
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER							
+!	VANTIVE US HLTHCARE	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Feb	CAHN
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER							
+ @	VANTIVE US HLTHCARE	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Feb	CAHN
PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER							
@	VANTIVE US HLTHCARE	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Feb	CAHN

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER							
+!	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018883	001	Nov 30, 1984	Feb	CTEC
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER							
+!	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018883	002	Nov 30, 1984	Feb	CTEC
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER							
+!	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018883	003	Nov 30, 1984	Feb	CTEC
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER							
@	VANTIVE US HLTHCARE	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	001		Feb	CAHN

SOLUTION;INTRAPERITONEAL									
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
	@	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	003			Feb	CAHN
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
	@	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	002			Feb	CAHN
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	001	Dec 04, 1992		Feb	CAHN
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	002	Dec 04, 1992		Feb	CAHN
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER									
	+	@ VANTIVE US HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	003	Dec 04, 1992		Feb	CAHN
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	004	Dec 04, 1992		Feb	CAHN
DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	012	Jan 10, 1989		Feb	CAHN
DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	013	Jul 11, 1990		Feb	CAHN
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER									
	+	VANTIVE US HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	014	Jul 11, 1990		Feb	CTEC
AT	+		18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	014	Jul 11, 1990		Feb	CAHN
DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	015	Jul 11, 1990		Feb	CAHN
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
	@	VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	007	Jul 09, 1984		Feb	CAHN
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
	@	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	008	Jul 09, 1984		Feb	CAHN
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER									
	@	VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985		Feb	CAHN
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
	@	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	009	Jul 09, 1984		Feb	CAHN
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	004			Feb	CAHN
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
AT	+		25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020163	001	Dec 04, 1992		Feb	CAHN
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	005			Feb	CAHN
AT	+		25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020163	002	Dec 04, 1992		Feb	CAHN
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
	+	@ VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985		Feb	CAHN
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	006			Feb	CAHN
AT	+		25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020163	003	Dec 04, 1992		Feb	CAHN

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015		Feb	CAHN
---	---	---------------------	---	---------	-----	--------------	--	-----	------

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187	N207026	001	Jan 13, 2015		Feb	CAHN
---	---	---------------------	--	---------	-----	--------------	--	-----	------

CANDESARTAN CILEXETIL

TABLET;ORAL

CANDESARTAN CILEXETIL

AB	ZYDUS LIFESCIENCES	4MG	A091390	001	Aug 23, 2017	Jan CMFD
AB		8MG	A091390	002	Aug 23, 2017	Jan CMFD
AB		16MG	A091390	003	Aug 23, 2017	Jan CMFD
AB		32MG	A091390	004	Aug 23, 2017	Jan CMFD

CAPECITABINE

TABLET;ORAL

CAPECITABINE

BX	TEYRO LABS	150MG	A217237	001	Oct 23, 2023	Mar CTEC
BX		500MG	A217237	002	Oct 23, 2023	Mar CTEC

CARBAMAZEPINE

TABLET;ORAL

CARBAMAZEPINE

>A>	AB	ALEMBIC	200MG	A216623	001	Apr 16, 2025	Apr NEWA
		TABLET, EXTENDED RELEASE;ORAL					
		CARBAMAZEPINE					
	AB	ALKEM LABS LTD	100MG	A217277	001	Jan 14, 2025	Jan NEWA
	AB		200MG	A217277	002	Jan 14, 2025	Jan NEWA
	AB		400MG	A217277	003	Jan 14, 2025	Jan NEWA
>D>	AB	OSMOTICA PHARM US	100MG	A215664	001	Oct 22, 2024	Apr DISC
>A>	@		100MG	A215664	001	Oct 22, 2024	Apr DISC
>D>	AB		200MG	A215664	002	Oct 22, 2024	Apr DISC
>A>	@		200MG	A215664	002	Oct 22, 2024	Apr DISC
>D>	AB		400MG	A215664	003	Oct 22, 2024	Apr DISC
>A>	@		400MG	A215664	003	Oct 22, 2024	Apr DISC
	AB	TORRENT	100MG	A212524	001	Jan 13, 2025	Jan NEWA
	AB		200MG	A212524	002	Jan 13, 2025	Jan NEWA
	AB		400MG	A212524	003	Jan 13, 2025	Jan NEWA
	AB	YICHANG HUMANWELL	100MG	A219072	001	Jan 16, 2025	Jan NEWA
	AB		200MG	A219072	002	Jan 16, 2025	Jan NEWA
	AB		400MG	A219072	003	Jan 16, 2025	Jan NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

>A>	AB	MACLEODS PHARMS LTD	12.5MG;200MG;50MG	A214495	001	Apr 15, 2025	Apr NEWA
>A>	AB		18.75MG;200MG;75MG	A214495	002	Apr 15, 2025	Apr NEWA
>A>	AB		25MG;200MG;100MG	A214495	003	Apr 15, 2025	Apr NEWA
>A>	AB		31.25MG;200MG;125MG	A214495	004	Apr 15, 2025	Apr NEWA
>A>	AB		37.5MG;200MG;150MG	A214495	005	Apr 15, 2025	Apr NEWA
>A>	AB		50MG;200MG;200MG	A214495	006	Apr 15, 2025	Apr NEWA

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

	@	APOTEX INC	10MG;100MG	A077120	001	Jun 02, 2008	Mar DISC
	@		25MG;100MG	A077120	002	Jun 02, 2008	Mar DISC
	@		25MG;250MG	A077120	003	Jun 02, 2008	Mar DISC
AB		ASCENT PHARMS INC	10MG;100MG	A218939	001	Jan 14, 2025	Jan NEWA
AB			25MG;100MG	A218939	002	Jan 14, 2025	Jan NEWA
AB			25MG;250MG	A218939	003	Jan 14, 2025	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

	@	APOTEX	25MG;100MG	A076212	001	Jun 16, 2004	Mar DISC
	@		50MG;200MG	A076212	002	Jun 16, 2004	Mar DISC

CARBINOXAMINE MALEATE

TABLET;ORAL

CARBINOXAMINE MALEATE

	@	SENORES PHARMS	4MG	A090435	001	Apr 15, 2010	Jan CAHN
--	---	----------------	-----	---------	-----	--------------	----------

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

>D>	AA	ALLIED	350MG	A211789	001	Oct 20, 2021	Apr CAHN
	AA	FOSUN WANBANG	350MG	A081025	001	Apr 13, 1989	Jan CAHN
>A>	AA	POINTVIEW HLDINGS	350MG	A211789	001	Oct 20, 2021	Apr CAHN

CARVEDILOLTABLET; ORAL
CARVEDILOL

AB	GRAVITI PHARMS	3.125MG	A076649	001	Sep 05, 2007	Feb CAHN
AB		6.25MG	A076649	002	Sep 05, 2007	Feb CAHN
AB		12.5MG	A076649	003	Sep 05, 2007	Feb CAHN
AB		25MG	A076649	004	Sep 05, 2007	Feb CAHN
	@ NORVIUM BIOSCIENCE	3.125MG	A077316	001	Sep 05, 2007	Feb CAHN
	@	6.25MG	A077316	002	Sep 05, 2007	Mar DISC
AB		6.25MG	A077316	002	Sep 05, 2007	Feb CAHN
>D> AB		12.5MG	A077316	003	Sep 05, 2007	Apr DISC
>A>	@	12.5MG	A077316	003	Sep 05, 2007	Apr DISC
AB		12.5MG	A077316	003	Sep 05, 2007	Feb CAHN
>D> AB		25MG	A077316	004	Sep 05, 2007	Apr DISC
>A>	@	25MG	A077316	004	Sep 05, 2007	Apr DISC
AB		25MG	A077316	004	Sep 05, 2007	Feb CAHN

CEDAZURIDINE; DECITABINETABLET; ORAL
INQOVI

+!	TAIHO ONCOLOGY	100MG; 35MG	N212576	001	Jul 07, 2020	Feb CAHN
----	----------------	-------------	---------	-----	--------------	----------

CEFAZOLIN SODIUMINJECTABLE; INJECTION
CEFAZOLIN SODIUM

	QILU ANTIBIOTICS	EQ 3GM BASE/VIAL	A203661	003	Jan 24, 2024	Jan CAHN
AP		EQ 1GM BASE/VIAL	A203661	001	Dec 28, 2015	Jan CAHN
		EQ 2GM BASE/VIAL	A203661	002	Mar 11, 2022	Jan CAHN
AP	!	EQ 10GM BASE/VIAL	A209217	001	Oct 17, 2018	Jan CAHN

CEFEPIME HYDROCHLORIDEINJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

	! QILU ANTIBIOTICS	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan CAHN
AP	!	EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan CAHN
AP	!	EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan CAHN

CEFPODOXIME PROXETILFOR SUSPENSION; ORAL
VANTIN

+ @	PFIZER	EQ 50MG BASE/5ML	N050675	001	Aug 07, 1992	Mar CAHN
+ @		EQ 100MG BASE/5ML	N050675	002	Aug 07, 1992	Mar CAHN

TABLET; ORAL
VANTIN

+ @	PFIZER	EQ 100MG BASE	N050674	001	Aug 07, 1992	Mar CAHN
+ @		EQ 200MG BASE	N050674	002	Aug 07, 1992	Mar CAHN

CEFPROZILFOR SUSPENSION; ORAL
CEFPROZIL

@	APOTEX INC	125MG/5ML	A065351	001	Feb 29, 2012	Mar DISC
@		250MG/5ML	A065351	002	Feb 29, 2012	Mar DISC

TABLET; ORAL
CEFPROZIL

@	APOTEX INC	250MG	A065327	001	Mar 26, 2008	Mar DISC
@		500MG	A065327	002	Mar 26, 2008	Mar DISC

CEFTOBIPROLE MEDOCARIL SODIUMPOWDER; INTRAVENOUS
ZEVTERA

>D>	+ @	ISTX	667MG/VIAL	N218275	001	Apr 03, 2024	Apr CMFD
>A>	+!		667MG/VIAL	N218275	001	Apr 03, 2024	Apr CMFD
	+ @		667MG/VIAL	N218275	001	Apr 03, 2024	Mar CAHN

CEFTRIAXONE SODIUMINJECTABLE; INJECTION
CEFTRIAXONE

AP	QILU ANTIBIOTICS	EQ 10GM BASE/VIAL	A209218	001	Oct 17, 2018	Jan CAHN
----	------------------	-------------------	---------	-----	--------------	----------

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AP	QILU ANTIBIOTICS	EQ 250MG BASE/VIAL	A203702	001	Jun 29, 2016	Jan CAHN
AP		EQ 500MG BASE/VIAL	A203702	002	Jun 29, 2016	Jan CAHN
AP		EQ 1GM BASE/VIAL	A203702	003	Jun 29, 2016	Jan CAHN
AP		EQ 2GM BASE/VIAL	A203702	004	Jun 29, 2016	Jan CAHN

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

@	APOTEX	EQ 250MG BASE	A065069	001	Oct 02, 2002	Mar DISC
@		EQ 500MG BASE	A065069	002	Oct 02, 2002	Mar DISC

CELECOXIB

CAPSULE; ORAL

CELECOXIB

@	PANGEA	200MG	A212925	001	Dec 09, 2020	Feb CAHN
@		400MG	A212925	002	Dec 09, 2020	Feb CAHN
>A> AB	STRIDES PHARMA	100MG	A213127	001	Apr 29, 2025	Apr NEWA
>A> AB		200MG	A213127	002	Apr 29, 2025	Apr NEWA
>A> AB		400MG	A213127	003	Apr 29, 2025	Apr NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION; ORAL

ZYRTEC

+	@ J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Feb CRLD
---	------------------------	---------	---------	-----	--------------	----------

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE HYDROCHLORIDE

BX	RUBICON	30MG	A216682	001	Apr 06, 2023	Mar CTEC
----	---------	------	---------	-----	--------------	----------

CHENODIOL

TABLET; ORAL

CTEXLI

+	MIRUM	250MG	N219488	001	Feb 21, 2025	Feb NEWA
---	-------	-------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A>	@ APOZEAL PHARMS	4MG/5ML; 5MG/5ML; 60MG/5ML	A206660	001	May 15, 2017	Apr CAHN
>D>	@ SCIEGEN PHARMS INC	4MG/5ML; 5MG/5ML; 60MG/5ML	A206660	001	May 15, 2017	Apr CAHN

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

>A> AB	AUROBINDO PHARMA LTD	10MG	A216788	001	Apr 25, 2025	Apr NEWA
>A> AB		25MG	A216788	002	Apr 25, 2025	Apr NEWA
>A> AB		50MG	A216788	003	Apr 25, 2025	Apr NEWA
>A> AB		100MG	A216788	004	Apr 25, 2025	Apr NEWA
>A> AB		200MG	A216788	005	Apr 25, 2025	Apr NEWA
AB	ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Feb CAHN
AB		25MG	A212630	002	Nov 29, 2021	Feb CAHN
AB		50MG	A212630	003	Nov 29, 2021	Feb CAHN
AB		100MG	A212630	004	Nov 29, 2021	Feb CAHN
AB		200MG	A212630	005	Nov 29, 2021	Feb CAHN

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

@	AIPING PHARM INC	25MG	A087380	001		Jan CAHN
@		50MG	A087381	001		Jan CAHN
+	HEMICLOR					
+	PRM PHARMA	12.5MG	N218647	001	Mar 17, 2025	Mar NEWA

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AA	AJENAT PHARMS	250MG	A215540	001	Jan 24, 2023	Jan CAHN
AB	APPCO	375MG	A212047	001	Jan 27, 2023	Mar CAHN
AB		750MG	A212047	002	Jan 27, 2023	Mar CAHN
>A>	@ CHARTWELL RX	250MG	A087981	001	Sep 20, 1983	Apr CAHN

		TABLET;ORAL							
		CHLORZOXAZONE							
>D>	AB	@ STRIDES PHARMA	250MG		A087981	001	Sep 20, 1983	Apr	CAHN
<u>CHOLESTYRAMINE</u>									
		POWDER;ORAL							
		CHOLESTYRAMINE LIGHT							
>A>	AB	PHARMOBEDIENT CNSLTG	EQ 4GM RESIN/PACKET		A209599	001	Nov 12, 2020	Apr	CAHN
>A>	AB		EQ 4GM RESIN/SCOOPFUL		A209599	002	Nov 12, 2020	Apr	CAHN
>D>	AB	TAGI	EQ 4GM RESIN/PACKET		A209599	001	Nov 12, 2020	Apr	CAHN
>D>	AB		EQ 4GM RESIN/SCOOPFUL		A209599	002	Nov 12, 2020	Apr	CAHN
<u>CHOLINE FENOFIBRATE</u>									
		CAPSULE, DELAYED RELEASE;ORAL							
		FENOFIBRIC ACID							
>D>	AB	AUROBINDO PHARMA LTD	EQ 135MG FENOFIBRIC ACID		A212598	002	Jul 25, 2019	Apr	CHRS
>A>	AB	!	EQ 135MG FENOFIBRIC ACID		A212598	002	Jul 25, 2019	Apr	CHRS
		TRILIPIX							
>D>	AB	+! ABBVIE	EQ 135MG FENOFIBRIC ACID		N022224	002	Dec 15, 2008	Apr	DISC
>A>		+ @	EQ 135MG FENOFIBRIC ACID		N022224	002	Dec 15, 2008	Apr	DISC
<u>CICLOPIROX</u>									
		SHAMPOO;TOPICAL							
		CICLOPIROX							
AT	!	PADAGIS US	1%		A078594	001	Feb 16, 2010	Mar	CHRS
		LOPROX							
	+ @	BAUSCH	1%		N021159	001	Feb 28, 2003	Mar	DISC
<u>CILOSTAZOL</u>									
		TABLET;ORAL							
		CILOSTAZOL							
>D>		@ NOSTRUM LABS INC	50MG		A077708	001	Sep 28, 2009	Apr	CAHN
>D>		@	100MG		A077708	002	Sep 28, 2009	Apr	CAHN
>A>		@ SANKALP LIFECARE	50MG		A077708	001	Sep 28, 2009	Apr	CAHN
>A>		@	100MG		A077708	002	Sep 28, 2009	Apr	CAHN
<u>CINACALCET HYDROCHLORIDE</u>									
		TABLET;ORAL							
		CINACALCET HYDROCHLORIDE							
AB		PIRAMAL	EQ 30MG BASE		A210207	001	Aug 01, 2018	Jan	CAHN
AB			EQ 60MG BASE		A210207	002	Aug 01, 2018	Jan	CAHN
AB			EQ 90MG BASE		A210207	003	Aug 01, 2018	Jan	CAHN
<u>CIPROFLOXACIN; DEXAMETHASONE</u>									
		SUSPENSION/DROPS;OTIC							
>A>		CIPROFLOXACIN AND DEXAMETHASONE							
>A>	AB	AMNEAL	0.3%;0.1%		A216501	001	Mar 22, 2024	Apr	CTNA
>D>		CIPROFLOXACIN; DEXAMETHASONE							
>D>	AB	AMNEAL	0.3%;0.1%		A216501	001	Mar 22, 2024	Apr	CTNA
<u>CISATRACURIUM BESYLATE</u>									
		INJECTABLE;INJECTION							
		CISATRACURIUM BESYLATE							
AP		GLAND	EQ 2MG BASE/ML		A215516	001	May 24, 2022	Mar	CAHN
AP			EQ 2MG BASE/ML		A215516	003	Dec 14, 2022	Mar	CAHN
AP			EQ 10MG BASE/ML		A215516	002	May 24, 2022	Mar	CAHN
	@	HAINAN POLY	EQ 2MG BASE/ML		A216538	001	Mar 08, 2024	Feb	DISC
AP		HENGRUI PHARMA	EQ 2MG BASE/ML		A204960	003	Aug 30, 2017	Feb	CMS1
		CISATRACURIUM BESYLATE PRESERVATIVE FREE							
	@	HAINAN POLY	EQ 2MG BASE/ML		A216539	001	Aug 27, 2024	Feb	DISC
	@		EQ 10MG BASE/ML		A216539	002	Aug 27, 2024	Feb	DISC
<u>CITALOPRAM HYDROBROMIDE</u>									
		TABLET;ORAL							
		CITALOPRAM HYDROBROMIDE							
	@	APOTEX	EQ 10MG BASE		A077046	001	Nov 24, 2004	Mar	DISC
	@		EQ 20MG BASE		A077046	002	Nov 24, 2004	Mar	DISC
	@		EQ 40MG BASE		A077046	003	Nov 24, 2004	Mar	DISC

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

>D>	@ AJANTA PHARMA LTD	250MG	A206714	001	Apr 25, 2019	Apr CAHN
>D>	@	500MG	A206714	002	Apr 25, 2019	Apr CAHN
>A>	@ JUBILANT CADISTA	250MG	A206714	001	Apr 25, 2019	Apr CAHN
>A>	@	500MG	A206714	002	Apr 25, 2019	Apr CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

@ ALMAJECT	EQ 150MG BASE/ML	A062800	001	Jul 24, 1987	Feb DISC
@	EQ 150MG BASE/ML	A062943	001	Sep 29, 1988	Feb DISC

CLOBAZAM

SUSPENSION; ORAL

CLOBAZAM

@ VISTAPHARM LLC	2.5MG/ML	A210746	001	Jul 10, 2019	Jan CAHN
------------------	----------	---------	-----	--------------	----------

TABLET; ORAL

CLOBAZAM

AB	@ ESJAY PHARMA	5MG	A209308	003	Oct 19, 2021	Feb CAHN
		10MG	A209308	001	Oct 22, 2018	Feb CAHN
	@	20MG	A209308	002	Oct 22, 2018	Feb CAHN

CLOBETASOL PROPIONATE

LOTION; TOPICAL

IMPEKLO

+ @ NORVIUM BIOSCIENCE	0.05%	N213691	001	May 19, 2020	Jan CAHN
------------------------	-------	---------	-----	--------------	----------

SUSPENSION/DROPS; OPHTHALMIC

CLOBETASOL PROPIONATE

+! FORMOSA	0.05%	N218158	001	Mar 04, 2024	Feb CAHN
------------	-------	---------	-----	--------------	----------

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING; ORAL

CLONAZEPAM

@ SUN PHARM INDS INC	0.125MG	A078654	001	Aug 27, 2014	Jan DISC
@	0.25MG	A078654	002	Aug 27, 2014	Jan DISC
@	0.5MG	A078654	003	Aug 27, 2014	Jan DISC
@	1MG	A078654	004	Aug 27, 2014	Jan DISC
@	2MG	A078654	005	Aug 27, 2014	Jan DISC

CLONIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

>D>	@ DR REDDYS LABS SA	0.1MG	A210680	001	Apr 30, 2018	Apr CAHN
>A>	@ RUBICON RESEARCH	0.1MG	A210680	001	Apr 30, 2018	Apr CAHN
AB1	SOMERSET THERAPS LLC	0.1MG	A211433	001	Oct 12, 2018	Mar CMFD

CLOZAPINE

TABLET; ORAL

CLOZAPINE

>D> AB	SUN PHARM INDS INC	25MG	A075713	001	Nov 15, 2002	Apr DISC
>A>	@	25MG	A075713	001	Nov 15, 2002	Apr DISC
>D> AB		50MG	A075713	003	Aug 19, 2005	Apr DISC
>A>	@	50MG	A075713	003	Aug 19, 2005	Apr DISC
>D> AB		100MG	A075713	002	Nov 15, 2002	Apr DISC
>A>	@	100MG	A075713	002	Nov 15, 2002	Apr DISC
>D> AB		200MG	A075713	004	Nov 07, 2017	Apr DISC
>A>	@	200MG	A075713	004	Nov 07, 2017	Apr DISC

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZCOBIX

+ JANSSEN PRODS	150MG; EQ 675MG BASE	N205395	002	Mar 21, 2025	Mar NEWA
+!	150MG; EQ 800MG BASE	N205395	001	Jan 29, 2015	Mar CPOT
+!	150MG; 800MG	N205395	001	Jan 29, 2015	Mar CAIN

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH VC W/ CODEINE

>A>	@ CHARTWELL RX	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A088764	001	Oct 31, 1984	Apr CAHN
>D>	@ NOSTRUM LABS INC	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A088764	001	Oct 31, 1984	Apr CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

>A>	AA	CHARTWELL RX	10MG/5ML; 6.25MG/5ML	A090180	001	Mar 17, 2010	Apr CAHN
>D>	AA	NOSTRUM LABS INC	10MG/5ML; 6.25MG/5ML	A090180	001	Mar 17, 2010	Apr CAHN
	AA	XTTRIUM LABS INC	10MG/5ML; 6.25MG/5ML	A088875	001	Dec 17, 1984	Feb CAHN
		PROMETHAZINE WITH CODEINE					
		@ PHARM ASSOC	10MG/5ML; 6.25MG/5ML	A040650	001	Jan 31, 2006	Jan DISC

COLESEVELAM HYDROCHLORIDE

TABLET; ORAL

COLESEVELAM HYDROCHLORIDE

>A>	AB	MACLEODS PHARMS LTD	625MG	A204893	001	Apr 18, 2025	Apr NEWA
-----	----	---------------------	-------	---------	-----	--------------	----------

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

>D>	AP	NEXUS	EQ 150MG BASE/VIAL	A065177	001	Mar 19, 2004	Apr DISC
>A>		@	EQ 150MG BASE/VIAL	A065177	001	Mar 19, 2004	Apr DISC

COPPER

SYSTEM; INTRAUTERINE

MIUDELLA

+!	SEBELA WOMENS HLTH	N/A	N218201	001	Feb 24, 2025	Feb NEWA
----	--------------------	-----	---------	-----	--------------	----------

COPPER CU-64 DOTATATE

SOLUTION; INTRAVENOUS

DETECTNET

+!	CURIUM	4mL (1mCi/ML)	N213227	001	Sep 03, 2020	Jan CAHN
----	--------	---------------	---------	-----	--------------	----------

CROMOLYN SODIUM

CONCENTRATE; ORAL

GASTROCROM

AA	+!	VIATRIS SPECIALTY	100MG/5ML	N020479	001	Feb 29, 1996	Feb CAHN
----	----	-------------------	-----------	---------	-----	--------------	----------

SOLUTION; INHALATION

CROMOLYN SODIUM

>A>	AN	FERA PHARMS LLC	10MG/ML	A075437	001	Apr 21, 2000	Apr CAHN
>D>	AN	VIRTUS	10MG/ML	A075437	001	Apr 21, 2000	Apr CAHN

CUPRIC SULFATE

INJECTABLE; INJECTION

CUPRIC SULFATE

!	AM REGENT	EQ 0.4MG COPPER/ML	A216324	001	Dec 16, 2022	Jan CTEC
@	APOTEX CORP	EQ 0.4MG COPPER/ML	A218745	001	Aug 19, 2024	Jan DISC

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

>A>	AP	MEITHEAL	1MG/ML	A214316	001	Nov 15, 2024	Apr CAHN
>D>	AP	NANJING KING-FRIEND	1MG/ML	A214316	001	Nov 15, 2024	Apr CAHN
		DODEX					
		@ ACCORD HLTHCARE	1MG/ML	A083022	001		Jan DISC

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

>D>	AB	NEXTSOURCE	25MG	A218282	001	Dec 03, 2024	Apr CAHN
>D>	AB		50MG	A218282	002	Dec 03, 2024	Apr CAHN
>A>	AB	TRI-SOURCE PHARMA	25MG	A218282	001	Dec 03, 2024	Apr CAHN
>A>	AB		50MG	A218282	002	Dec 03, 2024	Apr CAHN

CYCLOSPORINE

EMULSION;OPHTHALMIC
CYCLOSPORINE

>D> BX	APOTEX	0.05%	A207606	001	Jan 12, 2023	Apr DISC
>A>	@	0.05%	A207606	001	Jan 12, 2023	Apr DISC
BX		0.05%	A207606	001	Jan 12, 2023	Mar CTEC
SOLUTION;ORAL						
CYCLOSPORINE						
	@ ABBVIE	100MG/ML	A065025	001	Mar 03, 2000	Feb DISC

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL

DABIGATRAN ETEXILATE MESYLATE

AB	DR REDDYS	EQ 75MG BASE	A208048	001	Jan 28, 2025	Jan NEWA
AB		EQ 110MG BASE	A208048	002	Jan 28, 2025	Jan NEWA
AB		EQ 150MG BASE	A208048	003	Jan 28, 2025	Jan NEWA
AB	MYLAN	EQ 75MG BASE	A208067	001	Feb 03, 2025	Jan NEWA
AB		EQ 150MG BASE	A208067	002	Feb 03, 2025	Jan NEWA

DACARBAZINE

INJECTABLE;INJECTION

DACARBAZINE

	@ HOSPIRA	200MG/VIAL	A075940	001	Oct 18, 2001	Mar DISC
--	-----------	------------	---------	-----	--------------	----------

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL

AMPYRA

AB	+! MERZ	10MG	N022250	001	Jan 22, 2010	Feb CAHN
----	---------	------	---------	-----	--------------	----------

DAPSONE

GEL;TOPICAL

DAPSONE

AB	AUROBINDO PHARMA LTD	5%	A218457	001	Apr 04, 2025	Mar NEWA
----	----------------------	----	---------	-----	--------------	----------

TABLET;ORAL

DAPSONE

>D> AB	NOSTRUM LABS INC	25MG	A203887	001	May 06, 2016	Apr CAHN
>D> AB		100MG	A203887	002	May 06, 2016	Apr CAHN
>A> AB	SOLIS PHARMS	25MG	A203887	001	May 06, 2016	Apr CAHN
>A> AB		100MG	A203887	002	May 06, 2016	Apr CAHN

DAPTOMYCIN

POWDER;INTRAVENOUS

DAPTOMYCIN

	@ FRESENIUS KABI USA	350MG/VIAL	A213396	001	Aug 01, 2024	Jan DISC
--	----------------------	------------	---------	-----	--------------	----------

DARUNAVIR

TABLET;ORAL

DARUNAVIR

AB	ANNORA PHARMA	600MG	A216168	001	Jan 21, 2025	Jan NEWA
AB		800MG	A216168	002	Jan 21, 2025	Jan NEWA

DASATINIB

TABLET;ORAL

DASATINIB

AB	BIOCON PHARMA	20MG	A217217	001	Mar 03, 2025	Feb NEWA
AB		50MG	A217217	002	Mar 03, 2025	Feb NEWA
AB		70MG	A217217	003	Mar 03, 2025	Feb NEWA
AB		80MG	A217217	004	Mar 03, 2025	Feb NEWA
AB		100MG	A217217	005	Mar 03, 2025	Feb NEWA
AB		140MG	A217217	006	Mar 03, 2025	Feb NEWA
AB	DR REDDYS	20MG	A213383	001	Mar 03, 2025	Feb NEWA
AB		50MG	A213383	002	Mar 03, 2025	Feb NEWA
AB		70MG	A213383	003	Mar 03, 2025	Feb NEWA
AB		80MG	A213383	004	Mar 03, 2025	Feb NEWA
AB		100MG	A213383	005	Mar 03, 2025	Feb NEWA
AB		140MG	A213383	006	Mar 03, 2025	Feb NEWA
>A> AB	EUGIA PHARMA	20MG	A216547	001	Apr 22, 2025	Apr NEWA
>A> AB		50MG	A216547	002	Apr 22, 2025	Apr NEWA
>A> AB		70MG	A216547	003	Apr 22, 2025	Apr NEWA
>A> AB		80MG	A216547	004	Apr 22, 2025	Apr NEWA
>A> AB		100MG	A216547	005	Apr 22, 2025	Apr NEWA

TABLET;ORAL

DASATINIB

>A>	AB		140MG	A216547	006	Apr 22, 2025	Apr NEWA
	AB	ZYDUS PHARMS	20MG	A218719	001	Mar 03, 2025	Feb NEWA
	AB		50MG	A218719	002	Mar 03, 2025	Feb NEWA
	AB		70MG	A218719	003	Mar 03, 2025	Feb NEWA
	AB		80MG	A218719	004	Mar 03, 2025	Feb NEWA
	AB		100MG	A218719	005	Mar 03, 2025	Feb NEWA
	AB		140MG	A218719	006	Mar 03, 2025	Feb NEWA

PHYRAGO

	+	HANDA THERAP	20MG	N216099	001	Dec 05, 2023	Jan CAHN
	+		50MG	N216099	002	Dec 05, 2023	Jan CAHN
	+		70MG	N216099	003	Dec 05, 2023	Jan CAHN
	+		80MG	N216099	004	Dec 05, 2023	Jan CAHN
	+		100MG	N216099	005	Dec 05, 2023	Jan CAHN
	+		140MG	N216099	006	Dec 05, 2023	Jan CAHN

DECITABINE

INJECTABLE;INTRAVENOUS

DECITABINE

>D>	AP	!	ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Apr CHRS
>A>	AP			50MG/VIAL	A203475	001	Feb 27, 2017	Apr CHRS
>D>	AP		DR REDDYS	50MG/VIAL	A203131	001	Jul 11, 2013	Apr CHRS
>A>	AP	!		50MG/VIAL	A203131	001	Jul 11, 2013	Apr CHRS

DEFERASIROX

TABLET;ORAL

DEFERASIROX

>A>	AB		JUBILANT GENERICS	90MG	A211660	001	Apr 11, 2025	Apr NEWA
>A>	AB			180MG	A211660	002	Apr 11, 2025	Apr NEWA
>A>	AB			360MG	A211660	003	Apr 11, 2025	Apr NEWA
>D>	AB		SUN PHARM	90MG	A211641	001	Jan 02, 2020	Apr DISC
>A>		@		90MG	A211641	001	Jan 02, 2020	Apr DISC
>D>	AB			180MG	A211641	003	Jun 15, 2020	Apr DISC
>A>		@		180MG	A211641	003	Jun 15, 2020	Apr DISC
>D>	AB			360MG	A211641	002	Jan 02, 2020	Apr DISC
>A>		@		360MG	A211641	002	Jan 02, 2020	Apr DISC

DEFLAZACORT

TABLET;ORAL

DEFLAZACORT

	AB		SUN PHARM	6MG	A217741	001	Mar 18, 2025	Mar NEWA
	AB			18MG	A217741	002	Mar 18, 2025	Mar NEWA
	AB			30MG	A217741	003	Mar 18, 2025	Mar NEWA
	AB			36MG	A217741	004	Mar 18, 2025	Mar NEWA
			JAYTHARI					
	AB		ZYDUS LIFESCIENCES	6MG	A219254	001	Apr 08, 2025	Mar NEWA
	AB			18MG	A219254	002	Apr 08, 2025	Mar NEWA
	AB			30MG	A219254	003	Apr 08, 2025	Mar NEWA
	AB			36MG	A219254	004	Apr 08, 2025	Mar NEWA

DESLORATADINE

TABLET;ORAL

DESLORATADINE

	AB		AJENAT PHARMS	5MG	A078355	001	Apr 19, 2012	Jan CAHN
--	----	--	---------------	-----	---------	-----	--------------	----------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-21

>A>			AVERI					
>A>			AVION PHARMS	0.15MG;0.03MG	A218933	001	May 02, 2025	Apr NEWA
			TABLET;ORAL-28					
>A>			AVERI					
>A>	AB		AVION PHARMS	0.15MG;0.03MG	A218933	002	May 02, 2025	Apr NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

	AB		MACLEODS PHARMS LTD	EQ 50MG BASE	A211427	001	Jan 15, 2025	Jan NEWA
	AB			EQ 100MG BASE	A211427	002	Jan 15, 2025	Jan NEWA
	AB		MEDICAP LABS	EQ 50MG BASE	A204805	001	May 07, 2019	Feb CAHN
	AB			EQ 100MG BASE	A204805	002	May 07, 2019	Feb CAHN

DEUTETRABENAZINE

TABLET; ORAL

AUSTEDO

+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017	Feb CAHN
+		6MG	N208082	001	Apr 03, 2017	Jan CTEC
+		9MG	N208082	002	Apr 03, 2017	Feb CAHN
+		9MG	N208082	002	Apr 03, 2017	Jan CTEC
+		12MG	N208082	003	Apr 03, 2017	Feb CAHN
+		12MG	N208082	003	Apr 03, 2017	Jan CTEC

DEUTETRABENAZINE

@	AUROBINDO PHARMA LTD	6MG	A215971	001	Dec 26, 2024	Jan DISC
@		9MG	A215971	002	Dec 26, 2024	Jan DISC
@		12MG	A215971	003	Dec 26, 2024	Jan DISC

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

>A>	AB	+	HIKMA	0.5MG	A084612	002		Apr CMS1
>A>	AB	+		0.75MG	A084612	003		Apr CMS1
>A>	AB	+	!	1MG	A084612	004	Sep 15, 1983	Apr CMS1
>A>	AB	+		1.5MG	A084612	005		Apr CMS1
>A>	AB	+	!	2MG	A084612	006		Apr CMS1
>A>	AB	+	!	6MG	A084612	007	Sep 15, 1983	Apr CMS1

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

POLMON

!	CARWIN PHARM ASSOC	2MG/5ML	A202520	001	Jul 16, 2018	Mar CAHN
!	CARWIN PHARMS	2MG/5ML	A202520	001	Jul 16, 2018	Feb CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	MEDICAP LABS	5MG	A078992	001	Nov 23, 2021	Feb CAHN
AB		10MG	A078992	002	Nov 23, 2021	Feb CAHN
AB		15MG	A078992	003	Nov 18, 2013	Feb CAHN
AB		30MG	A078992	004	Nov 18, 2013	Feb CAHN
AB		20MG	A078992	005	Nov 23, 2021	Feb CAHN
AB		40MG	A078992	006	Nov 23, 2021	Feb CAHN

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

@	RHODES PHARMS	2.5MG	A208756	001	Nov 20, 2017	Jan DISC
@		5MG	A208756	002	Nov 20, 2017	Jan DISC
@		10MG	A208756	003	Nov 20, 2017	Jan DISC

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP	MSN	EQ 250MG BASE/VIAL	A216748	001	Mar 26, 2025	Mar NEWA
AP		EQ 500MG BASE/VIAL	A216748	002	Mar 26, 2025	Mar NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE DM

>A>	AA	!	PAI HOLDINGS	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	Apr CAHN
>D>	AA	!	SLATE RUN PHARMA	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	Apr CAHN
			PROMETHAZINE W/ DEXTROMETHORPHAN					
AA			XTTRIUM LABS INC	15MG/5ML; 6.25MG/5ML	A088864	001	Jan 04, 1985	Feb CAHN

DIAZOXIDE CHOLINE

TABLET, EXTENDED RELEASE; ORAL

VYKAT XR

+	SOLENO THERAP	25MG	N216665	001	Mar 26, 2025	Mar NEWA
+		75MG	N216665	002	Mar 26, 2025	Mar NEWA
+	!	150MG	N216665	003	Mar 26, 2025	Mar NEWA

DICLOFENAC POTASSIUMFOR SOLUTION;ORAL
DICLOFENAC POTASSIUM

AB	TORRENT	50MG	A215891	001	Jan 22, 2025	Jan NEWA
	TABLET;ORAL					
	DICLOFENAC POTASSIUM					
AB	RK PHARMA	50MG	A075463	001	Jul 26, 1999	Mar CHRS
AB	! RUBICON	50MG	A075229	001	Nov 20, 1998	Mar CHRS

DICLOFENAC SODIUMGEL;TOPICAL
DICLOFENAC SODIUM

BX	ALEMBIC	3%	A212351	001	Jul 27, 2022	Mar CTEC
----	---------	----	---------	-----	--------------	----------

SOLUTION;TOPICAL
DICLOFENAC SODIUM

AB	ENCUBE	2%	A217646	001	Apr 09, 2025	Mar NEWA
----	--------	----	---------	-----	--------------	----------

TABLET, DELAYED RELEASE;ORAL
DICLOFENAC SODIUM

>D>	@ AUROBINDO PHARMA USA	50MG	A075281	002	Feb 12, 2002	Apr CMFD
>A> AB		50MG	A075281	002	Feb 12, 2002	Apr CMFD
>D>	@	75MG	A075281	003	Feb 12, 2002	Apr CMFD
>A> AB		75MG	A075281	003	Feb 12, 2002	Apr CMFD

TABLET, EXTENDED RELEASE;ORAL
DICLOFENAC SODIUM

>A> AB	NOVAST LABS	100MG	A216275	001	Sep 23, 2022	Apr CAHN
>D> AB	RICONPHARMA LLC	100MG	A216275	001	Sep 23, 2022	Apr CAHN

DICYCLOMINE HYDROCHLORIDEINJECTABLE;INJECTION
DICYCLOMINE HYDROCHLORIDE

>D> AP	NEXUS	10MG/ML	A206468	001	Feb 01, 2019	Apr DISC
>A>	@	10MG/ML	A206468	001	Feb 01, 2019	Apr DISC

TABLET;ORAL
DICYCLOMINE HYDROCHLORIDE

AB	RUBICON RESEARCH	20MG	A216736	001	Dec 14, 2022	Mar CAHN
!		40MG	A216736	002	Mar 25, 2025	Mar NEWA

DIETHYLPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
TENUATE DOSPAN

>A>	+ @ ANI PHARMS	75MG	N012546	001		Apr CAHN
>D>	+ @ NOSTRUM LABS INC	75MG	N012546	001		Apr CAHN

DIFELIKEFALIN ACETATESOLUTION;INTRAVENOUS
KORSUVA

>D>	+! CARA THERAP	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	N214916	001	Aug 23, 2021	Apr CAHN
>A>	+! VIFOR INTL	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	N214916	001	Aug 23, 2021	Apr CAHN

DIFLUPREDNATEEMULSION;OPHTHALMIC
DIFLUPREDNATE

AB	MYLAN LABS LTD	0.05%	A212566	001	Mar 20, 2025	Mar NEWA
AB	UPSHER SMITH LABS	0.05%	A218191	001	Feb 11, 2025	Jan NEWA

DIHYDROERGOTAMINE MESYLATEINJECTABLE;INJECTION
DIHYDROERGOTAMINE MESYLATE

@ CIPLA 1MG/ML

A212334	001	Sep 20, 2024	Jan DISC
---------	-----	--------------	----------

>A> POWDER;NASAL

>A> ATZUMI

>A>	+! SATSUMA PHARMS	EQ 5.2MG BASE	N217901	001	Apr 30, 2025	Apr NEWA
-----	-------------------	---------------	---------	-----	--------------	----------

SPRAY, METERED;NASAL
DIHYDROERGOTAMINE MESYLATE

AB	AGGREGA	0.5MG/SPRAY	A215228	001	Feb 26, 2025	Feb NEWA
----	---------	-------------	---------	-----	--------------	----------

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

>D>	AB1	AMTA	60MG	A219073	001	Mar 24, 2025	Apr CAHN
	AB1		60MG	A219073	001	Mar 24, 2025	Mar NEWA
>D>	AB1		90MG	A219073	002	Mar 24, 2025	Apr CAHN
	AB1		90MG	A219073	002	Mar 24, 2025	Mar NEWA
>D>	AB1		120MG	A219073	003	Mar 24, 2025	Apr CAHN
	AB1		120MG	A219073	003	Mar 24, 2025	Mar NEWA
>D>	AB3	SUN PHARM	120MG	A203023	001	Jun 08, 2017	Apr DISC
>A>	@		120MG	A203023	001	Jun 08, 2017	Apr DISC
	@		180MG	A203023	002	Jun 08, 2017	Mar DISC
	@		240MG	A203023	003	Jun 08, 2017	Mar DISC
	@		300MG	A203023	004	Jun 08, 2017	Feb DISC
>A>	AB1	UTOPIC PHARMS	60MG	A219073	001	Mar 24, 2025	Apr CAHN
>A>	AB1		90MG	A219073	002	Mar 24, 2025	Apr CAHN
>A>	AB1		120MG	A219073	003	Mar 24, 2025	Apr CAHN
		SOLUTION;INTRAVENOUS					
		DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE					
	+	HQ SPCLT PHARMA	100MG/100ML (1MG/ML)	N218038	001	Feb 21, 2025	Feb NEWA
	+		250MG/250ML (1MG/ML)	N218038	002	Feb 21, 2025	Feb NEWA

DIMETHYL FUMARATECAPSULE, DELAYED RELEASE;ORAL
DIMETHYL FUMARATE

@	CIPLA	120MG	A210305	001	Sep 24, 2020	Feb DISC
@		240MG	A210305	002	Sep 24, 2020	Feb DISC

DIPHENHYDRAMINE HYDROCHLORIDEINJECTABLE;INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

AP	!	NORVIUM BIOSCIENCE	50MG/ML	A040498	001	Jul 12, 2005	Feb CAHN
----	---	--------------------	---------	---------	-----	--------------	----------

DIPYRIDAMOLETABLET;ORAL
DIPYRIDAMOLE

AB		BARR LABS	75MG	A087717	001	Oct 03, 1990	Mar CAHN
----	--	-----------	------	---------	-----	--------------	----------

DIVALPROEX SODIUMTABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

@	APOTEX	EQ 125MG VALPROIC ACID	A077615	003	Jul 29, 2008	Mar DISC
@		EQ 250MG VALPROIC ACID	A077615	002	Jul 29, 2008	Mar DISC
@		EQ 500MG VALPROIC ACID	A077615	001	Jul 29, 2008	Mar DISC

DOCETAXELINJECTABLE;INJECTION
DOCETAXEL

>D>	AP	AMNEAL	20MG/ML (20MG/ML)	A209640	001	Jan 19, 2018	Apr CHRS
>A>	AP	!	20MG/ML (20MG/ML)	A209640	001	Jan 19, 2018	Apr CHRS
>D>	AP		80MG/4ML (20MG/ML)	A209640	002	Jan 19, 2018	Apr CHRS
>A>	AP	!	80MG/4ML (20MG/ML)	A209640	002	Jan 19, 2018	Apr CHRS
>D>	AP		160MG/8ML (20MG/ML)	A209640	003	Jan 19, 2018	Apr CHRS
>A>	AP	!	160MG/8ML (20MG/ML)	A209640	003	Jan 19, 2018	Apr CHRS
		TAXOTERE					
>D>	AP	+	SANOFI AVENTIS US	N020449	003	Aug 03, 2010	Apr DISC
>A>	AP	+	@	N020449	003	Aug 03, 2010	Apr DISC
>D>	AP	+	!	N020449	004	Aug 02, 2010	Apr DISC
>A>	AP	+	@	N020449	004	Aug 02, 2010	Apr DISC
>D>	AP	+	!	N020449	005	Apr 13, 2012	Apr CHRS
>A>	AP	+		N020449	005	Apr 13, 2012	Apr CHRS
		SOLUTION;INTRAVENOUS					
>D>		BEIZRAY					
>D>		+	ZHUHAI	N218711	001	Oct 23, 2024	Apr DISC
>A>		+	@	N218711	001	Oct 23, 2024	Apr DISC

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

>D>	AB	INDICUS PHARMA	5MG	A201634	001	Jun 13, 2012	Apr DISC
>A>		@	5MG	A201634	001	Jun 13, 2012	Apr DISC
>D>	AB		10MG	A201634	002	Jun 13, 2012	Apr DISC
>A>		@	10MG	A201634	002	Jun 13, 2012	Apr DISC

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB		AMNEAL	10MG;7MG	A208328	003	Feb 27, 2025	Feb NFTG
AB			10MG;21MG	A208328	004	Feb 27, 2025	Feb NEWA
AB	+	NAMZARIC ABBVIE	10MG;7MG	N206439	003	Jul 18, 2016	Feb CFTG

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT		SOMERSET THERAPS LLC	EQ 2% BASE	A215004	001	Feb 11, 2025	Jan NEWA
----	--	----------------------	------------	---------	-----	--------------	----------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT2		IDENTIRX	EQ 2% BASE;EQ 0.5% BASE	A216308	001	Feb 18, 2025	Feb NEWA
-----	--	----------	-------------------------	---------	-----	--------------	----------

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

AB		APPCO	EQ 1MG BASE	A209013	001	Apr 17, 2018	Mar CAHN
AB			EQ 2MG BASE	A209013	002	Apr 17, 2018	Mar CAHN
AB			EQ 4MG BASE	A209013	003	Apr 17, 2018	Mar CAHN
AB			EQ 8MG BASE	A209013	004	Apr 17, 2018	Mar CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

		@ ADAPTIS	EQ 150MG BASE	A213796	001	Apr 19, 2022	Jan DISC
AB		PTS CONSULTING	EQ 10MG BASE	A217975	001	Aug 21, 2023	Mar CAHN
AB			EQ 25MG BASE	A217975	002	Aug 21, 2023	Mar CAHN
AB			EQ 50MG BASE	A217975	003	Aug 21, 2023	Mar CAHN
AB			EQ 75MG BASE	A217975	004	Aug 21, 2023	Mar CAHN
AB			EQ 100MG BASE	A217975	005	Aug 21, 2023	Mar CAHN
BX		ZYDUS LIFESCIENCES	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar CTEC
BX			EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar CTEC
BX			EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar CTEC
BX			EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar CTEC
BX			EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar CTEC
BX			EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar CTEC

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

BX		MSN	EQ 3MG BASE	A214823	001	Apr 03, 2023	Mar CTEC
BX			EQ 6MG BASE	A214823	002	Apr 03, 2023	Mar CTEC

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB		MACLEODS PHARMS LTD	40MG	A210381	001	Mar 27, 2025	Mar NEWA
AB		PRINSTON INC	40MG	A217098	001	Jan 27, 2025	Jan NEWA

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

>A>		@ BIONPHARMA	EQ 50MG BASE	A209393	001	Dec 10, 2020	Apr CAHN
>A>		@	EQ 100MG BASE	A209393	002	Dec 10, 2020	Apr CAHN
AB	!	HIKMA INTL PHARMS	EQ 100MG BASE	A062396	001	May 07, 1984	Feb CHRS
>D>		@ NOSTRUM LABS INC	EQ 50MG BASE	A209393	001	Dec 10, 2020	Apr CAHN
>D>		@	EQ 100MG BASE	A209393	002	Dec 10, 2020	Apr CAHN
		VIBRAMYCIN					
	+	@ PFIZER	EQ 100MG BASE	N050007	002		Feb DISC

INJECTABLE;INJECTION
DOXYCYCLINE HYCLATE

	@ AMNEAL	EQ 100MG BASE/VIAL	A217487	001	Dec 04, 2024	Jan DISC
AP	PRECISION DOSE INC	EQ 100MG BASE/VIAL	A217078	001	Feb 21, 2025	Feb NEWA

DROXIDOPA

CAPSULE;ORAL
DROXIDOPA

>D>	AB	AJANTA PHARMA LTD	100MG	A214391	001	Feb 18, 2021	Apr CAHN
>D>	AB		200MG	A214391	002	Feb 18, 2021	Apr CAHN
>D>	AB		300MG	A214391	003	Feb 18, 2021	Apr CAHN
>A>	AB	JUBILANT CADISTA	100MG	A214391	001	Feb 18, 2021	Apr CAHN
>A>	AB		200MG	A214391	002	Feb 18, 2021	Apr CAHN
>A>	AB		300MG	A214391	003	Feb 18, 2021	Apr CAHN

EDARAVONE

SOLUTION;INTRAVENOUS
EDARAVONE

>D>	AP	LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Apr DISC
>A>		@	30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Apr DISC

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

>A>		@ CHARTWELL RX	600MG;200MG;300MG	A201802	001	Oct 03, 2023	Apr CAHN
>D>		@ STRIDES PHARMA	600MG;200MG;300MG	A201802	001	Oct 03, 2023	Apr CAHN

EFLORNITHINE HYDROCHLORIDE

CREAM;TOPICAL
VANIQA

	+	@ ABBVIE	13.9%	N021145	001	Jul 27, 2000	Feb CAHN
--	---	----------	-------	---------	-----	--------------	----------

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

ELIGLUSTAT TARTRATE

	@ APOTEX	EQ 84MG BASE	A212425	001	Jul 10, 2024	Jan DISC
--	----------	--------------	---------	-----	--------------	----------

ELTROMBOPAG OLAMINE

TABLET;ORAL

ELTROMBOPAG OLAMINE

AB		HETERO LABS LTD V	EQ 12.5MG ACID	A206788	001	Jan 17, 2025	Jan NFTG
AB			EQ 25MG ACID	A206788	002	Jan 17, 2025	Jan NFTG
AB			EQ 50MG ACID	A206788	003	Jan 17, 2025	Jan NFTG
AB			EQ 75MG ACID	A206788	004	Jan 17, 2025	Jan NFTG
		PROMACTA					
AB	+	NOVARTIS	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Jan CFTG
AB	+		EQ 25MG ACID	N022291	001	Nov 20, 2008	Jan CFTG
AB	+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Jan CFTG
AB	+	!	EQ 75MG ACID	N022291	003	Sep 08, 2009	Jan CFTG

ELUXADOLINE

TABLET;ORAL

ELUXADOLINE

AB		ZYDUS PHARMS	75MG	A213522	001	Mar 14, 2025	Mar NFTG
AB			100MG	A213522	002	Mar 14, 2025	Mar NFTG
		VIBERZI					
AB	+	ABBVIE	75MG	N206940	001	May 27, 2015	Mar CFTG
AB	+	!	100MG	N206940	002	May 27, 2015	Mar CFTG

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		HETERO LABS LTD III	100MG;150MG	A201806	002	Mar 03, 2025	Feb NEWA
AB			133MG;200MG	A201806	003	Mar 03, 2025	Feb NEWA
AB			167MG;250MG	A201806	004	Mar 03, 2025	Feb NEWA

ENFUVRTIDE

INJECTABLE;SUBCUTANEOUS
FUZEON

	+	@ ROCHE	90MG/VIAL	N021481	001	Mar 13, 2003	Mar DISC
--	---	---------	-----------	---------	-----	--------------	----------

ENZALUTAMIDE

CAPSULE;ORAL

ENZALUTAMIDE

@ ZYDUS PHARMS

40MG

A209667 001 Sep 26, 2024 Feb DISC

XTANDI

+! ASTELLAS

40MG

N203415 001 Aug 31, 2012 Feb CTEC

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

AKOVAZ

AP3 +! EXELA PHARMA

25MG/5ML (5MG/ML)

N208289 002 Aug 02, 2021 Mar CTEC

EMERPHED

AP1 +! NEXUS

50MG/10ML (5MG/ML)

N213407 001 Apr 17, 2020 Mar CTEC

AP +!

50MG/10ML (5MG/ML)

N213407 001 Apr 17, 2020 Jan CFTG

EPHEDRINE SULFATE

AP2 +! ENDO OPERATIONS

25MG/5ML (5MG/ML)

N213994 002 Apr 22, 2022 Mar CTEC

AP +!

25MG/5ML (5MG/ML)

N213994 002 Apr 22, 2022 Feb CFTG

AP2 +!

50MG/10ML (5MG/ML)

N213994 001 Oct 16, 2020 Mar CTEC

AP +!

50MG/10ML (5MG/ML)

N213994 001 Oct 16, 2020 Feb CFTG

AP2 FRESENIUS KABI USA

25MG/5ML (5MG/ML)

A218271 001 Mar 11, 2025 Mar CTEC

AP

25MG/5ML (5MG/ML)

A218271 001 Mar 11, 2025 Feb NFTG

AP2

50MG/10ML (5MG/ML)

A218271 002 Mar 11, 2025 Mar CTEC

AP

50MG/10ML (5MG/ML)

A218271 002 Mar 11, 2025 Feb NFTG

AP1 GLAND

50MG/10ML (5MG/ML)

A218211 001 Jan 16, 2025 Mar CTEC

AP

50MG/10ML (5MG/ML)

A218211 001 Jan 16, 2025 Jan NFTG

AP3 HIKMA

25MG/5ML (5MG/ML)

A217721 001 Oct 11, 2024 Mar CTEC

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

EPINASTINE HYDROCHLORIDE

@ RENOVA PHARMS

0.05%

A090870 001 Mar 14, 2011 Feb CAHN

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

EPINEPHRINE

AP GLAND PHARMA LTD

10MG/10ML (1MG/ML)

A219239 001 Feb 06, 2025 Jan NFTG

SOLUTION;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

EPINEPHRINE

AP +! BPI LABS

10MG/10ML (1MG/ML)

N205029 002 Feb 04, 2022 Jan CFTG

+! FRESENIUS KABI USA

30MG/30ML (1MG/ML)

N215425 001 Mar 13, 2025 Mar NEWA

AP GLAND

10MG/10ML (1MG/ML)

A219239 001 Feb 06, 2025 Mar CDFR

SPRAY;NASAL

NEFFY

>D> + ARS PHARMS OPERATION

1MG/SPRAY

N214697 002 Mar 05, 2025 Apr CHRS

>A> +!

1MG/SPRAY

N214697 002 Mar 05, 2025 Apr CHRS

+

1MG/SPRAY

N214697 002 Mar 05, 2025 Mar NEWA

EPINEPHRINE BITARTRATE

SOLUTION;INTRAVENOUS

EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+! BAXTER HLTHCARE CORP

EQ 16MG BASE/250ML (EQ 64MCG
BASE/ML)

N218475 001 Feb 28, 2025 Feb NEWA

EPLERENONE

TABLET;ORAL

EPLERENONE

@ THINKRX

25MG

A203896 001 Feb 02, 2017 Mar CAHN

@

50MG

A203896 002 Feb 02, 2017 Mar CAHN

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

>D> AP HONG KONG

2MG/ML

A213599 001 May 09, 2024 Apr CAHN

>D> AP

75MG/100ML

A213599 002 May 09, 2024 Apr CAHN

>A> AP

MEITHEAL

2MG/ML

A213599 001 May 09, 2024 Apr CAHN

>A> AP

75MG/100ML

A213599 002 May 09, 2024 Apr CAHN

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS

ERIBULIN MESYLATE

AP	CHIA TAI TIANQING	1MG/2ML (0.5MG/ML)	A218743	001	Mar 04, 2025	Feb NEWA
>A>	JIANGXI KVVIT PHARM	1MG/2ML (0.5MG/ML)	A218281	001	Jun 28, 2024	Apr CAHN
>D>	JIANGXI QINGFENG	1MG/2ML (0.5MG/ML)	A218281	001	Jun 28, 2024	Apr CAHN

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

@	APOTEX	EQ 25MG BASE	A208396	001	Nov 05, 2019	Jan DISC
@		EQ 100MG BASE	A208396	002	Nov 05, 2019	Jan DISC
@		EQ 150MG BASE	A208396	003	Nov 05, 2019	Jan DISC
@	SUN PHARM	EQ 25MG BASE	A210300	001	Nov 05, 2019	Jan DISC
@		EQ 100MG BASE	A210300	002	Nov 05, 2019	Feb DISC
@		EQ 150MG BASE	A210300	003	Nov 05, 2019	Jan DISC

ERTUGLIFLOZIN

TABLET; ORAL

ERTUGLIFLOZIN

>D>	AB	HETERO LABS LTD V	5MG	A217071	001	Sep 17, 2024	Apr DISC
>A>		@	5MG	A217071	001	Sep 17, 2024	Apr DISC
>D>	AB		15MG	A217071	002	Sep 17, 2024	Apr DISC
>A>		@	15MG	A217071	002	Sep 17, 2024	Apr DISC
		@	5MG	A216842	001	Jan 21, 2025	Feb DISC
	AB		5MG	A216842	001	Jan 21, 2025	Jan NEWA
		@	15MG	A216842	002	Jan 21, 2025	Feb DISC
	AB		15MG	A216842	002	Jan 21, 2025	Jan NEWA
		STEGLATRO					
>D>	AB	+ MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Apr CTEC
>A>		+	5MG	N209803	001	Dec 19, 2017	Apr CTEC
>D>	AB	+	15MG	N209803	002	Dec 19, 2017	Apr CTEC
>A>		+	15MG	N209803	002	Dec 19, 2017	Apr CTEC

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

>D>	!	AZURITY	EQ 250MG BASE	A060359	001		Apr DISC
>A>		@	EQ 250MG BASE	A060359	001		Apr DISC

ESLICARBAZEPINE ACETATE

TABLET; ORAL

ESLICARBAZEPINE ACETATE

>D>		@	APOTEX	200MG	A211236	001	Dec 07, 2023	Apr CMFD
>A>	AB			200MG	A211236	001	Dec 07, 2023	Apr CMFD
>D>		@		400MG	A211236	002	Dec 07, 2023	Apr CMFD
>A>	AB			400MG	A211236	002	Dec 07, 2023	Apr CMFD
>D>		@		600MG	A211236	003	Dec 07, 2023	Apr CMFD
>A>	AB			600MG	A211236	003	Dec 07, 2023	Apr CMFD
>D>		@		800MG	A211236	004	Dec 07, 2023	Apr CMFD
>A>	AB			800MG	A211236	004	Dec 07, 2023	Apr CMFD
	AB		LUPIN LTD	200MG	A211246	001	Mar 27, 2024	Mar CMFD
	AB			400MG	A211246	002	Mar 27, 2024	Mar CMFD
	AB			600MG	A211246	003	Mar 27, 2024	Mar CMFD
	AB			800MG	A211246	004	Mar 27, 2024	Mar CMFD

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

>D>	AB		GUANGZHOU NOVAKEN	EQ 20MG BASE	A213859	001	Nov 18, 2020	Apr CAHN
>A>	AB			EQ 20MG BASE	A213859	001	Nov 18, 2020	Apr CAHN
>D>	AB			EQ 40MG BASE	A213859	002	Nov 18, 2020	Apr CAHN
>A>	AB			EQ 40MG BASE	A213859	002	Nov 18, 2020	Apr CAHN
		@	IVAX SUB TEVA PHARMS	EQ 20MG BASE	A078003	001	Jan 26, 2015	Feb DISC
		@		EQ 40MG BASE	A078003	002	Jan 26, 2015	Feb DISC

FOR SUSPENSION, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

>A>	AB		AUROBINDO PHARMA LTD	EQ 5MG BASE/PACKET	A218948	001	Apr 15, 2025	Apr NEWA
>A>	AB			EQ 10MG BASE/PACKET	A219213	001	Apr 15, 2025	Apr NEWA
>A>	AB			EQ 20MG BASE/PACKET	A218948	002	Apr 15, 2025	Apr NEWA
>A>	AB			EQ 40MG BASE/PACKET	A218948	003	Apr 15, 2025	Apr NEWA
	AB		TORRENT	EQ 2.5MG BASE/PACKET	A212651	001	Mar 05, 2025	Feb NEWA

FOR SUSPENSION, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

AB	EQ 5MG BASE/PACKET	A212651	002	Mar 05, 2025	Feb NEWA
AB	EQ 10MG BASE/PACKET	A212652	001	Mar 05, 2025	Feb NEWA
AB	EQ 20MG BASE/PACKET	A212651	003	Mar 05, 2025	Feb NEWA
AB	EQ 40MG BASE/PACKET	A212651	004	Mar 05, 2025	Feb NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

@ NORVIUM BIOSCIENCE	EQ 20MG BASE;375MG	A204920	001	Jul 20, 2021	Feb CAHN
@	EQ 20MG BASE;500MG	A204920	002	Jul 20, 2021	Feb CAHN

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP	YANGTZE	EQ 40MG BASE/VIAL	A214046	001	Jan 08, 2025	Jan NEWA
----	---------	-------------------	---------	-----	--------------	----------

ESTRADIOL

CREAM;VAGINAL

ESTRADIOL

AB	ENCUBE	0.01%	A209767	001	Mar 05, 2018	Jan CAHN
----	--------	-------	---------	-----	--------------	----------

GEL;TRANSDERMAL

ESTRADIOL

AB	ENCUBE	0.1% (0.25GM/PACKET)	A218507	001	Mar 05, 2025	Feb NEWA
AB		0.1% (0.5GM/PACKET)	A218507	002	Mar 05, 2025	Feb NEWA
AB		0.1% (0.75GM/PACKET)	A218507	003	Mar 05, 2025	Feb NEWA
AB		0.1% (1.25GM/PACKET)	A218507	005	Mar 05, 2025	Feb NEWA
AB		0.1% (1GM/PACKET)	A218507	004	Mar 05, 2025	Feb NEWA

GEL, METERED;TRANSDERMAL

ELESTRIN

+!	VIATRIS	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Feb CAHN
----	---------	---------------------------	---------	-----	--------------	----------

TABLET;ORAL

ESTRADIOL

>D>	@ DR REDDYS LABS SA	0.5MG	A040114	003	Mar 14, 1996	Apr CAHN
>D>	@	1MG	A040114	001	Mar 14, 1996	Apr CAHN
>D>	@	2MG	A040114	002	Mar 14, 1996	Apr CAHN
>A>	@ RUBICON RESEARCH	0.5MG	A040114	003	Mar 14, 1996	Apr CAHN
>A>	@	1MG	A040114	001	Mar 14, 1996	Apr CAHN
>A>	@	2MG	A040114	002	Mar 14, 1996	Apr CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

GENCEPT 10/11-28

@ BARR LABS	0.035MG;0.035MG;0.5MG,1MG	A072697	001	Feb 28, 1992	Mar CAHN
-------------	---------------------------	---------	-----	--------------	----------

NORTREL 0.5/35-28

AB	BARR LABS	0.035MG;0.5MG	A072695	001	Feb 28, 1992	Mar CAHN
----	-----------	---------------	---------	-----	--------------	----------

NORTREL 1/35-28

AB	! BARR LABS	0.035MG;1MG	A072696	001	Feb 28, 1992	Mar CAHN
----	-------------	-------------	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL

KAITLIB FE

>D> AB	LUPIN LTD	0.025MG;0.8MG	A203448	001	Dec 17, 2015	Apr CHRS
>A> AB	!	0.025MG;0.8MG	A203448	001	Dec 17, 2015	Apr CHRS
>D>	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
>D> AB	+! TEVA BRANDED PHARM	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Apr DISC
>A>	+ @	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Apr DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	BARR LABS	0.02MG;1MG	A090938	001	Dec 01, 2014	Mar CAHN
----	-----------	------------	---------	-----	--------------	----------

TABLET;ORAL-21

JUNEL 1/20

AB	BARR LABS	0.02MG;1MG	A076380	001	May 30, 2003	Mar CAHN
----	-----------	------------	---------	-----	--------------	----------

TABLET;ORAL-28

BLISOVI FE 1.5/30

>D> BX	LUPIN LTD	0.03MG;1.5MG	A201585	001	Nov 18, 2015	Apr CTEC
>A> AB		0.03MG;1.5MG	A201585	001	Nov 18, 2015	Apr CTEC

EVEROLIMUSTABLET; ORAL
EVEROLIMUS

AB	BIOCON PHARMA	0.25MG	A216140	001	Apr 09, 2025	Mar	NEWA
AB		0.5MG	A216140	002	Apr 09, 2025	Mar	NEWA
AB		0.75MG	A216140	003	Apr 09, 2025	Mar	NEWA
AB		1MG	A216140	004	Apr 09, 2025	Mar	NEWA
	@ MYLAN	2.5MG	A212936	001	Jun 08, 2020	Mar	DISC
	@	5MG	A212936	002	Jun 08, 2020	Mar	DISC
	@	7.5MG	A212936	003	Jun 08, 2020	Mar	DISC
	@	10MG	A212936	004	Jun 08, 2020	Mar	DISC

TABLET, FOR SUSPENSION; ORAL
EVEROLIMUS

AB	AMNEAL	2MG	A218863	001	Jan 10, 2025	Jan	NEWA
AB		3MG	A218863	002	Jan 10, 2025	Jan	NEWA
AB		5MG	A218863	003	Jan 10, 2025	Jan	NEWA
AB	NATCO	2MG	A217640	001	Jan 28, 2025	Jan	NEWA
AB		3MG	A217640	002	Jan 28, 2025	Jan	NEWA
AB		5MG	A217640	003	Jan 28, 2025	Jan	NEWA

EXENATIDE SYNTHETIC

INJECTABLE; SUBCUTANEOUS

>D>	BYETTA						
>D> AP	+! ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Apr	DISC
>A>	+ @	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Apr	DISC
>D> AP	+!	600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Apr	DISC
>A>	+ @	600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Apr	DISC

EXENATIDE SYNTHETIC

>D> AP	AMNEAL	300MCG/1.2ML (250MCG/ML)	A206697	001	Nov 19, 2024	Apr	CHRS
>A> AP	!	300MCG/1.2ML (250MCG/ML)	A206697	001	Nov 19, 2024	Apr	CHRS
>A>	!	300MCG/1.2ML (250MCG/ML)	A206697	001	Nov 19, 2024	Apr	CTEC
>D> AP		600MCG/2.4ML (250MCG/ML)	A206697	002	Nov 19, 2024	Apr	CHRS
>A> AP	!	600MCG/2.4ML (250MCG/ML)	A206697	002	Nov 19, 2024	Apr	CHRS
>A>	!	600MCG/2.4ML (250MCG/ML)	A206697	002	Nov 19, 2024	Apr	CTEC

SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON BCISE

+ @ ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017	Mar	DISC
--------------------	-------------------------	---------	-----	--------------	-----	------

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

AB	TORRENT	10MG; 10MG	A209461	001	Jan 27, 2025	Jan	NEWA
AB		10MG; 20MG	A209461	002	Jan 27, 2025	Jan	NEWA
AB		10MG; 40MG	A209461	003	Jan 27, 2025	Jan	NEWA
AB		10MG; 80MG	A209461	004	Jan 27, 2025	Jan	NEWA

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

AB	APPCO	40MG/5ML	A217655	001	Jun 16, 2023	Mar	CAHN
----	-------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

FAMOTIDINE

	@ APOTEX	20MG	A075611	001	Jul 23, 2001	Mar	DISC
	@	40MG	A075611	002	Jul 23, 2001	Mar	DISC
AB	BEXIMCO PHARMS USA	20MG	A218631	001	Mar 25, 2025	Mar	NEWA
AB		40MG	A218631	002	Mar 25, 2025	Mar	NEWA

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

IBUPROFEN AND FAMOTIDINE

AB	ENDO OPERATIONS	26.6MG; 800MG	A203658	001	Mar 22, 2024	Feb	CTNA
	@ TORRENT	26.6MG; 800MG	A215925	001	Mar 18, 2024	Feb	CTNA
AB	ZYDUS PHARMS	26.6MG; 800MG	A218684	001	Feb 20, 2025	Feb	NEWA

FEBUXOSTAT

TABLET; ORAL

FEBUXOSTAT

AB	MSN	40MG	A210461	001	Dec 30, 2019	Jan	CTEC
AB		80MG	A210461	002	Dec 30, 2019	Jan	CTEC

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

>A>	AB	CHARTWELL RX	43MG	A090859	001	Mar 01, 2012	Apr CAHN
>A>	AB		130MG	A090859	002	Mar 01, 2012	Apr CAHN
>D>	AB	DR REDDYS LABS SA	43MG	A090859	001	Mar 01, 2012	Apr CAHN
>D>	AB		130MG	A090859	002	Mar 01, 2012	Apr CAHN

TABLET;ORAL

FENOFIBRATE

AB		CREEKWOOD PHARMS	40MG	A217732	001	Sep 07, 2023	Mar CTEC
AB			120MG	A217732	002	Sep 07, 2023	Mar CTEC
		@ MYLAN	54MG	A076520	001	Oct 25, 2007	Feb DISC
		@	160MG	A076520	003	Oct 25, 2007	Feb DISC
		@ SUN PHARM	48MG	A200884	001	Sep 07, 2017	Jan DISC
>D>	AB		145MG	A200884	002	Sep 07, 2017	Apr DISC
>A>		@	145MG	A200884	002	Sep 07, 2017	Apr DISC

FINASTERIDE; TADALAFIL

CAPSULE;ORAL

FINASTERIDE AND TADALAFIL

NOVITIUM PHARMA

5MG;5MG

A218499 001 Mar 19, 2025 Mar NEWA

FITUSIRAN SODIUM

SOLUTION;SUBCUTANEOUS

QFITLIA

+	!	GENZYME CORP	EQ 20MG BASE/0.2ML (EQ 20MG BASE/0.2ML)	N219019	001	Mar 28, 2025	Mar NEWA
+	!		EQ 50MG BASE/0.5ML (EQ 50MG BASE/0.5ML)	N219019	002	Mar 28, 2025	Mar NEWA

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP		BAMF	20-400mCi/ML	A216125	001	Mar 11, 2025	Feb NEWA
AP		SOFIE	20-300mCi/ML	A204463	001	Oct 21, 2014	Mar CAHN

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

AB1		ENCUBE	0.05%	A211410	001	Oct 16, 2018	Feb CMFD
-----	--	--------	-------	---------	-----	--------------	----------

GEL;TOPICAL

FLUOCINONIDE

AB		PADAGIS US	0.05%	A209030	001	Jun 19, 2018	Feb CMFD
----	--	------------	-------	---------	-----	--------------	----------

SOLUTION;TOPICAL

FLUOCINONIDE

AT		QUAGEN	0.05%	A216389	001	Feb 26, 2025	Feb NEWA
		@ SAPTALIS PHARMS	0.05%	A207554	001	Mar 18, 2019	Feb CAHN

FLUORESCEIN SODIUM

INJECTABLE;INTRAVENOUS

FLUORESCEIN SODIUM

AP		NEXUS	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A215709	001	Sep 25, 2023	Mar CAHN
AP			EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	Mar CAHN

FLUORODOPA F-18

SOLUTION;INTRAVENOUS

FLUORODOPA F18

+	!	FEINSTEIN	1-40mCi/ML	N200655	001	Oct 10, 2019	Feb CPOT
---	---	-----------	------------	---------	-----	--------------	----------

FLUOROURACIL

CREAM;TOPICAL

FLUOROURACIL

AB		ENCUBE	5%	A216942	001	Feb 12, 2025	Jan NEWA
----	--	--------	----	---------	-----	--------------	----------

INJECTABLE;INJECTION

FLUOROURACIL

AP		KINDOS	5GM/100ML (50MG/ML)	A215699	001	Feb 06, 2025	Jan NEWA
----	--	--------	---------------------	---------	-----	--------------	----------

FLUOXETINE HYDROCHLORIDE

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

>D>	AA	NOSTRUM LABS INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	Apr CAHN
>A>	AA	SOLIS PHARMS	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	Apr CAHN
TABLET; ORAL							
FLUOXETINE HYDROCHLORIDE							
		@ APPCO	EQ 10MG BASE	A211696	001	Jan 30, 2019	Feb CAHN
		@	EQ 20MG BASE	A211696	002	Jan 30, 2019	Feb CAHN
>D>	AB	AUROBINDO PHARMA LTD	EQ 60MG BASE	A213265	001	Jun 10, 2020	Apr CHRS
>A>	AB	!	EQ 60MG BASE	A213265	001	Jun 10, 2020	Apr CHRS
		@ CHARTWELL RX	EQ 10MG BASE	A211444	001	Sep 13, 2022	Mar CAHN
		@	EQ 20MG BASE	A211444	002	Sep 13, 2022	Mar CAHN
>D>	AB	+! TWI PHARMS	EQ 60MG BASE	N202133	001	Oct 06, 2011	Apr DISC
>A>		+ @	EQ 60MG BASE	N202133	001	Oct 06, 2011	Apr DISC

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

SYMBYAX

		+ @ LILLY	EQ 25MG BASE;EQ 3MG BASE	N021520	001	Apr 09, 2007	Feb DISC
		+ @	EQ 25MG BASE;EQ 6MG BASE	N021520	002	Dec 24, 2003	Feb DISC
		+ @	EQ 25MG BASE;EQ 12MG BASE	N021520	004	Dec 24, 2003	Feb DISC
		+ @	EQ 50MG BASE;EQ 6MG BASE	N021520	003	Dec 24, 2003	Feb DISC
		+ @	EQ 50MG BASE;EQ 12MG BASE	N021520	005	Dec 24, 2003	Feb DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

AB		ZAMEER PHARMS	1MG	A215141	001	Oct 20, 2021	Feb CAHN
AB			2.5MG	A215141	002	Oct 20, 2021	Feb CAHN
AB			5MG	A215141	003	Oct 20, 2021	Feb CAHN
AB			10MG	A215141	004	Oct 20, 2021	Feb CAHN

FLUTICASONE PROPIONATE

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

		@ CHARTWELL RX	0.005%	A076300	001	May 14, 2004	Mar CAHN
--	--	----------------	--------	---------	-----	--------------	----------

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA		AIPING PHARM INC	1MG	A091145	001	Jul 12, 2013	Mar CAHN
----	--	------------------	-----	---------	-----	--------------	----------

FORMOTEROL FUMARATE

SOLUTION; INHALATION

FORMOTEROL FUMARATE

AN		DEVA HOLDING AS	0.02MG/2ML	A218308	001	Feb 11, 2025	Jan NEWA
AN		DR REDDYS	0.02MG/2ML	A215907	001	Jan 30, 2025	Jan NEWA
		PERFOROMIST					
AN		+! VIATRIS SPECIALTY	0.02MG/2ML	N022007	001	May 11, 2007	Feb CAHN

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

>D>	AP	PIRAMAL CRITICAL	EQ 150MG BASE/VIAL	A214683	001	May 16, 2023	Apr DISC
>A>		@	EQ 150MG BASE/VIAL	A214683	001	May 16, 2023	Apr DISC
		@ PRAXGEN	EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Jan CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

		@ APOTEX	10MG	A076906	001	May 17, 2005	Mar DISC
		@	20MG	A076906	002	May 17, 2005	Mar DISC
		@	40MG	A076906	003	May 17, 2005	Mar DISC

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVATRIPTAN SUCCINATE

>A>	AB	LEADING	EQ 2.5MG BASE	A216998	001	Apr 16, 2025	Apr NEWA
-----	----	---------	---------------	---------	-----	--------------	----------

FUROSEMIDETABLET; ORAL
FUROSEMIDE

@ NORVIUM BIOSCIENCE 80MG A070082 001 Oct 29, 1986 Feb CAHN

GABAPENTINSOLUTION; ORAL
GABAPENTIN

AA AJENAT PHARMS 250MG/5ML A091286 001 Mar 14, 2016 Jan CAHN
 >D> @ PAI HOLDINGS PHARM 250MG/5ML A211330 001 Dec 03, 2019 Apr CMFD
 >A> AA 250MG/5ML A211330 001 Dec 03, 2019 Apr CMFD

TABLET; ORAL
GABAPENTIN

@ APOTEX 100MG A077894 001 Oct 10, 2006 Mar DISC
 @ 300MG A077894 002 Oct 10, 2006 Mar DISC
 @ 400MG A077894 003 Oct 10, 2006 Mar DISC
 IVAX SUB TEVA PHARMS 300MG A076017 002 Apr 28, 2004 Mar CTEC

GADOBUTROLSOLUTION; INTRAVENOUS
GADOBUTROL

>A> AP HAINAN POLY PHARM 1.20944GM/2ML (604.72MG/ML) A217480 003 Apr 16, 2025 Apr NEWA
 >A> AP 6.0472GM/10ML (604.72MG/ML) A217480 004 Apr 16, 2025 Apr NEWA
 >A> AP 18.1416GM/30ML (604.72MG/ML) A217480 005 Apr 16, 2025 Apr NEWA
 >A> AP 39.3068GM/65ML (604.72MG/ML) A217480 006 Apr 16, 2025 Apr NEWA

GADOTERIDOLINJECTABLE; INJECTION
GADOTERIDOL

AP HAINAN POLY 279.3MG/ML A218749 001 Feb 11, 2025 Jan NFTG
 PROHANCE
 AP +! BRACCO 279.3MG/ML N020131 001 Nov 16, 1992 Jan CFTG

GALLIUM GA-68 GOZETOTIDEPOWDER; INTRAVENOUS
GOZELLIX

+! TELIX INNOVATIONS N/A N219592 001 Mar 20, 2025 Mar NEWA

GANCICLOVIRSOLUTION; INTRAVENOUS
GANZYK-RTU

>D> GANZYK-RTU
 >D> +! EXELA PHARMA 500MG/250ML (2MG/ML) N209347 001 Feb 17, 2017 Apr DISC
 >A> + @ 500MG/250ML (2MG/ML) N209347 001 Feb 17, 2017 Apr DISC

GANIRELIX ACETATEINJECTABLE; INJECTION
GANIRELIX ACETATE

>A> AP QILU 250MCG/0.5ML A218855 001 Apr 23, 2025 Apr NEWA

GEMFIBROZILTABLET; ORAL
GEMFIBROZIL

@ APOTEX 600MG A075034 001 Jul 20, 1998 Mar DISC

GEPOTIDACIN MESYLATETABLET; ORAL
BLUJEP

+! GLAXOSMITHKLINE EQ 750MG BASE N218230 001 Mar 25, 2025 Mar NEWA

GLATIRAMER ACETATEINJECTABLE; SUBCUTANEOUS
GLATIRAMER ACETATE

>A> AP CHEMI SPA 20MG/ML A208468 001 May 07, 2025 Apr NEWA
 >A> AP 40MG/ML A208468 002 May 07, 2025 Apr NEWA

GLIMEPIRIDE

TABLET; ORAL						
AMARYL						
	+ @ SANOFI AVENTIS US	1MG	N020496	001	Nov 30, 1995	Feb DISC
	+ @	2MG	N020496	002	Nov 30, 1995	Feb DISC
	+ @	4MG	N020496	003	Nov 30, 1995	Feb DISC
GLIMEPIRIDE						
AB	! DR REDDYS LABS LTD	1MG	A077091	001	Oct 06, 2005	Feb CHRS

GLIPIZIDE

TABLET; ORAL						
GLIPIZIDE						
	@ AIPING PHARM INC	5MG	A074305	001	Apr 07, 1995	Jan CAHN
	@	10MG	A074305	002	Apr 07, 1995	Jan CAHN
>D>	@ OXFORD PHARMS	5MG	A074378	001	Nov 28, 1994	Apr CMFD
>A> AB		5MG	A074378	001	Nov 28, 1994	Apr CMFD
>D>	@	10MG	A074378	002	Nov 28, 1994	Apr CMFD
>A> AB		10MG	A074378	002	Nov 28, 1994	Apr CMFD
TABLET, EXTENDED RELEASE; ORAL						
GLUCOTROL XL						
>D> AB	+ PFIZER	2.5MG	N020329	003	Aug 10, 1999	Apr DISC
>A>	+ @	2.5MG	N020329	003	Aug 10, 1999	Apr DISC
>D>	+ @	5MG	N020329	001	Apr 26, 1994	Apr CMFD
>A> AB	+ @	5MG	N020329	001	Apr 26, 1994	Apr CMFD
>D> AB	+!	10MG	N020329	002	Apr 26, 1994	Apr CHRS
>A> AB	+	10MG	N020329	002	Apr 26, 1994	Apr CHRS

GLUCAGON

SOLUTION; INTRAVENOUS						
GVOKE VIALDX						
	+! XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	006	Mar 14, 2025	Mar NEWA

GLYCOPYRROLATE

INJECTABLE; INJECTION						
GLYCOPYRROLATE						
	@ XIROMED	0.2MG/ML	A212227	001	Mar 04, 2021	Jan DISC
SOLUTION; ORAL						
GLYCOPYRROLATE						
AA	MSN	1MG/5ML	A216084	001	Apr 08, 2025	Mar NEWA
TABLET; ORAL						
GLYCOPYRROLATE						
AA	CHARTWELL RX	1MG	A040847	001	Mar 21, 2008	Feb CAHN
AA		2MG	A040847	002	Mar 21, 2008	Feb CAHN

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC						
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN						
AT	SAPTALIS PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A065187	001	Oct 28, 2005	Feb CAHN

GRANISETRON HYDROCHLORIDE

SOLUTION; ORAL						
GRANISETRON HYDROCHLORIDE						
	INTRA SANA LABS	EQ 2MG BASE/10ML	A219282	001	Mar 17, 2025	Mar NEWA
TABLET; ORAL						
GRANISETRON HYDROCHLORIDE						
	@ APOTEX INC	EQ 1MG BASE	A078843	001	Feb 27, 2008	Mar DISC

GUANFACINE HYDROCHLORIDE

TABLET; ORAL						
GUANFACINE HYDROCHLORIDE						
BX	RUBICON	EQ 1MG BASE	A216762	001	Oct 17, 2023	Mar CTEC
BX		EQ 2MG BASE	A216762	002	Oct 17, 2023	Mar CTEC
TABLET, EXTENDED RELEASE; ORAL						
GUANFACINE HYDROCHLORIDE						
AB	FOSUN WANBANG	EQ 1MG BASE	A217638	001	Jun 12, 2024	Mar CMFD
	@	EQ 1MG BASE	A217638	001	Jun 12, 2024	Jan CAHN
AB		EQ 2MG BASE	A217638	002	Jun 12, 2024	Mar CMFD
	@	EQ 2MG BASE	A217638	002	Jun 12, 2024	Jan CAHN
AB		EQ 3MG BASE	A217638	003	Jun 12, 2024	Mar CMFD
	@	EQ 3MG BASE	A217638	003	Jun 12, 2024	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL
GUANFACINE HYDROCHLORIDE

AB		EQ 4MG BASE	A217638	004	Jun 12, 2024	Mar CMFD
	@	EQ 4MG BASE	A217638	004	Jun 12, 2024	Jan CAHN
>A>	AB	RUBICON EQ 1MG BASE	A219689	001	Apr 15, 2025	Apr NEWA
>A>	AB	EQ 2MG BASE	A219689	002	Apr 15, 2025	Apr NEWA
>A>	AB	EQ 3MG BASE	A219689	003	Apr 15, 2025	Apr NEWA
>A>	AB	EQ 4MG BASE	A219689	004	Apr 15, 2025	Apr NEWA

HALCINONIDE

SOLUTION;TOPICAL
HALCINONIDE

!	ENCUBE	0.1%	A217671	001	May 29, 2024	Mar CMFD
@		0.1%	A217671	001	May 29, 2024	Jan DISC

HALOBETASOL PROPIONATE

LOTION;TOPICAL
ULTRAVATE

>D>	+	@ LACER PHARMA	0.05%	N208183	001	Nov 06, 2015	Apr CMFD
>A>	+	!	0.05%	N208183	001	Nov 06, 2015	Apr CMFD
	+	@	0.05%	N208183	001	Nov 06, 2015	Jan CAHN

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION;TOPICAL
DUOBRII

>D>	+	!	BAUSCH	0.01%;0.045%	N209354	001	Apr 25, 2019	Apr CFTG
>A>	AB	+	!	0.01%;0.045%	N209354	001	Apr 25, 2019	Apr CFTG
>A>			HALOBETASOL PROPIONATE AND TAZAROTENE					
>A>	AB		TARO	0.01%;0.045%	A217190	001	May 02, 2025	Apr NFTG

HALOPERIDOL

TABLET;ORAL
HALOPERIDOL

AB		APPCO	0.5MG	A211061	001	Jan 08, 2020	Feb CAHN
AB			1MG	A211061	002	Jan 08, 2020	Feb CAHN
AB			2MG	A211061	003	Jan 08, 2020	Feb CAHN
AB			5MG	A211061	004	Jan 08, 2020	Feb CAHN
AB			10MG	A211061	005	Jan 08, 2020	Feb CAHN
AB			20MG	A211061	006	Jan 08, 2020	Feb CAHN

HALOPERIDOL LACTATE

INJECTABLE;INJECTION
HALOPERIDOL

@	FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019	Feb DISC
---	--------------------	----------------	---------	-----	--------------	----------

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM

	@	B BRAUN MEDICAL INC	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018	Jan DISC
		HIKMA	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jan CTEC
AP		PLANO PHARMS	1,000 UNITS/ML	A091682	001	Jun 08, 2011	Mar CAHN
AP			5,000 UNITS/ML	A091682	002	Jun 08, 2011	Mar CAHN
AP			10,000 UNITS/ML	A201002	001	Jun 08, 2011	Mar CAHN
		HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	+	B BRAUN	5,000 UNITS/100ML	N019953	003	Mar 25, 2025	Mar NEWA
	+		10,000 UNITS/100ML	N019953	004	Mar 25, 2025	Mar NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

>A>	@	APOZEAL PHARMS	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Apr CAHN
>D>	@	NOSTRUM LABS INC	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	Apr CAHN
>A>	@	SANKALP LIFECARE	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	Apr CAHN
>D>	@	SCIEGEN PHARMS INC	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Apr CAHN
AA		XTTRIUM LABS INC	1.5MG/5ML;5MG/5ML	A088008	001	Mar 03, 1983	Feb CAHN

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL
MICROZIDE

>D>	AB	+	!	TEVA BRANDED PHARM	12.5MG	N020504	001	Dec 27, 1996	Apr CAHN
>A>	AB	+	!		12.5MG	N020504	001	Dec 27, 1996	Apr CAHN

FOR SUSPENSION;ORAL
INZIRQO

	+! NOVITIUM PHARMA	10MG/ML	N219141	001	Jan 28, 2025	Jan NEWA
	TABLET;ORAL					
	HYDROCHLOROTHIAZIDE					
AB	UNICHEM	12.5MG	A040907	003	Apr 03, 2025	Mar NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

	TABLET;ORAL					
	METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE					
AB	SENORES PHARMS	25MG;50MG	A215789	001	Jan 08, 2025	Jan NEWA
AB		25MG;100MG	A215789	002	Jan 08, 2025	Jan NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

	TABLET;ORAL					
	QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
	@ APOTEX	12.5MG;EQ 10MG BASE	A091524	001	Mar 12, 2013	Jan DISC
	@	12.5MG;EQ 20MG BASE	A091524	002	Mar 12, 2013	Jan DISC
	@	25MG;EQ 20MG BASE	A091524	003	Mar 12, 2013	Jan DISC

HYDROCHLOROTHIAZIDE; TELMISARTAN

	TABLET;ORAL					
	TELMISARTAN AND HYDROCHLOROTHIAZIDE					
AB	MANKIND PHARMA	12.5MG;40MG	A218406	001	Mar 03, 2025	Feb NEWA
AB		12.5MG;80MG	A218406	002	Mar 03, 2025	Feb NEWA
AB		25MG;80MG	A218406	003	Mar 03, 2025	Feb NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

	CAPSULE;ORAL					
	TRIAMTERENE AND HYDROCHLOROTHIAZIDE					
AB	MACLEODS PHARMS LTD	25MG;37.5MG	A214611	001	Jan 28, 2025	Jan NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

	TABLET;ORAL					
	HYDROCODONE					
>D>	@ NOSTRUM LABS INC	5MG;200MG	A077723	003	Nov 06, 2006	Apr CAHN
>A>	@ STRIDES PHARMA	5MG;200MG	A077723	003	Nov 06, 2006	Apr CAHN
	HYDROCODONE BITARTRATE AND IBUPROFEN					
>D>	@ NOSTRUM LABS INC	7.5MG;200MG	A077723	001	Nov 06, 2006	Apr CAHN
>D>	@	10MG;200MG	A077723	002	Nov 06, 2006	Apr CAHN
>A>	@ STRIDES PHARMA	7.5MG;200MG	A077723	001	Nov 06, 2006	Apr CAHN
>A>	@	10MG;200MG	A077723	002	Nov 06, 2006	Apr CAHN

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

	SOLUTION;ORAL					
	HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
>A>	@ APOZEAL PHARMS	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Apr CAHN
>D>	@ SCIEGEN PHARMS INC	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Apr CAHN

HYDROCORTISONE

	LOTION;TOPICAL					
	ALA-SCALP					
	+ LEGACY PHARMA	2%	A083231	001		Mar CRLD
	TABLET;ORAL					
	HYDROCORTISONE					
>A> AB	NOVITIUM PHARMA	5MG	A217881	001	May 02, 2025	Apr NEWA
>A> AB		10MG	A217881	002	May 02, 2025	Apr NEWA
>A> AB		20MG	A217881	003	May 02, 2025	Apr NEWA

HYDROCORTISONE ACETATE

AEROSOL, METERED;RECTAL
CORTIFOAM

+!	VIATRIS	10%	N017351	001	Feb 10, 1982	Feb CAHN
----	---------	-----	---------	-----	--------------	----------

CREAM;TOPICAL
MICORT-HC

@	LEGACY PHARMA	2%	A040398	001	Mar 29, 2002	Jan CAHN
---	---------------	----	---------	-----	--------------	----------

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

@ SAPTALIS PHARMS 1%;EQ 3.5MG BASE/ML;10,000
UNITS/ML

A065216 001 Oct 31, 2005 Feb CAHN

SUSPENSION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT SAPTALIS PHARMS 1%;EQ 3.5MG BASE/ML;10,000
UNITS/ML

A065219 001 May 01, 2006 Feb CAHN

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

>A> AA BIONPHARMA 10MG/5ML

A219289 001 Apr 28, 2025 Apr NEWA

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

>A> @ APPCO 10MG

A040812 001 Mar 12, 2008 Apr CAHN

>A> @ 25MG

A040812 002 Mar 12, 2008 Apr CAHN

>A> @ 50MG

A040812 003 Mar 12, 2008 Apr CAHN

AB ! GRAVITI PHARMS 50MG

A217652 003 Aug 17, 2023 Mar CHRS

>D> @ INVAGEN PHARMS 10MG

A040812 001 Mar 12, 2008 Apr CAHN

>D> @ 25MG

A040812 002 Mar 12, 2008 Apr CAHN

>D> @ 50MG

A040812 003 Mar 12, 2008 Apr CAHN

AB + PLIVA 50MG

A088619 001 Jan 10, 1986 Mar CHRS

+ @ STRIDES PHARMA 50MG

A087604 001 Jan 22, 1982 Mar CRLD

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB BARR LABS EQ 50MG HYDROCHLORIDE
EQ 100MG HYDROCHLORIDE

A088487 001 Jun 15, 1984 Mar CAHN

A088488 001 Jun 15, 1984 Mar CAHN

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

ICATIBANT ACETATE

>A> @ CAPLIN EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

A213054 001 Oct 05, 2020 Apr CAHN

>D> @ DR REDDYS EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

A213054 001 Oct 05, 2020 Apr CAHN

ICODEXTRIN

SOLUTION;INTRAPERITONEAL

EXTRANEAL

+! VANTIVE US HLTHCARE 7.5GM/100ML

N021321 001 Dec 20, 2002 Feb CAHN

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

>A> AB CSPC OUYI EQ 100MG BASE

A212193 001 Apr 21, 2025 Apr NEWA

>A> AB EQ 400MG BASE

A212193 002 Apr 21, 2025 Apr NEWA

>A> AB HETERO LABS LTD V EQ 100MG BASE

A212975 001 Apr 14, 2025 Apr NEWA

>A> AB EQ 400MG BASE

A212975 002 Apr 14, 2025 Apr NEWA

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

@ APOTEX INC 5%

A091308 001 Apr 06, 2012 Mar DISC

INDOMETHACIN

SUPPOSITORY;RECTAL

INDOMETHACIN

AB AMNEAL 50MG

A215399 001 Feb 24, 2025 Feb NEWA

IOMEPROL

SOLUTION;INTRA-ARTERIAL

IOMERVU

+ @ BRACCO 15GM IODINE/50ML (300MG IODINE/ML)

N216016 002 Nov 27, 2024 Mar DISC

+ @ 17.5GM IODINE/50ML (350MG
IODINE/ML)

N216016 006 Nov 27, 2024 Mar DISC

+ @ 20GM IODINE/50ML (400MG IODINE/ML)

N216016 010 Nov 27, 2024 Mar DISC

+ @ 25GM IODINE/100ML (250MG
IODINE/ML)

N216016 001 Nov 27, 2024 Mar DISC

+ @ 30GM IODINE/100ML (300MG
IODINE/ML)

N216016 003 Nov 27, 2024 Mar DISC

SOLUTION; INTRA-ARTERIAL
IOMERVU

+ @	35GM IODINE/100ML (350MG IODINE/ML)	N216016	007	Nov 27, 2024	Mar DISC
+ @	40GM IODINE/100ML (400MG IODINE/ML)	N216016	011	Nov 27, 2024	Mar DISC
+ @	60GM IODINE/150ML (400MG IODINE/ML)	N216016	012	Nov 27, 2024	Mar DISC
+ @	45GM IODINE/150ML (300MG IODINE/ML)	N216016	004	Nov 27, 2024	Mar DISC
+ @	52.5GM IODINE/150ML (350MG IODINE/ML)	N216016	008	Nov 27, 2024	Mar DISC
+ @	60GM IODINE/200ML (300MG IODINE/ML)	N216016	005	Nov 27, 2024	Mar DISC
+ @	70GM IODINE/200ML (350MG IODINE/ML)	N216016	009	Nov 27, 2024	Mar DISC
+ @	80GM IODINE/200ML (400MG IODINE/ML)	N216016	013	Nov 27, 2024	Mar DISC

SOLUTION; INTRAVENOUS
IOMERVU

+ @ BRACCO	15GM IODINE/50ML (300MG IODINE/ML)	N216017	002	Nov 27, 2024	Mar DISC
+ @	17.5GM IODINE/50ML (350MG IODINE/ML)	N216017	006	Nov 27, 2024	Mar DISC
+ @	20GM IODINE/50ML (400MG IODINE/ML)	N216017	010	Nov 27, 2024	Mar DISC
+ @	25GM IODINE/100ML (250MG IODINE/ML)	N216017	001	Nov 27, 2024	Mar DISC
+ @	30GM IODINE/100ML (300MG IODINE/ML)	N216017	003	Nov 27, 2024	Mar DISC
+ @	35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024	Mar DISC
+ @	40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024	Mar DISC
+ @	60GM IODINE/150ML (400MG IODINE/ML)	N216017	012	Nov 27, 2024	Mar DISC
+ @	45GM IODINE/150ML (300MG IODINE/ML)	N216017	004	Nov 27, 2024	Mar DISC
+ @	52.5GM IODINE/150ML (350MG IODINE/ML)	N216017	008	Nov 27, 2024	Mar DISC
+ @	60GM IODINE/200ML (300MG IODINE/ML)	N216017	005	Nov 27, 2024	Mar DISC
+ @	70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024	Mar DISC
+ @	80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024	Mar DISC

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL
IPRATROPIUM BROMIDE

AB	LUPIN	0.021MG/SPRAY	A217912	001	Feb 07, 2025	Jan NEWA
AB		0.042MG/SPRAY	A217886	001	Jan 27, 2025	Jan NEWA
AB	RUBICON	0.021MG/SPRAY	A219222	001	Jan 14, 2025	Jan NEWA

ISONIAZID

SYRUP; ORAL
ISONIAZID

AA	CHARTWELL RX	50MG/5ML	A081118	001	Jul 21, 1997	Feb CMFD
AA	+! CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983	Feb CTEC

ISOTRETINOIN

CAPSULE; ORAL
AMNESTEEM

AB1	MYLAN PHARMS INC	30MG	A075945	004	Mar 17, 2025	Mar NEWA
-----	------------------	------	---------	-----	--------------	----------

ITRACONAZOLE

CAPSULE; ORAL
ITRACONAZOLE

AB	RISING	100MG	A205724	001	Dec 13, 2016	Feb CMFD
----	--------	-------	---------	-----	--------------	----------

IVABRADINE HYDROCHLORIDE

TABLET; ORAL
IVABRADINE HYDROCHLORIDE

>A>	AB	MSN	EQ 5MG BASE	A213483	001	Apr 28, 2025	Apr NEWA
>A>	AB		EQ 7.5MG BASE	A213483	002	Apr 28, 2025	Apr NEWA

IVERMECTINTABLET;ORAL
IVERMECTIN

AB	RUBICON	3MG	A215922	001	Jan 22, 2025	Jan NEWA
		6MG	A215922	002	Jan 22, 2025	Jan NFTG

KETAMINE HYDROCHLORIDEINJECTABLE;INJECTION
KETAMINE HYDROCHLORIDE

>A>	AP	FRESENIUS KABI USA	EQ 100MG BASE/ML	A215808	003	Apr 18, 2025	Apr NEWA
-----	----	--------------------	------------------	---------	-----	--------------	----------

KETOCONAZOLESHAMPOO;TOPICAL
KETOCONAZOLE

AB	ZYDUS LIFESCIENCES	2%	A218559	001	Mar 07, 2025	Feb NEWA
----	--------------------	----	---------	-----	--------------	----------

LACOSAMIDESOLUTION;ORAL
LACOSAMIDE

@	APOTEX	10MG/ML	A206355	001	Sep 26, 2022	Feb DISC
---	--------	---------	---------	-----	--------------	----------

LACTULOSEFOR SOLUTION;ORAL
LACTULOSE

AA	!	CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10, 1997	Mar CTEC
AA	!		20GM/PACKET	A074712	002	Dec 10, 1997	Mar CTEC
AA		PAI HOLDINGS	10GM/PACKET	A217914	001	Mar 14, 2025	Mar NEWA
AA			20GM/PACKET	A217914	002	Mar 14, 2025	Mar NEWA

SOLUTION;ORAL
LACTULOSE

@	VISTAPHARM LLC	10GM/15ML	A074138	001	Sep 30, 1992	Jan CAHN
---	----------------	-----------	---------	-----	--------------	----------

LAMIVUDINETABLET;ORAL
LAMIVUDINE

AB	APPCO	150MG	A206974	001	Nov 21, 2016	Mar CAHN	
AB		300MG	A206974	002	Nov 21, 2016	Mar CAHN	
	@	NORVIUM BIOSCIENCE	150MG	A078545	001	Mar 05, 2019	Feb CAHN
	@		300MG	A078545	002	Mar 05, 2019	Feb CAHN

LAMOTRIGINETABLET;ORAL
LAMOTRIGINE

@	AIPING PHARM INC	25MG	A078645	001	Jan 27, 2009	Jan CAHN
@		100MG	A078645	002	Jan 27, 2009	Jan CAHN
@		150MG	A078645	003	Jan 27, 2009	Jan CAHN
@		200MG	A078645	004	Jan 27, 2009	Jan CAHN

LANTHANUM CARBONATETABLET, CHEWABLE;ORAL
LANTHANUM CARBONATE

AB	ALKEM LABS LTD	EQ 500MG BASE	A202329	001	Mar 13, 2025	Mar NEWA
AB		EQ 750MG BASE	A202329	002	Mar 13, 2025	Mar NEWA
AB		EQ 1GM BASE	A202329	003	Mar 13, 2025	Mar NEWA

LATANOPROSTSOLUTION/DROPS;OPHTHALMIC
LATANOPROST

>A>	@	CARNEGIE	0.005%	A202077	001	Feb 11, 2013	Apr CAHN
>A>	AT	MICRO LABS	0.005%	A219306	001	Apr 14, 2025	Apr NEWA
>D>	@	RYAN LABS	0.005%	A202077	001	Feb 11, 2013	Apr CAHN

LATANOPROSTENE BUNODSOLUTION/DROPS;OPHTHALMIC
LATANOPROSTENE BUNOD

>A>	AB	GLAND	0.024%	A217387	001	Apr 29, 2025	Apr NFTG
		VYZULTA					
>D>	+	BAUSCH AND LOMB	0.024%	N207795	001	Nov 02, 2017	Apr CFTG
>A>	AB	+	0.024%	N207795	001	Nov 02, 2017	Apr CFTG

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

AB	FOSUN WANBANG	10MG	A077087	001	Sep 13, 2005	Jan CAHN
AB		20MG	A077087	002	Sep 13, 2005	Jan CAHN

LENALIDOMIDE

CAPSULE; ORAL

LENALIDOMIDE

AB	AMNEAL	2.5MG	A216213	001	Jan 31, 2025	Jan NEWA
AB		5MG	A216213	002	Jan 31, 2025	Jan NEWA
AB		10MG	A216213	003	Jan 31, 2025	Jan NEWA
AB		15MG	A216213	004	Jan 31, 2025	Jan NEWA
AB		20MG	A216213	005	Jan 31, 2025	Jan NEWA
AB		25MG	A216213	006	Jan 31, 2025	Jan NEWA
AB	BIOCON PHARMA	2.5MG	A215759	001	Mar 03, 2025	Feb NEWA
AB		5MG	A215759	002	Mar 03, 2025	Feb NEWA
AB		10MG	A215759	003	Mar 03, 2025	Feb NEWA
AB		15MG	A215759	004	Mar 03, 2025	Feb NEWA
AB		20MG	A215759	005	Mar 03, 2025	Feb NEWA
AB		25MG	A215759	006	Mar 03, 2025	Feb NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

>D>	AN	MANKIND PHARMA	EQ 0.0103% BASE	A218770	001	Oct 21, 2024	Apr DISC
>A>	@		EQ 0.0103% BASE	A218770	001	Oct 21, 2024	Apr DISC
>D>	AN		EQ 0.021% BASE	A218770	002	Oct 21, 2024	Apr DISC
>A>	@		EQ 0.021% BASE	A218770	002	Oct 21, 2024	Apr DISC
>D>	AN		EQ 0.042% BASE	A218770	003	Oct 21, 2024	Apr DISC
>A>	@		EQ 0.042% BASE	A218770	003	Oct 21, 2024	Apr DISC

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

LEVETIRACETAM IN SODIUM CHLORIDE

AP	CAPLIN	500MG/100ML (5MG/ML)	A219562	001	Jan 16, 2025	Jan NEWA
AP		1GM/100ML (10MG/ML)	A219562	002	Jan 16, 2025	Jan NEWA
AP		1.5GM/100ML (15MG/ML)	A219562	003	Jan 16, 2025	Jan NEWA

SOLUTION; ORAL

LEVETIRACETAM

AA	AJENAT PHARMS	100MG/ML	A090461	001	Sep 30, 2010	Jan CAHN
----	---------------	----------	---------	-----	--------------	----------

TABLET; ORAL

LEVETIRACETAM

@ CHINA RESOURCES

@

500MG

1GM

A205102 004 Dec 16, 2015 Jan CAHN

A205102 003 Dec 16, 2015 Jan CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

@ APOTEX

1GM

A202958 001 Feb 25, 2015 Mar DISC

TABLET, FOR SUSPENSION; ORAL

SPRITAM

>D>	+	APRECIA PHARMS	500MG	N207958	002	Jul 31, 2015	Apr CHRS
>A>	+	!	500MG	N207958	002	Jul 31, 2015	Apr CHRS
>D>	+		750MG	N207958	003	Jul 31, 2015	Apr DISC
>A>	+	@	750MG	N207958	003	Jul 31, 2015	Apr DISC
>D>	+	!	1GM	N207958	004	Jul 31, 2015	Apr DISC
>A>	+	@	1GM	N207958	004	Jul 31, 2015	Apr DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	SYNTHON BV	5MG	A090229	001	Nov 26, 2010	Feb CAHN
----	------------	-----	---------	-----	--------------	----------

LEVODOPA

POWDER; INHALATION

INBRIJA

+! MERZ

42MG

N209184 001 Dec 21, 2018 Feb CAHN

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

@	APOTEX INC	250MG	A090787	001	Sep 29, 2011	Mar	DISC
@		500MG	A090787	002	Sep 29, 2011	Mar	DISC
@		750MG	A090787	003	Sep 29, 2011	Mar	DISC

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

>A>	AB	ACERTIS PHARMS	2MG	A211484	001	Dec 13, 2018	Apr	CAHN
	BX	NOVITIUM PHARMA	1MG	A213479	003	Jul 20, 2021	Mar	CTEC
	BX		2MG	A213479	001	Jul 01, 2020	Mar	CTEC
	BX		3MG	A213479	002	Jan 12, 2021	Mar	CTEC
	AB		3MG	A213479	002	Jan 12, 2021	Mar	CHRS
	!	SUN PHARM INDS INC	3MG	A213906	002	Apr 25, 2023	Mar	CTEC
	AB	!	3MG	A213906	002	Apr 25, 2023	Mar	CHRS
>D>	AB	VIRTUS	2MG	A211484	001	Dec 13, 2018	Apr	CAHN

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	STERISCIENCE	100MCG/VIAL	A216729	001	Mar 05, 2025	Feb	NEWA
AP		200MCG/VIAL	A216729	002	Mar 05, 2025	Feb	NEWA
AP		500MCG/VIAL	A216729	003	Mar 05, 2025	Feb	NEWA

SOLUTION; ORAL

THYQUIDITY

>D>	+	!	AZURITY	100MCG/5ML	N214047	001	Nov 30, 2020	Apr	CAHN
>A>	+	!	STEVENS J	100MCG/5ML	N214047	001	Nov 30, 2020	Apr	CAHN

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

EUTHYROX

>A>	AB2	EMD SERONO INC	0.025MG	N021292	001	May 31, 2002	Apr	CAHN
>A>	AB2		0.05MG	N021292	002	May 31, 2002	Apr	CAHN
>A>	AB2		0.075MG	N021292	003	May 31, 2002	Apr	CAHN
>A>	AB2		0.088MG	N021292	004	May 31, 2002	Apr	CAHN
>A>	AB2		0.1MG	N021292	005	May 31, 2002	Apr	CAHN
>A>	AB2		0.112MG	N021292	006	May 31, 2002	Apr	CAHN
>A>	AB2		0.125MG	N021292	007	May 31, 2002	Apr	CAHN
>A>	AB2		0.137MG	N021292	008	May 31, 2002	Apr	CAHN
>A>	AB2		0.15MG	N021292	009	May 31, 2002	Apr	CAHN
>A>	AB2		0.175MG	N021292	010	May 31, 2002	Apr	CAHN
>A>	AB2		0.2MG	N021292	011	May 31, 2002	Apr	CAHN
>A>		@	0.3MG	N021292	012	May 31, 2002	Apr	CAHN
>D>	AB2	PROVELL	0.025MG	N021292	001	May 31, 2002	Apr	CAHN
>D>	AB2		0.05MG	N021292	002	May 31, 2002	Apr	CAHN
>D>	AB2		0.075MG	N021292	003	May 31, 2002	Apr	CAHN
>D>	AB2		0.088MG	N021292	004	May 31, 2002	Apr	CAHN
>D>	AB2		0.1MG	N021292	005	May 31, 2002	Apr	CAHN
>D>	AB2		0.112MG	N021292	006	May 31, 2002	Apr	CAHN
>D>	AB2		0.125MG	N021292	007	May 31, 2002	Apr	CAHN
>D>	AB2		0.137MG	N021292	008	May 31, 2002	Apr	CAHN
>D>	AB2		0.15MG	N021292	009	May 31, 2002	Apr	CAHN
>D>	AB2		0.175MG	N021292	010	May 31, 2002	Apr	CAHN
>D>	AB2		0.2MG	N021292	011	May 31, 2002	Apr	CAHN
>D>		@	0.3MG	N021292	012	May 31, 2002	Apr	CAHN
		LEVOTHYROXINE SODIUM						
		@ AUROBINDO PHARMA	0.137MG	A216414	001	Jul 16, 2024	Jan	DISC
		@	0.15MG	A216414	002	Jul 16, 2024	Jan	DISC
		@	0.175MG	A216414	003	Jul 16, 2024	Jan	DISC
		@	0.2MG	A216414	004	Jul 16, 2024	Jan	DISC
		@	0.3MG	A216414	005	Jul 16, 2024	Jan	DISC
AB1,		MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Feb	CTEC
AB2,								
AB3,								
AB4								
AB1,			0.025MG	A211417	001	Dec 21, 2022	Feb	CTEC
AB2,								
AB4								
AB1,			0.05MG	A211417	002	Dec 21, 2022	Feb	CTEC
AB2,								

TABLET;ORAL
LEVOTHYROXINE SODIUM

AB3, AB4 AB1,	0.05MG	A211417	002	Dec 21, 2022	Feb CTEC
AB2, AB4 AB1,	0.075MG	A211417	003	Dec 21, 2022	Feb CTEC
AB2, AB3, AB4 AB1,	0.075MG	A211417	003	Dec 21, 2022	Feb CTEC
AB2, AB4 AB1,	0.088MG	A211417	004	Dec 21, 2022	Feb CTEC
AB2, AB3, AB4 AB1,	0.088MG	A211417	004	Dec 21, 2022	Feb CTEC
AB2, AB4 AB1,	0.1MG	A211417	005	Dec 21, 2022	Feb CTEC
AB2, AB3, AB4 AB1,	0.1MG	A211417	005	Dec 21, 2022	Feb CTEC
AB2, AB4 AB1,	0.112MG	A211417	006	Dec 21, 2022	Feb CTEC
AB2, AB3, AB4 AB1,	0.112MG	A211417	006	Dec 21, 2022	Feb CTEC
AB2, AB4 AB1,	0.125MG	A211417	007	Dec 21, 2022	Feb CTEC
AB2, AB3, AB4 AB1,	0.125MG	A211417	007	Dec 21, 2022	Feb CTEC
AB2, AB4 AB1,	0.137MG	A211417	008	Dec 21, 2022	Feb CTEC
AB2, AB3, AB4 AB1,	0.137MG	A211417	008	Dec 21, 2022	Feb CTEC
AB2, AB4 AB1,	0.15MG	A211417	009	Dec 21, 2022	Feb CTEC
AB2, AB3, AB4 AB1,	0.15MG	A211417	009	Dec 21, 2022	Feb CTEC
AB2, AB4 AB1,	0.175MG	A211417	010	Dec 21, 2022	Feb CTEC
AB2, AB3, AB4 AB1,	0.175MG	A211417	010	Dec 21, 2022	Feb CTEC
AB2, AB4 AB1,	0.2MG	A211417	011	Dec 21, 2022	Feb CTEC
AB2, AB3, AB4 AB1,	0.2MG	A211417	011	Dec 21, 2022	Feb CTEC
AB2, AB4 AB1,	0.3MG	A211417	012	Dec 21, 2022	Feb CTEC
AB2, AB3, AB4 AB1,	0.3MG	A211417	012	Dec 21, 2022	Feb CTEC
AB2, AB4					

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

BX	ALEMBIC	5%	A211469	001	Nov 23, 2018	Mar CTEC	
>A>	AT	CHARTWELL RX	5%	A208660	001	Jan 05, 2021	Apr CAHN
>D>	AT	DR REDDYS	5%	A208660	001	Jan 05, 2021	Apr CAHN

PATCH; TOPICAL

LIDOCAINE

AB	AVEVA	1.8%	A217221	001	Mar 25, 2025	Mar NFTG
	ZTLIDO					
AB	+! SCILEX PHARMS	1.8%	N207962	001	Feb 28, 2018	Mar CFTG

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

AP	ANTHEA PHARMA	1%	A219535	001	Apr 02, 2025	Mar NEWA
----	---------------	----	---------	-----	--------------	----------

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE

AT	XTTRIUM LABS INC	2%	A087872	001	Nov 18, 1982	Feb CAHN
----	------------------	----	---------	-----	--------------	----------

SOLUTION; TOPICAL

LIDOCAINE HYDROCHLORIDE

AT	XTTRIUM LABS INC	4%	A087881	001	Nov 18, 1982	Feb CAHN
----	------------------	----	---------	-----	--------------	----------

LINEZOLID

SOLUTION; INTRAVENOUS

LINEZOLID

AP	NORVIUM BIOSCIENCE	200MG/100ML (2MG/ML)	A205154	001	Dec 06, 2017	Feb CAHN
AP		600MG/300ML (2MG/ML)	A205154	002	Dec 06, 2017	Feb CAHN

LIRAGLUTIDE

SOLUTION; SUBCUTANEOUS

LIRAGLUTIDE

AP	NANJING KING-FRIEND	18MG/3ML (6MG/ML)	A218115	001	Apr 02, 2025	Mar NEWA
----	---------------------	-------------------	---------	-----	--------------	----------

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

LISDEXAMFETAMINE DIMESYLATE

AB	GRANULES	10MG	A218987	001	Jan 29, 2025	Jan NEWA
AB		20MG	A218987	002	Jan 29, 2025	Jan NEWA
AB		30MG	A218987	003	Jan 29, 2025	Jan NEWA
AB		40MG	A218987	004	Jan 29, 2025	Jan NEWA
AB		50MG	A218987	005	Jan 29, 2025	Jan NEWA
AB		60MG	A218987	006	Jan 29, 2025	Jan NEWA
AB		70MG	A218987	007	Jan 29, 2025	Jan NEWA
AB	SANDOZ	20MG	A202836	001	Jul 26, 2024	Jan CMFD
AB		30MG	A202836	002	Jul 26, 2024	Jan CMFD
AB		40MG	A202836	003	Jul 26, 2024	Jan CMFD
AB		50MG	A202836	004	Jul 26, 2024	Jan CMFD
AB		60MG	A202836	005	Jul 26, 2024	Jan CMFD
AB		70MG	A202836	006	Jul 26, 2024	Jan CMFD

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

	@ NORVIUM BIOSCIENCE	450MG	A202219	001	Aug 08, 2012	Mar DISC
AB		450MG	A202219	001	Aug 08, 2012	Feb CAHN

LOFEXIDINE HYDROCHLORIDE

TABLET; ORAL

LOFEXIDINE HYDROCHLORIDE

AB	MSN	EQ 0.18MG BASE	A218699	001	Feb 24, 2025	Feb NEWA
----	-----	----------------	---------	-----	--------------	----------

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

>A>	@ AVIV PHARMA	2MG/ML	A074535	001	Sep 12, 1996	Apr CAHN
>A>	@	4MG/ML	A074535	002	Sep 12, 1996	Apr CAHN
>D>	@ DR REDDYS	2MG/ML	A074535	001	Sep 12, 1996	Apr CAHN
>D>	@	4MG/ML	A074535	002	Sep 12, 1996	Apr CAHN
>D>	AP	HOSPIRA	A074282	001	May 27, 1994	Apr DISC
>A>	@	2MG/ML	A074282	001	May 27, 1994	Apr DISC

INJECTABLE; INJECTION								
LORAZEPAM								
>D>	AP	4MG/ML	A074282	002	May 27, 1994	Apr	DISC	
>A>	@	4MG/ML	A074282	002	May 27, 1994	Apr	DISC	
<u>LOSARTAN POTASSIUM</u>								
SUSPENSION; ORAL								
ARBLI								
+	! SCIENTURE	10MG/ML	N218772	001	Mar 13, 2025	Mar	NEWA	
TABLET; ORAL								
LOSARTAN POTASSIUM								
	@ APOTEX	25MG	A218551	001	Jun 04, 2024	Jan	DISC	
	@	50MG	A218551	002	Jun 04, 2024	Jan	DISC	
	@	100MG	A218551	003	Jun 04, 2024	Jan	DISC	
<u>LOTEPREDNOL ETABONATE</u>								
SUSPENSION/DROPS; OPHTHALMIC								
LOTEPREDNOL ETABONATE								
AB	PADAGIS US	0.5%	A215204	001	Jan 29, 2025	Jan	NEWA	
<u>LURASIDONE HYDROCHLORIDE</u>								
TABLET; ORAL								
LURASIDONE HYDROCHLORIDE								
AB	CHARTWELL RX	20MG	A212091	001	Dec 28, 2020	Mar	CAHN	
AB		40MG	A212091	002	Dec 28, 2020	Mar	CAHN	
AB		60MG	A212091	003	Dec 28, 2020	Mar	CAHN	
AB		80MG	A212091	004	Dec 28, 2020	Mar	CAHN	
AB		120MG	A212091	005	Dec 28, 2020	Mar	CAHN	
AB	TORRENT	60MG	A208055	005	Jan 13, 2025	Jan	NEWA	
<u>MARALIXIBAT CHLORIDE</u>								
>A>	TABLET; ORAL							
>A>	LIVMARLI							
>A>	+	MIRUM	EQ 10MG BASE	N219485	001	Apr 10, 2025	Apr	NEWA
>A>	+		EQ 15MG BASE	N219485	002	Apr 10, 2025	Apr	NEWA
>A>	+		EQ 20MG BASE	N219485	003	Apr 10, 2025	Apr	NEWA
>A>	+	!	EQ 30MG BASE	N219485	004	Apr 10, 2025	Apr	NEWA
<u>MEFENAMIC ACID</u>								
CAPSULE; ORAL								
MEFENAMIC ACID								
AB	AJENAT PHARMS	250MG	A091608	001	Jun 02, 2014	Jan	CAHN	
<u>MEGESTROL ACETATE</u>								
SUSPENSION; ORAL								
MEGACE ES								
+	@ ENDO OPERATIONS	125MG/ML	N021778	001	Jul 05, 2005	Feb	DISC	
MEGESTROL ACETATE								
	! TWI PHARMS	125MG/ML	A203139	001	Aug 27, 2014	Feb	CTEC	
AB	!	125MG/ML	A203139	001	Aug 27, 2014	Feb	CHRS	
>D>	@ XTTRIUM LABS INC	40MG/ML	A076721	001	Nov 01, 2004	Apr	CMFD	
>A>	AB	40MG/ML	A076721	001	Nov 01, 2004	Apr	CMFD	
<u>MELOXICAM</u>								
SOLUTION; INTRAVENOUS								
>A>	QAMZOVA							
>A>	+	! NANJING DELOVA	30MG/ML (30MG/ML)	N217593	001	Apr 22, 2025	Apr	NEWA
TABLET; ORAL								
MELOXICAM								
AB	GRAVITI PHARMS	7.5MG	A077931	001	Jul 25, 2006	Feb	CAHN	
AB		15MG	A077931	002	Jul 25, 2006	Feb	CAHN	
<u>MELOXICAM; RIZATRIPTAN BENZOATE</u>								
TABLET; ORAL								
SYMBRAVO								
+	! AXSOME	20MG; EQ 10MG BASE	N215431	001	Jan 30, 2025	Jan	NEWA	

MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
MEMANTINE HYDROCHLORIDE

@ APOTEX	7MG	A206135	001	Nov 22, 2016	Mar	DISC
@	14MG	A206135	002	Nov 22, 2016	Mar	DISC
@	21MG	A206135	003	Nov 22, 2016	Mar	DISC
@	28MG	A206135	004	Nov 22, 2016	Mar	DISC

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

>A>	@ APOZEAL PHARMS	2MG/ML	A205446	001	Dec 07, 2015	Apr	CAHN
>D>	@ SCIEGEN PHARMS INC	2MG/ML	A205446	001	Dec 07, 2015	Apr	CAHN

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

>D>	@ ALLIED	5MG	A090073	001	Sep 04, 2015	Apr	CAHN
>D>	@	10MG	A090073	002	Sep 04, 2015	Apr	CAHN
>A>	@ POINTVIEW HLDINGS	5MG	A090073	001	Sep 04, 2015	Apr	CAHN
>A>	@	10MG	A090073	002	Sep 04, 2015	Apr	CAHN
>D>	@ YILING	5MG	A212947	001	Apr 03, 2020	Apr	CMFD
>A> AB		5MG	A212947	001	Apr 03, 2020	Apr	CMFD
>D>	@	10MG	A212947	002	Apr 03, 2020	Apr	CMFD
>A> AB		10MG	A212947	002	Apr 03, 2020	Apr	CMFD

MERCAPTOPURINESUSPENSION;ORAL
MERCAPTOPURINE

AB	HIKMA	20MG/ML	A216418	001	Feb 26, 2025	Feb	NFTG
	PURIXAN						
AB	+! NOVA LABS LTD	20MG/ML	N205919	001	Apr 28, 2014	Feb	CFTG

MEROPENEMINJECTABLE;INJECTION
MEROPENEM

>D> AP	ACS DOBFAR	500MG/VIAL	A091404	001	Oct 26, 2011	Apr	CHRS
>A> AP	!	500MG/VIAL	A091404	001	Oct 26, 2011	Apr	CHRS
>D> AP		1GM/VIAL	A091404	002	Oct 26, 2011	Apr	CHRS
>A> AP	!	1GM/VIAL	A091404	002	Oct 26, 2011	Apr	CHRS
>D>	MERREM IV						
>D> AP	+! PFIZER	500MG/VIAL	N050706	003	Jun 21, 1996	Apr	DISC
>A>	+ @	500MG/VIAL	N050706	003	Jun 21, 1996	Apr	DISC
>D> AP	+!	1GM/VIAL	N050706	001	Jun 21, 1996	Apr	DISC
>A>	+ @	1GM/VIAL	N050706	001	Jun 21, 1996	Apr	DISC

MESALAMINEENEMA;RECTAL
MESALAMINE

>A> AB	NOVITIUM PHARMA	4GM/60ML	A215269	001	Apr 16, 2025	Apr	NEWA
--------	-----------------	----------	---------	-----	--------------	-----	------

SUPPOSITORY;RECTAL
MESALAMINE

>A> AB	RISING	1GM	A219028	001	Apr 14, 2025	Apr	NEWA
--------	--------	-----	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE;ORAL

MESALAMINE

AB	AMNEAL	800MG	A215067	001	Feb 18, 2025	Feb	NEWA
----	--------	-------	---------	-----	--------------	-----	------

MESNATABLET;ORAL
MESNA

AB	RICONPHARMA LLC	400MG	A218871	001	Jan 13, 2025	Jan	NFTG
	MESNEX						
AB	+! BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002	Jan	CFTG

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL

METFORMIN HYDROCHLORIDE

AB	ANNORA PHARMA	500MG/5ML	A215008	001	Mar 13, 2025	Mar	NEWA
>A> AB	BIONPHARMA	500MG/5ML	A219151	001	Apr 14, 2025	Apr	NEWA
AB	VISTAPHARM LLC	500MG/5ML	A212677	001	Aug 19, 2022	Jan	CAHN

TABLET;ORAL

METFORMIN HYDROCHLORIDE

@ APOTEX	500MG	A075984	001	Apr 23, 2002	Mar	DISC
@	500MG	A090666	001	Dec 07, 2011	Mar	DISC
@	850MG	A075984	002	Apr 23, 2002	Mar	DISC

TABLET;ORAL									
METFORMIN HYDROCHLORIDE									
	@	850MG		A090666	002	Dec 07, 2011	Mar	DISC	
	@	1GM		A075984	003	Apr 23, 2002	Mar	DISC	
	@	1GM		A090666	003	Dec 07, 2011	Mar	DISC	
TABLET, EXTENDED RELEASE;ORAL									
METFORMIN HYDROCHLORIDE									
AB1	MEDICAP LABS	500MG		A202306	001	Feb 23, 2017	Feb	CAHN	
AB		750MG		A202306	002	Feb 23, 2017	Feb	CAHN	
	@ SUN PHARM	500MG		A202917	001	Aug 01, 2016	Jan	DISC	
	@	1GM		A202917	002	Aug 01, 2016	Jan	DISC	
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE</u>									
TABLET, EXTENDED RELEASE;ORAL									
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE									
AB	DR REDDYS LABS SA	500MG;EQ 5MG BASE		A207678	001	Aug 09, 2023	Jan	CTNA	
AB		1GM;EQ 2.5MG BASE		A207678	002	Aug 09, 2023	Jan	CTNA	
AB	!	1GM;EQ 5MG BASE		A207678	003	Aug 09, 2023	Jan	CTNA	
<u>METHADONE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
METHADONE HYDROCHLORIDE									
>A> AP	HIKMA	10MG/ML		A218609	001	May 05, 2025	Apr	NEWA	
TABLET, FOR SUSPENSION;ORAL									
METHADONE HYDROCHLORIDE									
AA	VISTAPHARM LLC	40MG		A075082	001	Mar 25, 1998	Jan	CAHN	
<u>METHENAMINE HIPPURATE</u>									
TABLET;ORAL									
METHENAMINE HIPPURATE									
AB	ZYDUS LIFESCIENCES	1GM		A219661	001	Mar 10, 2025	Feb	NEWA	
<u>METHIMAZOLE</u>									
TABLET;ORAL									
METHIMAZOLE									
AB	AIPING PHARM INC	5MG		A040547	001	Feb 18, 2005	Mar	CAHN	
AB		10MG		A040547	002	Feb 18, 2005	Mar	CAHN	
	@	20MG		A040547	004	Feb 18, 2005	Mar	CAHN	
AB	SQUARE PHARMS PLC	5MG		A218830	001	Feb 05, 2025	Jan	NEWA	
AB		10MG		A218830	002	Feb 05, 2025	Jan	NEWA	
<u>METHOCARBAMOL</u>									
TABLET;ORAL									
METHOCARBAMOL									
>D> AA	ALLIED	500MG		A212623	001	Apr 30, 2021	Apr	CAHN	
>D> AA		750MG		A212623	002	Apr 30, 2021	Apr	CAHN	
>A> AA	POINTVIEW HLDINGS	500MG		A212623	001	Apr 30, 2021	Apr	CAHN	
>A> AA		750MG		A212623	002	Apr 30, 2021	Apr	CAHN	
<u>METHYLENE BLUE</u>									
SOLUTION;INTRAVENOUS									
METHYLENE BLUE									
AP	HIKMA	50MG/10ML (5MG/ML)		A216959	001	Dec 17, 2024	Jan	CAHN	
AP	MEITHEAL	50MG/10ML (5MG/ML)		A217380	001	Jan 23, 2025	Jan	CAHN	
AP	NANJING KING-FRIEND	50MG/10ML (5MG/ML)		A217380	001	Jan 23, 2025	Jan	NEWA	
<u>METHYLNALTREXONE BROMIDE</u>									
SOLUTION;SUBCUTANEOUS									
METHYLNALTREXONE BROMIDE									
	@ ACTAVIS LLC	8MG/0.4ML (8MG/0.4ML)		A208112	001	Aug 26, 2024	Mar	DISC	
	@	12MG/0.6ML (12MG/0.6ML)		A208112	002	Aug 26, 2024	Mar	DISC	
RELISTOR									
+	! SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)		N021964	002	Sep 27, 2010	Mar	CTEC	
+	!	12MG/0.6ML (12MG/0.6ML)		N021964	003	Sep 27, 2010	Mar	CTEC	
<u>METHYLPHENIDATE</u>									
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL									
COTEMPLA XR-ODT									
>D>	+ @ NEOS THERAPS INC	34.6MG		N205489	004	Aug 19, 2024	Apr	CMFD	
>A>	+	34.6MG		N205489	004	Aug 19, 2024	Apr	CMFD	

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ ESJAY PHARMA 5MG/5ML
 @ 10MG/5ML

A201466 001 Nov 12, 2013 Feb CAHN
 A201466 002 Nov 12, 2013 Feb CAHN

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>D> @ NOSTRUM LABS INC 2.5MG
 >D> @ 5MG
 >D> @ 10MG
 >A> @ STRIDES PHARMA 2.5MG
 >A> @ 5MG
 >A> @ 10MG

A204954 001 Jan 26, 2017 Apr CAHN
 A204954 002 Jan 26, 2017 Apr CAHN
 A204954 003 Jan 26, 2017 Apr CAHN
 A204954 001 Jan 26, 2017 Apr CAHN
 A204954 002 Jan 26, 2017 Apr CAHN
 A204954 003 Jan 26, 2017 Apr CAHN

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

>A> AB HIKMA 80MG/ML

A219145 001 Apr 16, 2025 Apr NEWA

METHYLTESTOSTERONE

TABLET;ORAL

ANDROID 25

>D> BP BAUSCH 25MG
 >A> @ 25MG
 BP 25MG

A087147 001 Apr DISC
 A087147 001 Apr DISC
 A087147 001 Mar CAHN

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@ VISTAPHARM LLC EQ 5MG BASE/5ML

A075051 001 Jan 26, 2001 Jan CAHN

METOPROLOL TARTRATE

>A> SOLUTION;ORAL

>A> LOPRESSOR

>A> +! RUBICON 10MG/ML

N219373 001 Apr 10, 2025 Apr NEWA

TABLET;ORAL

METOPROLOL TARTRATE

AB SCIEGEN PHARMS INC 25MG
 AB 50MG
 AB 100MG
 >D> AB SUN PHARM INDS INC 25MG
 >A> @ 25MG

A208955 001 Feb 05, 2020 Jan CAHN
 A208955 002 Feb 05, 2020 Jan CAHN
 A208955 003 Feb 05, 2020 Jan CAHN
 A076670 001 Jan 15, 2004 Apr DISC
 A076670 001 Jan 15, 2004 Apr DISC

METRONIDAZOLE

CREAM;TOPICAL

METRONIDAZOLE

BX ZYDUS LIFESCIENCES 0.75%

A217128 001 Apr 21, 2023 Mar CTEC

GEL;VAGINAL

METRONIDAZOLE

@ ENCUBE 1.3%
 NUVESSA

A216795 001 Mar 18, 2024 Jan DISC

+! CHEMO RESEARCH SL 1.3%

N205223 001 Mar 24, 2014 Jan CTEC

METYROSINE

CAPSULE;ORAL

METYROSINE

AB CEROVENE INC 250MG

A218620 001 Apr 09, 2025 Mar NEWA

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS

MICAFUNGIN SODIUM

AP QILU PHARM HAINAN EQ 50MG BASE/VIAL
 AP EQ 100MG BASE/VIAL

A219273 001 Apr 03, 2025 Mar NEWA
 A219273 002 Apr 03, 2025 Mar NEWA

MIDAZOLAM

SOLUTION;INTRAVENOUS

>A> MIDAZOLAM IN 0.8% SODIUM CHLORIDE
 >A> STERINOVA INC 50MG/50ML (1MG/ML)
 >A> 100MG/100ML (1MG/ML)

A218454 001 May 01, 2025 Apr NFTG
 A218454 002 May 01, 2025 Apr NFTG

MIGLUSTAT

CAPSULE;ORAL

MIGLUSTAT

	@ CHARTWELL RX	100MG	A209325	001	Feb 03, 2022	Mar CAHN
AB	NAVINTA LLC	100MG	A219111	001	Mar 14, 2025	Mar NEWA
	@ VERANOVA	100MG	A209325	001	Feb 03, 2022	Feb CAHN

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

>D>	MILNACIPRAN HYDROCHLORIDE					
>D> AB	HETERO LABS LTD V	12.5MG	A205147	001	Oct 03, 2024	Apr DISC
>A>	@	12.5MG	A205147	001	Oct 03, 2024	Apr DISC
>D> AB		25MG	A205147	002	Oct 03, 2024	Apr DISC
>A>	@	25MG	A205147	002	Oct 03, 2024	Apr DISC
>D> AB		50MG	A205147	003	Oct 03, 2024	Apr DISC
>A>	@	50MG	A205147	003	Oct 03, 2024	Apr DISC
>D> AB		100MG	A205147	004	Oct 03, 2024	Apr DISC
>A>	@	100MG	A205147	004	Oct 03, 2024	Apr DISC
	SAVELLA					
>D> AB	+ ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Apr CTEC
>A>	+	12.5MG	N022256	001	Jan 14, 2009	Apr CTEC
>D> AB	+	25MG	N022256	002	Jan 14, 2009	Apr CTEC
>A>	+	25MG	N022256	002	Jan 14, 2009	Apr CTEC
>D> AB	+!	50MG	N022256	003	Jan 14, 2009	Apr CTEC
>A>	+!	50MG	N022256	003	Jan 14, 2009	Apr CTEC
>D> AB	+	100MG	N022256	004	Jan 14, 2009	Apr CTEC
>A>	+	100MG	N022256	004	Jan 14, 2009	Apr CTEC

MINOCYCLINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EMROSI

	+! JOURNEY	EQ 40MG BASE	N219015	001	Nov 01, 2024	Mar CPOT
	INJECTABLE;INJECTION					
	MINOCYCLINE HYDROCHLORIDE					
AP	NEXUS	EQ 100MG BASE/VIAL	A214934	001	Oct 24, 2024	Mar CAHN

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

>A> AB	SAWAI USA	50MG	A217061	001	May 06, 2025	Apr NEWA
--------	-----------	------	---------	-----	--------------	----------

MIRDAMETINIB

CAPSULE;ORAL

GOMEKLI

	+ SPRINGWORKS	1MG	N219389	001	Feb 11, 2025	Feb NEWA
	+!	2MG	N219389	002	Feb 11, 2025	Feb NEWA
	TABLET, FOR SUSPENSION;ORAL					
	GOMEKLI					
	+! SPRINGWORKS	1MG	N219379	001	Feb 11, 2025	Feb NEWA

MITOMYCIN

INJECTABLE;INJECTION

MITOMYCIN

>D>	@ ACCORD HLTHCARE	20MG/VIAL	A064144	002	Apr 30, 1998	Apr CMFD
>A> AP		20MG/VIAL	A064144	002	Apr 30, 1998	Apr CMFD
	@	20MG/VIAL	A064144	002	Apr 30, 1998	Jan DISC
AP	! MEITHEAL	20MG/VIAL	A214505	002	Sep 08, 2022	Jan CHRS

MODAFINIL

TABLET;ORAL

PROVIGIL

AB	+ NUVO PHARMS	100MG	N020717	001	Dec 24, 1998	Jan CAHN
AB	+!	200MG	N020717	002	Dec 24, 1998	Jan CAHN

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE

	@ APOTEX INC	7.5MG	A078454	001	Jun 02, 2008	Mar DISC
	@	15MG	A078454	002	Jun 02, 2008	Mar DISC

MOMETASONE FUROATE

CREAM; TOPICAL

MOMETASONE FUROATE

@ CHARTWELL MOLECULAR

0.1%

A076591 001 Apr 18, 2007 Feb CAHN

MORPHINE SULFATE

SOLUTION; ORAL

MORPHINE SULFATE

>D>	+	HIKMA	20MG/5ML	N022195	002	Mar 17, 2008	Apr CTEC
>A> AA	+		20MG/5ML	N022195	002	Mar 17, 2008	Apr CTEC
	+		20MG/5ML	N022195	002	Mar 17, 2008	Feb CTEC
>D>	@	NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014	Apr CAHN
>D>	@		20MG/5ML	A201011	002	Feb 05, 2014	Apr CAHN
>D>	@		100MG/5ML	A201011	003	Oct 06, 2016	Apr CAHN
	@	RHODES PHARMS	10MG/5ML	A206308	001	Jun 22, 2017	Jan DISC
	@		20MG/5ML	A206420	001	Jul 12, 2016	Jan DISC
	@		100MG/5ML	A206308	002	Jun 22, 2017	Jan DISC
>A>	@	SANKALP LIFECARE	10MG/5ML	A201011	001	Feb 05, 2014	Apr CAHN
>A>	@		20MG/5ML	A201011	002	Feb 05, 2014	Apr CAHN
>A>	@		100MG/5ML	A201011	003	Oct 06, 2016	Apr CAHN
>D>	@	WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Apr CMFD
>A> AA			10MG/5ML	A211454	001	Feb 12, 2021	Apr CMFD
	@		10MG/5ML	A211454	001	Feb 12, 2021	Feb DISC
>D>	@		20MG/5ML	A211454	002	Feb 12, 2021	Apr CMFD
>A> AA			20MG/5ML	A211454	002	Feb 12, 2021	Apr CMFD
	@		20MG/5ML	A211454	002	Feb 12, 2021	Feb DISC
>D>	@		100MG/5ML	A211454	003	Feb 12, 2021	Apr CMFD
>A> AA			100MG/5ML	A211454	003	Feb 12, 2021	Apr CMFD
	@		100MG/5ML	A211454	003	Feb 12, 2021	Feb DISC

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

@ NOVEL LABS INC

15MG

A203602 001 Dec 16, 2015 Feb DISC

@

30MG

A203602 002 Dec 16, 2015 Feb DISC

@

60MG

A203602 003 Dec 16, 2015 Feb DISC

@

100MG

A203602 004 Dec 16, 2015 Feb DISC

@

200MG

A203602 005 Dec 16, 2015 Feb DISC

MOTIXAFORTIDE ACETATE

POWDER; SUBCUTANEOUS

APHEXDA

+! AYRMID PHARMA EQ 62MG BASE/VIAL

N217159 001 Sep 08, 2023 Mar CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1		MANKIND PHARMA	EQ 0.5% BASE	A217988	001	Jan 27, 2025	Jan NEWA
		@ NORVIUM BIOSCIENCE	EQ 0.5% BASE	A206447	001	Mar 30, 2020	Feb CAHN

MUPIROCIN CALCIUM

CREAM; TOPICAL

MUPIROCIN

BX ALEMBIC EQ 2% BASE

A213053 001 Nov 16, 2021 Mar CTEC

MYCOPHENOLATE MOFETIL

FOR SUSPENSION; ORAL

MYCOPHENOLATE MOFETIL

>D> AB		TEVA PHARMS USA	200MG/ML	A211272	001	Jan 25, 2022	Apr DISC
>A>	@		200MG/ML	A211272	001	Jan 25, 2022	Apr DISC
AB		VISTAPHARM LLC	200MG/ML	A210370	001	Feb 12, 2019	Jan CAHN

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC SODIUM

AB		FOSUN WANBANG	EQ 180MG BASE	A216637	001	May 29, 2024	Jan CAHN
AB			EQ 360MG BASE	A216637	002	May 29, 2024	Jan CAHN

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM

>D>	AP	FRESENIUS	EQ 10GM BASE/VIAL	A206761	001	Jun 02, 2020	Apr DISC
>A>		@	EQ 10GM BASE/VIAL	A206761	001	Jun 02, 2020	Apr DISC

NALBUPHINE HYDROCHLORIDE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
NALBUPHINE

		@ ABRAXIS PHARM	10MG/ML (10MG/ML)	A070751	001	Jul 02, 1986	Mar CPOT
		@	10MG/ML	A070751	001	Jul 02, 1986	Mar CDFR
		@	20MG/ML (20MG/ML)	A070752	001	Sep 24, 1986	Mar CPOT
		@	20MG/ML	A070752	001	Sep 24, 1986	Mar CDFR
		@	200MG/10ML (20MG/ML)	A070752	002	Sep 24, 1986	Mar NEWA
		NALBUPHINE HYDROCHLORIDE					
		@ ABBOTT	20MG/ML (20MG/ML)	A070917	001	Feb 03, 1989	Mar CPOT
		@	20MG/ML	A070917	001	Feb 03, 1989	Mar CDFR
		@ ABRAXIS PHARM	100MG/10ML (10MG/ML)	A070751	002	Jul 02, 1986	Mar NEWA
		@ DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998	Mar CDFR
		@	20MG/ML	A074471	002	Mar 19, 1998	Mar CDFR
		@	100MG/10ML (10MG/ML)	A074471	001	Mar 19, 1998	Mar CPOT
		@	200MG/10ML (20MG/ML)	A074471	002	Mar 19, 1998	Mar CPOT
AP	!	HOSPIRA	10MG/ML (10MG/ML)	A070914	001	Feb 03, 1989	Mar CPOT
AP	!		10MG/ML	A070914	001	Feb 03, 1989	Mar CDFR
AP	!		10MG/ML	A070915	001	Feb 03, 1989	Mar CDFR
AP	!		20MG/ML (20MG/ML)	A070916	001	Feb 03, 1989	Mar CPOT
AP	!		20MG/ML	A070916	001	Feb 03, 1989	Mar CDFR
AP	!		20MG/ML	A070918	001	Feb 03, 1989	Mar CDFR
AP	!		100MG/10ML (10MG/ML)	A070915	001	Feb 03, 1989	Mar CPOT
AP	!		200MG/10ML (20MG/ML)	A070918	001	Feb 03, 1989	Mar CPOT
		@ IGI LABS INC	10MG/ML (10MG/ML)	A072070	001	Apr 10, 1989	Mar CPOT
		@	10MG/ML	A072070	001	Apr 10, 1989	Mar CDFR
		@	10MG/ML (10MG/ML)	A072071	001	Apr 10, 1989	Mar CPOT
		@	10MG/ML	A072071	001	Apr 10, 1989	Mar CDFR
		@	10MG/ML (10MG/ML)	A072072	001	Apr 10, 1989	Mar CPOT
		@	10MG/ML	A072072	001	Apr 10, 1989	Mar CDFR
		@	20MG/ML (20MG/ML)	A072073	001	Apr 10, 1989	Mar CPOT
		@	20MG/ML	A072073	001	Apr 10, 1989	Mar CDFR
		@	20MG/ML (20MG/ML)	A072074	001	Apr 10, 1989	Mar CPOT
		@	20MG/ML	A072074	001	Apr 10, 1989	Mar CDFR
		@	20MG/ML (20MG/ML)	A072075	001	Apr 10, 1989	Mar CPOT
		@	20MG/ML	A072075	001	Apr 10, 1989	Mar CDFR
		@	100MG/10ML (10MG/ML)	A072070	002	Apr 10, 1989	Mar NEWA
		@	200MG/10ML (20MG/ML)	A072073	002	Apr 10, 1989	Mar NEWA
		@ RISING	10MG/ML	A206506	001	Feb 06, 2019	Mar CDFR
		@	10MG/ML (10MG/ML)	A207595	001	Jan 11, 2019	Mar CPOT
		@	10MG/ML	A207595	001	Jan 11, 2019	Mar CDFR
		@	20MG/ML	A206506	002	Feb 06, 2019	Mar CDFR
		@	20MG/ML (20MG/ML)	A207595	002	Jan 11, 2019	Mar CPOT
		@	20MG/ML	A207595	002	Jan 11, 2019	Mar CDFR
		@	100MG/10ML (10MG/ML)	A206506	001	Feb 06, 2019	Mar CPOT
		@	200MG/10ML (20MG/ML)	A206506	002	Feb 06, 2019	Mar CPOT
AP		SOMERSET THERAPS LLC	10MG/ML	A216049	001	Sep 19, 2024	Mar CDFR
AP			10MG/ML (10MG/ML)	A216050	001	Sep 19, 2024	Mar CPOT
AP			10MG/ML	A216050	001	Sep 19, 2024	Mar CDFR
AP			20MG/ML	A216049	002	Sep 19, 2024	Mar CDFR
AP			20MG/ML (20MG/ML)	A216050	002	Sep 19, 2024	Mar CPOT
AP			20MG/ML	A216050	002	Sep 19, 2024	Mar CDFR
AP			100MG/10ML (10MG/ML)	A216049	001	Sep 19, 2024	Mar CPOT
AP			200MG/10ML (20MG/ML)	A216049	002	Sep 19, 2024	Mar CPOT
		NUBAIN					
		+ @ ENDO OPERATIONS	10MG/ML (10MG/ML)	N018024	001		Mar CPOT
		+ @	10MG/ML	N018024	001		Mar CDFR
		+ @	20MG/ML (20MG/ML)	N018024	002	May 27, 1982	Mar CPOT
		+ @	20MG/ML	N018024	002	May 27, 1982	Mar CDFR
		+ @	20MG/2ML (10MG/ML)	N018024	004		Mar NEWA
		+ @	100MG/10ML (10MG/ML)	N018024	003		Mar NEWA
		+ @	200MG/10ML (20MG/ML)	N018024	005	Mar 02, 1984	Mar NEWA

NALMEFENE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
ZURNAI (AUTOINJECTOR)

+ @ PURDUE PHARMA LP	EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	Jan DISC
----------------------	---	---------	-----	--------------	----------

NALOXONE HYDROCHLORIDE

SPRAY;NASAL
KLOXXADO

>D>	+! HIKMA	8MG/SPRAY	N212045	001	Apr 29, 2021	Apr CFTG
>A> AB	+!	8MG/SPRAY	N212045	001	Apr 29, 2021	Apr CFTG
NALOXONE HYDROCHLORIDE						
>A> AB	PADAGIS ISRAEL	8MG/SPRAY	A216719	001	Apr 24, 2025	Apr NFTG

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 2.5MG BASE	A212661	001	Jan 28, 2025	Jan NEWA
AB		EQ 5MG BASE	A212661	002	Jan 28, 2025	Jan NEWA
AB		EQ 10MG BASE	A212661	003	Jan 28, 2025	Jan NEWA
AB		EQ 20MG BASE	A212661	004	Jan 28, 2025	Jan NEWA

NIACIN

TABLET, EXTENDED RELEASE;ORAL
NIACIN

>A> AB	ZYDUS PHARMS	500MG	A203285	001	Apr 28, 2025	Apr NEWA
>A> AB		750MG	A203285	002	Apr 28, 2025	Apr NEWA
>A> AB		1GM	A203285	003	Apr 28, 2025	Apr NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INJECTION
NICARDIPINE HYDROCHLORIDE

@ AMNEAL	25MG/10ML (2.5MG/ML)	A215406	001	Oct 31, 2024	Jan DISC
----------	----------------------	---------	-----	--------------	----------

NILOTINIB D-TARTRATE

CAPSULE;ORAL

NILOTINIB D-TARTRATE

+	CIPLA	EQ 50MG BASE	N218922	001	Feb 19, 2025	Feb NEWA
+		EQ 150MG BASE	N218922	002	Feb 19, 2025	Feb NEWA
+!		EQ 200MG BASE	N218922	003	Feb 19, 2025	Feb NEWA

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

NILOTINIB HYDROCHLORIDE

>D>	@ APOTEX	EQ 50MG BASE	A203640	001	Jan 05, 2024	Apr CMFD
>A> AB		EQ 50MG BASE	A203640	001	Jan 05, 2024	Apr CMFD
>D>	@	EQ 150MG BASE	A203640	002	Jan 05, 2024	Apr CMFD
>A> AB		EQ 150MG BASE	A203640	002	Jan 05, 2024	Apr CMFD
>D>	@	EQ 200MG BASE	A203640	003	Jan 05, 2024	Apr CMFD
>A> AB		EQ 200MG BASE	A203640	003	Jan 05, 2024	Apr CMFD
TASIGNA						
>D>	+ NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr CTEC
>A> AB	+	EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr CTEC
>D>	+	EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr CTEC
>A> AB	+	EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr CTEC
>D>	+!	EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr CTEC
>A> AB	+!	EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr CTEC

NIMODIPINE

SOLUTION;ORAL

NIMODIPINE

AB	ALKEM LABS LTD	6MG/ML	A213409	001	Jan 22, 2025	Jan NFTG
NYMALIZE						
AB	+! AZURITY	6MG/ML	N203340	002	Apr 08, 2020	Jan CFTG

NITAZOXANIDE

TABLET;ORAL

NITAZOXANIDE

>A> AB	ANI PHARMS	500MG	A214844	001	Feb 03, 2025	Apr CAHN
>A> AB	ANNORA PHARMA	500MG	A218701	001	Apr 15, 2025	Apr NEWA
AB	! RISING	500MG	A213820	001	Nov 27, 2020	Jan CTEC

		TABLET;ORAL					
		NITAZOXANIDE					
>D>	AB	ZENARA	500MG	A214844	001	Feb 03, 2025	Apr CAHN
	AB		500MG	A214844	001	Feb 03, 2025	Jan NEWA
		<u>NITRIC OXIDE</u>					
		GAS;INHALATION					
		NOXIVENT					
>D>	!	LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	Apr DISC
>A>	@		100PPM	A207141	001	Oct 02, 2018	Apr DISC
		<u>NITROFURANTOIN</u>					
		SUSPENSION;ORAL					
		NITROFURANTOIN					
	AB	APPCO	25MG/5ML	A208909	001	Jan 14, 2025	Jan NEWA
>D>	AB	NOSTRUM LABS INC	25MG/5ML	A201355	001	Aug 14, 2013	Apr CAHN
>A>	AB	STRIDES PHARMA	25MG/5ML	A201355	001	Aug 14, 2013	Apr CAHN
		<u>NITROGLYCERIN</u>					
		OINTMENT;TRANSDERMAL					
		NITROGLYCERIN					
>A>	AB	ENCUBE	2%	A218235	001	Apr 15, 2025	Apr NFTG
>D>	+	FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988	Apr CFTG
>A>	AB	+	2%	A087355	001	Jul 08, 1988	Apr CFTG
		<u>NOREPINEPHRINE BITARTRATE</u>					
		INJECTABLE;INJECTION					
		NOREPINEPHRINE BITARTRATE					
AP	ASPIRO	EQ 1MG BASE/ML		A219163	001	Jan 31, 2025	Jan NEWA
AP	BIOCON PHARMA	EQ 1MG BASE/ML		A219443	001	Mar 21, 2025	Mar NEWA
		<u>NYSTATIN</u>					
		CREAM;TOPICAL					
		NYSTATIN					
AT	AUROBINDO PHARMA	100,000 UNITS/GM		A219527	001	Mar 21, 2025	Mar NEWA
>A>	@	CHARTWELL RX	100,000 UNITS/GM	A065315	001	May 31, 2006	Apr CAHN
>D>	@	STRIDES PHARMA	100,000 UNITS/GM	A065315	001	May 31, 2006	Apr CAHN
		SUSPENSION;ORAL					
		NYSTATIN					
AA	XTTRIUM LABS INC	100,000 UNITS/ML		A062512	001	Oct 29, 1984	Jan CAHN
		<u>NYSTATIN; TRIAMCINOLONE ACETONIDE</u>					
		CREAM;TOPICAL					
		NYSTATIN AND TRIAMCINOLONE ACETONIDE					
>A>	AT	CHARTWELL RX	100,000 UNITS/GM;0.1%	A208326	001	Oct 26, 2016	Apr CAHN
>D>	AT	DR REDDYS	100,000 UNITS/GM;0.1%	A208326	001	Oct 26, 2016	Apr CAHN
		<u>OFLOXACIN</u>					
		SOLUTION/DROPS;OPHTHALMIC					
		OFLOXACIN					
	@	AMNEAL	0.3%	A211524	001	Mar 01, 2024	Feb DISC
		<u>OLICERIDINE</u>					
		SOLUTION;INTRAVENOUS					
		OLINVYK					
	+	@ TREVENA	1MG/ML (1MG/ML)	N210730	001	Oct 30, 2020	Jan DISC
	+	@	2MG/2ML (1MG/ML)	N210730	002	Oct 30, 2020	Jan DISC
		<u>OLMESARTAN MEDOXOMIL</u>					
		TABLET;ORAL					
		OLMESARTAN MEDOXOMIL					
AB	JUBILANT GENERICS	5MG		A205482	001	Apr 24, 2017	Mar CMFD
AB		20MG		A205482	002	Apr 24, 2017	Mar CMFD
AB		40MG		A205482	003	Apr 24, 2017	Mar CMFD
		<u>OMAVELOXOLONE</u>					
		CAPSULE;ORAL					
		SKYCLARYS					
	+	BIOGEN US	50MG	N216718	001	Feb 28, 2023	Jan CAHN

OMEGA-3-ACID ETHYL ESTERSCAPSULE;ORAL
LOVAZA

AB	+!	WAYLIS THERAP	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Feb CAHN
----	----	---------------	--	---------	-----	--------------	----------

ONDANSETRONTABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

@	NORVIUM BIOSCIENCE	4MG	A078139	001	Jun 25, 2007	Feb CAHN
@		8MG	A078139	002	Jun 25, 2007	Feb CAHN

ONDANSETRON HYDROCHLORIDEINJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

@	HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076781	001	Dec 26, 2006	Mar DISC
---	--------------------	----------------	---------	-----	--------------	----------

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

@	APOTEX	EQ 4MG BASE	A077306	001	Jun 25, 2007	Mar DISC
@		EQ 8MG BASE	A077306	002	Jun 25, 2007	Mar DISC

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB		ZHEJIANG POLY PHARM	EQ 75MG BASE	A218009	001	Nov 24, 2023	Mar CAHN
----	--	---------------------	--------------	---------	-----	--------------	----------

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB		JUBILANT GENERICS	EQ 6MG BASE/ML	A213695	001	Mar 03, 2025	Feb NEWA
----	--	-------------------	----------------	---------	-----	--------------	----------

OSPEMIFENE

TABLET;ORAL

OSPEMIFENE

>D>	AB	HETERO LABS LTD V	60MG	A215574	001	Feb 13, 2024	Apr DISC
-----	----	-------------------	------	---------	-----	--------------	----------

>A>		@	60MG	A215574	001	Feb 13, 2024	Apr DISC
-----	--	---	------	---------	-----	--------------	----------

OSPHEANA

>D>	AB	+!	DUCHESNAY	60MG	N203505	001	Feb 26, 2013	Apr CTEC
-----	----	----	-----------	------	---------	-----	--------------	----------

>A>		+!		60MG	N203505	001	Feb 26, 2013	Apr CTEC
-----	--	----	--	------	---------	-----	--------------	----------

OXALIPLATIN

INJECTABLE;INTRAVENOUS

OXALIPLATIN

AP		HETERO LABS LTD VI	50MG/10ML (5MG/ML)	A217925	001	Jan 27, 2025	Jan NEWA
----	--	--------------------	--------------------	---------	-----	--------------	----------

AP			100MG/20ML (5MG/ML)	A217925	002	Jan 27, 2025	Jan NEWA
----	--	--	---------------------	---------	-----	--------------	----------

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AB		LEADING	10MG	A218261	001	Mar 03, 2025	Feb NEWA
----	--	---------	------	---------	-----	--------------	----------

AB			15MG	A218261	002	Mar 03, 2025	Feb NEWA
----	--	--	------	---------	-----	--------------	----------

AB			30MG	A218261	003	Mar 03, 2025	Feb NEWA
----	--	--	------	---------	-----	--------------	----------

OXCARBAZEPINE

TABLET, EXTENDED RELEASE;ORAL

OXCARBAZEPINE

>D>		@	AJANTA PHARMA LTD	150MG	A217659	001	Feb 22, 2024	Apr CMFD
-----	--	---	-------------------	-------	---------	-----	--------------	----------

>A>	AB			150MG	A217659	001	Feb 22, 2024	Apr CMFD
-----	----	--	--	-------	---------	-----	--------------	----------

>D>		@		300MG	A217659	002	Feb 22, 2024	Apr CMFD
-----	--	---	--	-------	---------	-----	--------------	----------

>A>	AB			300MG	A217659	002	Feb 22, 2024	Apr CMFD
-----	----	--	--	-------	---------	-----	--------------	----------

>D>		@		600MG	A217659	003	Feb 22, 2024	Apr CMFD
-----	--	---	--	-------	---------	-----	--------------	----------

>A>	AB			600MG	A217659	003	Feb 22, 2024	Apr CMFD
-----	----	--	--	-------	---------	-----	--------------	----------

>A>	AB		AUROBINDO PHARMA LTD	150MG	A219241	001	Apr 30, 2025	Apr NEWA
-----	----	--	----------------------	-------	---------	-----	--------------	----------

>A>	AB			300MG	A219241	002	Apr 30, 2025	Apr NEWA
-----	----	--	--	-------	---------	-----	--------------	----------

>A>	AB			600MG	A219241	003	Apr 30, 2025	Apr NEWA
-----	----	--	--	-------	---------	-----	--------------	----------

>D>		@	RICONPHARMA LLC	150MG	A215796	001	Nov 22, 2024	Apr CMFD
-----	--	---	-----------------	-------	---------	-----	--------------	----------

>A>	AB			150MG	A215796	001	Nov 22, 2024	Apr CMFD
-----	----	--	--	-------	---------	-----	--------------	----------

>D>		@		300MG	A215796	002	Nov 22, 2024	Apr CMFD
-----	--	---	--	-------	---------	-----	--------------	----------

>A>	AB			300MG	A215796	002	Nov 22, 2024	Apr CMFD
-----	----	--	--	-------	---------	-----	--------------	----------

>D>		@		600MG	A215796	003	Nov 22, 2024	Apr CMFD
-----	--	---	--	-------	---------	-----	--------------	----------

>A>	AB			600MG	A215796	003	Nov 22, 2024	Apr CMFD
-----	----	--	--	-------	---------	-----	--------------	----------

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

>D> AA	PHARM ASSOC	100MG/5ML	A206822	001	Aug 15, 2017	Apr	DISC
>A>	@	100MG/5ML	A206822	001	Aug 15, 2017	Apr	DISC
	@ VISTAPHARM LLC	100MG/5ML	A202537	001	Jul 30, 2012	Jan	CAHN

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

@ NOVEL LABS INC	5MG	A204021	001	Jun 12, 2017	Feb	DISC
@	10MG	A204021	002	Jun 12, 2017	Feb	DISC
@	15MG	A204021	003	Jun 12, 2017	Feb	DISC
@	20MG	A204021	004	Jun 12, 2017	Feb	DISC
@	30MG	A204021	005	Jun 12, 2017	Feb	DISC

PACLITAXEL

POWDER; INTRAVENOUS

PACLITAXEL

AB	CIPLA	100MG/VIAL	A209657	001	Apr 10, 2025	Mar	NEWA
----	-------	------------	---------	-----	--------------	-----	------

PALBOCICLIB

TABLET; ORAL

PALBOCICLIB

>D>	@ SYNTHON PHARMS INC	75MG	A215570	001	Jun 05, 2024	Apr	CAHN
>D>	@	100MG	A215570	002	Jun 05, 2024	Apr	CAHN
>D>	@	125MG	A215570	003	Jun 05, 2024	Apr	CAHN
>A>	@ ZYDUS LIFESCIENCES	75MG	A215570	001	Jun 05, 2024	Apr	CAHN
>A>	@	100MG	A215570	002	Jun 05, 2024	Apr	CAHN
>A>	@	125MG	A215570	003	Jun 05, 2024	Apr	CAHN

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

PALIPERIDONE

AB	DR REDDYS	3MG	A205559	001	Feb 19, 2025	Feb	NEWA
AB		6MG	A205559	002	Feb 19, 2025	Feb	NEWA
AB		9MG	A205559	003	Feb 19, 2025	Feb	NEWA

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	AUROBINDO PHARMA LTD	EQ 40MG BASE	A217923	001	Mar 31, 2025	Mar	NEWA
AB	CIPLA	EQ 40MG BASE	A217458	001	Mar 31, 2025	Mar	NEWA

INJECTABLE; INTRAVENOUS

PANTOPRAZOLE SODIUM

AP	ALEMBIC	EQ 40MG BASE/VIAL	A219230	001	Mar 31, 2025	Mar	NEWA
----	---------	-------------------	---------	-----	--------------	-----	------

POWDER; INTRAVENOUS

PANTOPRAZOLE SODIUM

@ FRESENIUS KABI USA	EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	Feb	DISC
+! HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Feb	CTEC

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	GRAVITI PHARMS	EQ 20MG BASE	A219087	001	Jan 16, 2025	Jan	NEWA
AB		EQ 40MG BASE	A219087	002	Jan 16, 2025	Jan	NEWA
	@ INGENUS PHARMS LLC	EQ 40MG BASE	A211368	001	Mar 01, 2019	Jan	DISC

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

>A> AB	CHARTWELL RX	1MCG	A091412	001	Jun 24, 2014	Apr	CAHN
>A> AB		2MCG	A091412	002	Jun 24, 2014	Apr	CAHN
>A> AB		4MCG	A091412	003	Jun 24, 2014	Apr	CAHN
>D> AB	DR REDDYS	1MCG	A091412	001	Jun 24, 2014	Apr	CAHN
>D> AB		2MCG	A091412	002	Jun 24, 2014	Apr	CAHN
>D> AB		4MCG	A091412	003	Jun 24, 2014	Apr	CAHN

SOLUTION; INTRAVENOUS

PARICALCITOL

>A> AP	CAPLIN	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Apr	CAHN
>A> AP		0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Apr	CAHN
>A> AP		0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Apr	CAHN
>D> AP	DR REDDYS	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Apr	CAHN
>D> AP		0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Apr	CAHN
>D> AP		0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Apr	CAHN

PENCICLOVIRCREAM; TOPICAL
PENCICLOVIR

BX	TORRENT	1%	A216981	001	Aug 07, 2023	Mar CTEC
----	---------	----	---------	-----	--------------	----------

PERPHENAZINETABLET; ORAL
PERPHENAZINE

AB	JUBILANT GENERICS	2MG	A213694	001	Mar 18, 2025	Mar NEWA
AB		4MG	A213694	002	Mar 18, 2025	Mar NEWA
AB		8MG	A213694	003	Mar 18, 2025	Mar NEWA
AB		16MG	A213694	004	Mar 18, 2025	Mar NEWA

PHENDIMETRAZINE TARTRATETABLET; ORAL
BONTRIL PDM

AA	+! BAUSCH	35MG	A085272	001		Mar CAHN
----	-----------	------	---------	-----	--	----------

PHENYLEPHRINE HYDROCHLORIDESOLUTION; INTRAVENOUS
BIORPHEN

AP	+! DR REDDYS LABS SA	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019	Feb CFTG
AP	SOMERSET THERAPS LLC	0.5MG/5ML (0.1MG/ML)	A215617	001	Feb 14, 2025	Feb NFTG

PHENYTOINSUSPENSION; ORAL
PHENYTOIN

@ VISTAPHARM LLC	125MG/5ML	A040342	001	Jan 31, 2001	Jan CAHN
@	125MG/5ML	A040342	002	Aug 18, 2005	Jan CAHN

PHYTONADIONEINJECTABLE; INJECTION
PHYTONADIONE

>A> AB1	CAPLIN	10MG/ML	A219212	001	Apr 17, 2025	Apr NEWA
	TABLET; ORAL PHYTONADIONE					
	@ HIKMA	5MG	A212112	001	Dec 19, 2024	Feb DISC

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

>A>	PILOCARPINE HYDROCHLORIDE					
>A> AB	AMNEAL	1.25%	A217733	001	Apr 28, 2025	Apr NFTG
	VUITY					
>D>	+! ABBVIE	1.25%	N214028	001	Oct 28, 2021	Apr CFTG
>A> AB	+!	1.25%	N214028	001	Oct 28, 2021	Apr CFTG

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

POWDER; INTRAVENOUS

>A>	PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER					
>A>	+! B BRAUN MEDICAL INC	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	N206056	001	Apr 03, 2025	Apr NEWA
>A>	+!	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	N206056	002	Apr 03, 2025	Apr NEWA
>A>	+!	EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	N206056	003	Apr 03, 2025	Apr NEWA

PIROXICAMCAPSULE; ORAL
PIROXICAM

>D> AB	NOSTRUM LABS INC	10MG	A074118	002	Jun 15, 1993	Apr CAHN
>D> AB		20MG	A074118	001	Jun 15, 1993	Apr CAHN
>A> AB	SOLIS PHARMS	10MG	A074118	002	Jun 15, 1993	Apr CAHN
>A> AB		20MG	A074118	001	Jun 15, 1993	Apr CAHN

PITOLISANT HYDROCHLORIDETABLET; ORAL
WAKIX

+	HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Feb CAHN
+		EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Feb CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

>D>	@ NOSTRUM LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A202060	001	Mar 08, 2017	Apr CAHN
>A>	@ SOLIS PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A202060	001	Mar 08, 2017	Apr CAHN

POMALIDOMIDE

CAPSULE;ORAL

POMALIDOMIDE

	@ APOTEX	1MG	A210164	001	Jun 11, 2024	Jan DISC
	@	2MG	A210164	002	Jun 11, 2024	Jan DISC
	@	3MG	A210164	003	Jun 11, 2024	Jan DISC
	@	4MG	A210164	004	Jun 11, 2024	Jan DISC
>D> AB	HETERO LABS LTD V	1MG	A210236	001	Sep 26, 2024	Apr DISC
>A>	@	1MG	A210236	001	Sep 26, 2024	Apr DISC
>D> AB		2MG	A210236	002	Sep 26, 2024	Apr DISC
>A>	@	2MG	A210236	002	Sep 26, 2024	Apr DISC
>D> AB		3MG	A210236	003	Sep 26, 2024	Apr DISC
>A>	@	3MG	A210236	003	Sep 26, 2024	Apr DISC
>D> AB		4MG	A210236	004	Sep 26, 2024	Apr DISC
>A>	@	4MG	A210236	004	Sep 26, 2024	Apr DISC
	POMALYST					
>D> AB	+ BRISTOL	1MG	N204026	001	Feb 08, 2013	Apr CTEC
>A>	+	1MG	N204026	001	Feb 08, 2013	Apr CTEC
>D> AB	+	2MG	N204026	002	Feb 08, 2013	Apr CTEC
>A>	+	2MG	N204026	002	Feb 08, 2013	Apr CTEC
>D> AB	+	3MG	N204026	003	Feb 08, 2013	Apr CTEC
>A>	+	3MG	N204026	003	Feb 08, 2013	Apr CTEC
>D> AB	+!	4MG	N204026	004	Feb 08, 2013	Apr CTEC
>A>	+!	4MG	N204026	004	Feb 08, 2013	Apr CTEC

POSACONAZOLE

TABLET, DELAYED RELEASE;ORAL

POSACONAZOLE

AB	MSN	100MG	A218434	001	Feb 24, 2025	Feb NEWA
>A> AB	QILU PHARM HAINAN	100MG	A217720	001	Apr 23, 2025	Apr NEWA

POTASSIUM CHLORIDE

FOR SOLUTION;ORAL

POTASSIUM CHLORIDE

AA	AJENAT PHARMS	20MEQ	A212183	001	May 06, 2019	Jan CAHN
AA	+! GENUS	20MEQ	N208019	001	Aug 19, 2015	Jan CHRS
	+ @	40MEQ	N208019	003	Aug 25, 2023	Jan DISC

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

AP	NEXUS	2MEQ/ML	A217704	001	Aug 14, 2023	Mar CAHN
----	-------	---------	---------	-----	--------------	----------

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA	AJENAT PHARMS	20MEQ/15ML	A216156	001	Mar 07, 2023	Jan CAHN
AA		40MEQ/15ML	A216156	002	Mar 07, 2023	Jan CAHN
AA	ASCENT PHARMS INC	20MEQ/15ML	A211992	001	Apr 09, 2025	Mar NEWA
AA		40MEQ/15ML	A211992	002	Apr 09, 2025	Mar NEWA

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

>D> AB1	GUANGZHOU NOVAKEN	10MEQ	A214395	001	Jan 28, 2021	Apr CAHN
>A> AB1		10MEQ	A214395	001	Jan 28, 2021	Apr CAHN
>D> AB1		20MEQ	A214395	002	Jan 28, 2021	Apr CAHN
>A> AB1		20MEQ	A214395	002	Jan 28, 2021	Apr CAHN

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS

POTASSIUM PHOSPHATES

AP	CIPLA	1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)	A217892	001	Jan 24, 2025	Jan NEWA
AP		3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)	A217892	002	Jan 24, 2025	Jan NEWA
AP		11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML)	A217892	003	Jan 24, 2025	Jan NEWA

PRALATREXATESOLUTION; INTRAVENOUS
FOLOTYN

AP	+	ACROTECH BIOPHARMA	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Feb CFTG
AP	+	!	40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Feb CFTG
PRALATREXATE							
AP		DR REDDYS	20MG/ML (20MG/ML)	A206183	001	Mar 10, 2025	Feb NFTG
AP			40MG/2ML (20MG/ML)	A206183	002	Mar 10, 2025	Feb NFTG

PREDNISONETABLET; ORAL
PREDNISONE

		@ AIPING PHARM INC	5MG	A080336	002		Jan CAHN
>D>	AB	ALLIED	5MG	A212629	001	Dec 05, 2023	Apr CAHN
>D>	AB		10MG	A212629	002	Dec 05, 2023	Apr CAHN
>D>	AB		20MG	A212629	003	Dec 05, 2023	Apr CAHN
>A>	AB	+	1MG	A080352	002	Apr 22, 1982	Apr CMS1
>A>	AB	+	2.5MG	A080352	003	Apr 22, 1982	Apr CMS1
>A>	AB	+	10MG	A080352	004		Apr CMS1
>A>	AB	+	20MG	A080352	005		Apr CMS1
>A>	AB	+	50MG	A080352	006		Apr CMS1
>A>	AB	POINTVIEW HLDINGS	5MG	A212629	001	Dec 05, 2023	Apr CAHN
>A>	AB		10MG	A212629	002	Dec 05, 2023	Apr CAHN
>A>	AB		20MG	A212629	003	Dec 05, 2023	Apr CAHN

PREGABALINCAPSULE; ORAL
PREGABALIN

>D>	AB	ACTAVIS ELIZABETH	25MG	A091025	001	Jul 09, 2020	Apr DISC
>A>		@	25MG	A091025	001	Jul 09, 2020	Apr DISC
>D>	AB		50MG	A091025	002	Jul 09, 2020	Apr DISC
>A>		@	50MG	A091025	002	Jul 09, 2020	Apr DISC
>D>	AB		75MG	A091025	003	Jul 09, 2020	Apr DISC
>A>		@	75MG	A091025	003	Jul 09, 2020	Apr DISC
>D>	AB		100MG	A091025	004	Jul 09, 2020	Apr DISC
>A>		@	100MG	A091025	004	Jul 09, 2020	Apr DISC
>D>	AB		150MG	A091025	005	Jul 09, 2020	Apr DISC
>A>		@	150MG	A091025	005	Jul 09, 2020	Apr DISC
>D>	AB		200MG	A091025	006	Jul 09, 2020	Apr DISC
>A>		@	200MG	A091025	006	Jul 09, 2020	Apr DISC
>D>	AB		225MG	A091025	007	Jul 09, 2020	Apr DISC
>A>		@	225MG	A091025	007	Jul 09, 2020	Apr DISC
>D>	AB		300MG	A091025	008	Jul 09, 2020	Apr DISC
>A>		@	300MG	A091025	008	Jul 09, 2020	Apr DISC
>D>	AB	APOTEX	25MG	A211685	001	Jul 07, 2021	Apr DISC
>A>		@	25MG	A211685	001	Jul 07, 2021	Apr DISC
>D>	AB		50MG	A211685	002	Jul 07, 2021	Apr DISC
>A>		@	50MG	A211685	002	Jul 07, 2021	Apr DISC
>D>	AB		75MG	A211685	003	Jul 07, 2021	Apr DISC
>A>		@	75MG	A211685	003	Jul 07, 2021	Apr DISC
>D>	AB		100MG	A211685	004	Jul 07, 2021	Apr DISC
>A>		@	100MG	A211685	004	Jul 07, 2021	Apr DISC
>D>	AB		150MG	A211685	005	Jul 07, 2021	Apr DISC
>A>		@	150MG	A211685	005	Jul 07, 2021	Apr DISC
>D>	AB		200MG	A211685	006	Jul 07, 2021	Apr DISC
>A>		@	200MG	A211685	006	Jul 07, 2021	Apr DISC
>D>	AB		225MG	A211685	007	Jul 07, 2021	Apr DISC
>A>		@	225MG	A211685	007	Jul 07, 2021	Apr DISC
>D>	AB		300MG	A211685	008	Jul 07, 2021	Apr DISC
>A>		@	300MG	A211685	008	Jul 07, 2021	Apr DISC
	AB	HLTHCARE	25MG	A091222	001	Feb 21, 2025	Feb NEWA
	AB		50MG	A091222	002	Feb 21, 2025	Feb NEWA
	AB		75MG	A091222	003	Feb 21, 2025	Feb NEWA
	AB		100MG	A091222	004	Feb 21, 2025	Feb NEWA
	AB		150MG	A091222	005	Feb 21, 2025	Feb NEWA
	AB		200MG	A091222	006	Feb 21, 2025	Feb NEWA
	AB		225MG	A091222	007	Feb 21, 2025	Feb NEWA
	AB		300MG	A091222	008	Feb 21, 2025	Feb NEWA
	AB	TORRENT	25MG	A206942	001	Feb 21, 2025	Feb NEWA
	AB		50MG	A206942	002	Feb 21, 2025	Feb NEWA
	AB		75MG	A206942	003	Feb 21, 2025	Feb NEWA
	AB		100MG	A206942	004	Feb 21, 2025	Feb NEWA

CAPSULE;ORAL
PREGABALIN

AB		150MG	A206942	005	Feb 21, 2025	Feb NEWA
AB		200MG	A206942	006	Feb 21, 2025	Feb NEWA
AB		225MG	A206942	007	Feb 21, 2025	Feb NEWA
AB		300MG	A206942	008	Feb 21, 2025	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL
PREGABALIN

	@ ALVOGEN	82.5MG	A211593	001	Apr 13, 2021	Feb DISC
	@	165MG	A211593	002	Apr 13, 2021	Feb DISC
	@	330MG	A211593	003	Apr 13, 2021	Feb DISC
	@ APOTEX	165MG	A213313	001	Apr 13, 2021	Jan DISC
	@	330MG	A213313	002	Apr 13, 2021	Jan DISC
AB	HQ PHARMA	330MG	A217857	001	Jan 28, 2025	Jan NEWA

PRIMIDONETABLET;ORAL
PRIMIDONE

>A>	@ CHARTWELL RX	50MG	A040862	001	Oct 03, 2008	Apr CAHN
>A>	@	250MG	A040862	002	Oct 03, 2008	Apr CAHN
>D>	@ DR REDDYS LABS LTD	50MG	A040862	001	Oct 03, 2008	Apr CAHN
>D>	@	250MG	A040862	002	Oct 03, 2008	Apr CAHN

>D> PROBENECID; SULOPENEM ETZADROXIL>D> TABLET;ORAL
>D> ORLYNVAH

>D>	+! ITERUM THERAP	500MG;500MG	N213972	001	Oct 25, 2024	Apr DISC
>A>	+ @	500MG;500MG	N213972	001	Oct 25, 2024	Apr DISC

PROCAINAMIDE HYDROCHLORIDEINJECTABLE;INJECTION
PROCAINAMIDE HYDROCHLORIDE

AP	CAPLIN	100MG/ML	A218674	001	Feb 04, 2025	Jan NEWA
AP		500MG/ML	A218674	002	Feb 04, 2025	Jan NEWA

PROCHLORPERAZINESUPPOSITORY;RECTAL
COMPAZINE

	+ @ GLAXOSMITHKLINE	2.5MG	N011127	003		Mar CRLD
	+ @	5MG	N011127	001		Mar CMS1
	+ @	5MG	N011127	001		Mar CRLD
	+ @	25MG	N011127	002		Mar CMS1
	+ @	25MG	N011127	002		Mar CRLD

PROCHLORPERAZINE EDISYLATEINJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

>D> AP	NEXUS	EQ 5MG BASE/ML	A204860	001	Feb 15, 2019	Apr DISC
>A>	@	EQ 5MG BASE/ML	A204860	001	Feb 15, 2019	Apr DISC

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

>D> AA	NOSTRUM LABS INC	6.25MG/5ML	A040891	001	Mar 13, 2009	Apr CAHN
>A> AA	STRIDES PHARMA	6.25MG/5ML	A040891	001	Mar 13, 2009	Apr CAHN
	PROMETHAZINE PLAIN					
AA	+! XTTRIUM LABS INC	6.25MG/5ML	A087953	001	Nov 15, 1982	Feb CAHN

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

PROTRIPTYLINE HYDROCHLORIDE

>D> AB	EPIC PHARMA LLC	10MG	A202220	002	Nov 19, 2012	Apr CHRS
>A> AB	!	10MG	A202220	002	Nov 19, 2012	Apr CHRS
>D> AB	HIKMA	5MG	A078913	001	Sep 16, 2008	Apr DISC
>A>	@	5MG	A078913	001	Sep 16, 2008	Apr DISC
>D> AB	!	10MG	A078913	002	Sep 16, 2008	Apr DISC
>A>	@	10MG	A078913	002	Sep 16, 2008	Apr DISC

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB	GRAVITI PHARMS	EQ 25MG BASE	A077380	001	Mar 27, 2012	Feb CAHN
AB		EQ 50MG BASE	A077380	002	Mar 27, 2012	Feb CAHN
AB		EQ 100MG BASE	A077380	003	Mar 27, 2012	Feb CAHN
AB		EQ 150MG BASE	A077380	004	Mar 27, 2012	Feb CAHN
AB		EQ 200MG BASE	A077380	005	Mar 27, 2012	Feb CAHN
AB		EQ 300MG BASE	A077380	006	Mar 27, 2012	Feb CAHN
AB		EQ 400MG BASE	A077380	007	Mar 27, 2012	Feb CAHN

SEROQUEL

AB	+! CHEPLAPHARM	EQ 25MG BASE	N020639	001	Sep 26, 1997	Mar CAHN
AB	+	EQ 50MG BASE	N020639	007	Oct 04, 2005	Mar CAHN
AB	+	EQ 100MG BASE	N020639	002	Sep 26, 1997	Mar CAHN
	+ @	EQ 150MG BASE	N020639	004	Dec 20, 1998	Mar CAHN
AB	+	EQ 200MG BASE	N020639	003	Sep 26, 1997	Mar CAHN
AB	+!	EQ 300MG BASE	N020639	005	Jul 26, 2000	Mar CAHN
AB	+	EQ 400MG BASE	N020639	006	Oct 04, 2005	Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

QUETIAPINE FUMARATE

AB	MEDICAP LABS	EQ 50MG BASE	A202939	001	May 09, 2017	Feb CAHN
AB		EQ 150MG BASE	A202939	002	May 09, 2017	Feb CAHN
AB		EQ 200MG BASE	A202939	003	May 09, 2017	Feb CAHN
AB		EQ 300MG BASE	A202939	004	May 09, 2017	Feb CAHN
AB		EQ 400MG BASE	A202939	005	May 09, 2017	Feb CAHN

SEROQUEL XR

AB	+ CHEPLAPHARM	EQ 50MG BASE	N022047	001	May 17, 2007	Mar CAHN
AB	+	EQ 150MG BASE	N022047	005	Aug 11, 2008	Mar CAHN
AB	+!	EQ 200MG BASE	N022047	002	May 17, 2007	Mar CAHN
AB	+	EQ 300MG BASE	N022047	003	May 17, 2007	Mar CAHN
AB	+	EQ 400MG BASE	N022047	004	May 17, 2007	Mar CAHN

RALTEGRAVIR POTASSIUM

TABLET; ORAL

ISENTRESS

	+! MSD SUB MERCK	EQ 400MG BASE	N022145	001	Oct 12, 2007	Jan CTEC
	ISENTRESS HD					
>D>	+! MSD SUB MERCK	EQ 600MG BASE	N022145	002	May 26, 2017	Apr CFTG
>A> AB	+!	EQ 600MG BASE	N022145	002	May 26, 2017	Apr CFTG

RALTEGRAVIR POTASSIUM

	@ HETERO LABS LTD III	EQ 400MG BASE	A203540	001	Dec 19, 2024	Jan DISC
>A> AB	LUPIN LTD	EQ 600MG BASE	A217990	001	May 06, 2025	Apr NFTG

RAMELTEON

TABLET; ORAL

RAMELTEON

AB	APPCO	8MG	A213815	001	Oct 26, 2020	Mar CAHN
BX	AUROBINDO PHARMA LTD	8MG	A215972	001	Jul 10, 2023	Mar CTEC
BX	I3 PHARMS	8MG	A212650	001	Apr 10, 2020	Mar CTEC
BX	XIROMED	8MG	A216209	001	Nov 25, 2022	Mar CTEC

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

	@ APOTEX	EQ 150MG BASE	A074680	001	Sep 12, 1997	Mar DISC
	@	EQ 300MG BASE	A074680	002	Sep 12, 1997	Mar DISC

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANOLAZINE

AB	ARTHUR GRP	500MG	A212781	001	Mar 23, 2020	Jan CAHN
AB		1GM	A212781	002	Mar 23, 2020	Jan CAHN
AB	! CADILA	1GM	A210188	002	Aug 19, 2019	Mar CHRS
>A> AB	JUBILANT GENERICS	500MG	A211361	001	Apr 15, 2025	Apr NEWA
>A> AB		1GM	A211361	002	Apr 15, 2025	Apr NEWA
	@ SUN PHARM	500MG	A211707	001	May 28, 2019	Mar DISC
	@	1GM	A211707	002	May 28, 2019	Mar DISC
AB	TORRENT	500MG	A210407	001	Feb 04, 2025	Jan NEWA
AB		1GM	A210407	002	Feb 04, 2025	Jan NEWA

RASAGILINE MESYLATE

TABLET; ORAL

RASAGILINE MESYLATE

>A>	@	CARNEGIE	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Apr CAHN
>A>	@		EQ 1MG BASE	A201942	002	Nov 18, 2021	Apr CAHN
>D>	@	RYAN LABS	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Apr CAHN
>D>	@		EQ 1MG BASE	A201942	002	Nov 18, 2021	Apr CAHN
>A> AB		TORRENT	EQ 0.5MG BASE	A210150	001	May 05, 2025	Apr NEWA
>A> AB			EQ 1MG BASE	A210150	002	May 05, 2025	Apr NEWA

REGORAFENIB

TABLET; ORAL

REGORAFENIB

AB		ACTAVIS LABS FL	40MG	A209728	001	Jan 13, 2025	Jan NFTG
		STIVARGA					
AB	+	BAYER HLTHCARE	40MG	N203085	001	Sep 27, 2012	Jan CFTG

REPAGLINIDE

TABLET; ORAL

REPAGLINIDE

@	SUN PHARM INDS INC	1MG	A077571	002	Jul 11, 2013	Feb DISC
@		2MG	A077571	003	Jul 11, 2013	Feb DISC

RIFAMPIN

CAPSULE; ORAL

RIFADIN

>A>	+	@	SANOFI AVENTIS US	150MG	N050420	002	Apr CMS1
-----	---	---	-------------------	-------	---------	-----	----------

RILUZOLE

TABLET; ORAL

RILUZOLE

AB		NORVIUM BIOSCIENCE	50MG	A203042	001	Jul 01, 2013	Feb CAHN
----	--	--------------------	------	---------	-----	--------------	----------

RISDIPLAM

TABLET; ORAL

EVRYSDI

+	!	GENENTECH INC	5MG	N219285	001	Feb 11, 2025	Feb NEWA
---	---	---------------	-----	---------	-----	--------------	----------

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE; ORAL

RISEDRONATE SODIUM

>D> AB		SUN PHARM	35MG	A203925	001	Jul 09, 2019	Apr DISC
>A>	@		35MG	A203925	001	Jul 09, 2019	Apr DISC

RISPERIDONE

SOLUTION; ORAL

RISPERIDONE

>A>	@	APOZEAL PHARMS	1MG/ML	A078909	001	Jul 29, 2009	Apr CAHN
	@	LANNETT CO INC	1MG/ML	A079158	001	Dec 03, 2010	Feb DISC
>D>	@	SCIEGEN PHARMS INC	1MG/ML	A078909	001	Jul 29, 2009	Apr CAHN

TABLET; ORAL

RISPERIDONE

@	APOTEX INC	0.25MG	A077953	001	Sep 15, 2008	Mar DISC
@		0.5MG	A077953	002	Sep 15, 2008	Mar DISC
@		1MG	A077953	003	Sep 15, 2008	Mar DISC
@		2MG	A077953	004	Sep 15, 2008	Mar DISC
@		3MG	A077953	005	Sep 15, 2008	Mar DISC
@		4MG	A077953	006	Sep 15, 2008	Mar DISC

RIVAROXABAN

TABLET; ORAL

RIVAROXABAN

>A> AB		APOTEX	2.5MG	A217810	001	May 02, 2025	Apr NEWA
>A> AB		AUROBINDO PHARMA LTD	2.5MG	A208544	001	Apr 10, 2025	Apr NEWA
AB		LUPIN LTD	2.5MG	A208555	001	Mar 03, 2025	Feb NFTG
AB		TARO	2.5MG	A208557	001	Mar 03, 2025	Feb NFTG
		XARELTO					
AB	+	JANSSSEN PHARMS	2.5MG	N022406	004	Oct 11, 2018	Feb CFTG

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINE

@ ALVOGEN	4.6MG/24HR	A204403	001	Sep 03, 2015	Mar DISC
@	9.5MG/24HR	A204403	002	Sep 03, 2015	Mar DISC
@	13.3MG/24HR	A204403	003	Aug 31, 2015	Mar DISC

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB	NORVIUM BIOSCIENCE	EQ 5MG BASE	A201993	001	Dec 31, 2012	Feb CAHN
AB		EQ 10MG BASE	A201993	002	Dec 31, 2012	Feb CAHN

ROFLUMILAST

TABLET;ORAL

ROFLUMILAST

AB	AUROBINDO PHARMA LTD	250MCG	A213298	002	Jan 31, 2025	Jan NEWA
	@ SENORES PHARMS	250MCG	A208236	002	Oct 19, 2023	Feb CAHN
	@	500MCG	A208236	001	Oct 03, 2018	Feb CAHN

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	ANTHEA PHARMA	40MG/20ML (2MG/ML)	A219883	001	Mar 21, 2025	Mar NEWA
AP		150MG/30ML (5MG/ML)	A219883	002	Mar 21, 2025	Mar NEWA
AP		200MG/20ML (10MG/ML)	A219883	003	Mar 21, 2025	Mar NEWA

ROSUVASTATIN CALCIUM

TABLET;ORAL

CRESTOR

AB	+ ASTRAZENECA	EQ 5MG BASE	N021366	002	Aug 12, 2003	Jan CAHN
AB	+	EQ 10MG BASE	N021366	003	Aug 12, 2003	Jan CAHN
AB	+	EQ 20MG BASE	N021366	004	Aug 12, 2003	Jan CAHN
AB	+!	EQ 40MG BASE	N021366	005	Aug 12, 2003	Jan CAHN

RUFINAMIDE

SUSPENSION;ORAL

RUFINAMIDE

>A>	AB	MSN	40MG/ML	A214817	001	Apr 15, 2025	Apr NEWA
-----	----	-----	---------	---------	-----	--------------	----------

SACUBITRIL; VALSARTAN

TABLET;ORAL

SACUBITRIL AND VALSARTAN

AB	DR REDDYS	24MG;26MG	A213627	001	Jan 13, 2025	Jan NEWA
AB		49MG;51MG	A213627	002	Jan 13, 2025	Jan NEWA
AB		97MG;103MG	A213627	003	Jan 13, 2025	Jan NEWA
AB	LUPIN	24MG;26MG	A213808	001	Jan 08, 2025	Jan NEWA
AB		49MG;51MG	A213808	002	Jan 08, 2025	Jan NEWA
AB		97MG;103MG	A213808	003	Jan 08, 2025	Jan NEWA

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

ZELVYSIA

>A>	AB	SHANGHAI AUCYUN	100MG/PACKET	A218645	001	Apr 29, 2025	Apr NEWA
>A>	AB		500MG/PACKET	A218645	002	Apr 29, 2025	Apr NEWA

SCOPOLAMINE

SYSTEM;TRANSDERMAL

SCOPOLAMINE

>D>	AB	RICONPHARMA LLC	1MG/72HR	A212342	001	Nov 24, 2020	Apr CHRS
>A>	AB	!	1MG/72HR	A212342	001	Nov 24, 2020	Apr CHRS
		TRANSDERM SCOP					
>D>	AB	+! BAXTER HLTHCARE CORP	1MG/72HR	N017874	001		Apr CHRS
>A>	AB	+	1MG/72HR	N017874	001		Apr CHRS

SELENIOS ACID

SOLUTION;INTRAVENOUS

SELENIOS ACID

	+!	AM REGENT	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Feb CTEC
AP	+!		EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Jan CFTG

SOLUTION;INTRAVENOUS								
SELENIUM ACID								
		SELENIUM/ML)						
AP	+	EQ 600MCG SELENIUM/10ML (EQ 60MCG	N209379	001	Apr 30, 2019	Feb	CFTG	
		SELENIUM/ML)						
AP	FRESENIUS KABI USA	EQ 60MCG SELENIUM/ML (EQ 60MCG	A218779	001	Feb 10, 2025	Jan	NFTG	
		SELENIUM/ML)						
AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG	A218779	001	Feb 10, 2025	Feb	CMS1	
		SELENIUM/ML)						
AP	SUN PHARM	EQ 600MCG SELENIUM/10ML (EQ 60MCG	A219547	001	Feb 20, 2025	Feb	NEWA	
		SELENIUM/ML)						
<u>SELINEXOR</u>								
TABLET;ORAL								
XPOVIO								
+	KARYOPHARM THERAPS	10MG	N212306	005	Mar 10, 2025	Mar	NEWA	
<u>SELPERCATINIB</u>								
CAPSULE;ORAL								
RETEVMO								
+	ELI LILLY AND CO	40MG	N213246	001	May 08, 2020	Jan	CAHN	
+	!	80MG	N213246	002	May 08, 2020	Jan	CAHN	
TABLET;ORAL								
RETEVMO								
+	ELI LILLY AND CO	40MG	N218160	001	Apr 10, 2024	Jan	CAHN	
+		80MG	N218160	002	Apr 10, 2024	Jan	CAHN	
+		120MG	N218160	003	Apr 10, 2024	Jan	CAHN	
+	!	160MG	N218160	004	Apr 10, 2024	Jan	CAHN	
<u>SEVELAMER CARBONATE</u>								
FOR SUSPENSION;ORAL								
SEVELAMER CARBONATE								
	@ INVAGEN PHARMS	800MG/PACKET	A206234	001	Jul 12, 2024	Jan	DISC	
	@	2.4GM/PACKET	A206234	002	Jul 12, 2024	Jan	DISC	
AB	TORRENT	800MG/PACKET	A215909	001	Feb 27, 2025	Feb	NEWA	
AB		2.4GM/PACKET	A215909	002	Feb 27, 2025	Feb	NEWA	
<u>SEVELAMER HYDROCHLORIDE</u>								
TABLET;ORAL								
SEVELAMER HYDROCHLORIDE								
BX	AUROBINDO PHARMA LTD	400MG	A212599	001	Jul 11, 2023	Mar	CTEC	
BX		800MG	A212599	002	Jul 11, 2023	Mar	CTEC	
AB	NAVINTA LLC	800MG	A218966	001	Feb 03, 2025	Jan	NEWA	
<u>SILDENAFIL CITRATE</u>								
FOR SUSPENSION;ORAL								
SILDENAFIL CITRATE								
AB	APPCO	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Feb	CAHN	
AB	CHARTWELL RX	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Feb	CAHN	
TABLET;ORAL								
SILDENAFIL CITRATE								
AB	JUBILANT GENERICS	EQ 20MG BASE	A202954	001	Mar 06, 2025	Feb	NEWA	
<u>SILODOSIN</u>								
CAPSULE;ORAL								
SILODOSIN								
AB	TORRENT	4MG	A210396	001	Feb 10, 2025	Jan	NEWA	
AB		8MG	A210396	002	Feb 10, 2025	Jan	NEWA	
<u>SIMVASTATIN</u>								
TABLET;ORAL								
SIMVASTATIN								
AB	GRAVITI PHARMS	5MG	A077752	005	Jan 23, 2008	Feb	CAHN	
AB		10MG	A077752	001	Dec 20, 2006	Feb	CAHN	
AB		20MG	A077752	002	Dec 20, 2006	Feb	CAHN	
AB		40MG	A077752	003	Dec 20, 2006	Feb	CAHN	
AB		80MG	A077752	004	Dec 20, 2006	Feb	CAHN	

SIPONIMODTABLET; ORAL
MAYZENT

>D>	+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Apr CFTG
>A>	AB	+	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Apr CFTG
>D>		+	EQ 1MG BASE	N209884	003	Aug 24, 2021	Apr CFTG
>A>	AB	+	EQ 1MG BASE	N209884	003	Aug 24, 2021	Apr CFTG
>D>		+	EQ 2MG BASE	N209884	002	Mar 26, 2019	Apr CFTG
>A>	AB	+	EQ 2MG BASE	N209884	002	Mar 26, 2019	Apr CFTG
>A>		SIPONIMOD					
>A>	AB	RICONPHARMA LLC	EQ 0.25MG BASE	A218444	001	Apr 22, 2025	Apr NFTG
>A>	AB		EQ 1MG BASE	A218444	002	Apr 22, 2025	Apr NFTG
>A>	AB		EQ 2MG BASE	A218444	003	Apr 22, 2025	Apr NFTG

SIROLIMUSPOWDER; INTRAVENOUS
FYARRO

+	!	AADI SUB	100MG/VIAL	N213312	001	Nov 22, 2021	Mar CAHN
---	---	----------	------------	---------	-----	--------------	----------

SITAGLIPTIN HYDROCHLORIDESOLUTION; ORAL
BRYNOVIN

+	!	AZURITY	EQ 25MG BASE/ML	N219122	001	Jan 16, 2025	Jan NEWA
---	---	---------	-----------------	---------	-----	--------------	----------

SODIUM CHLORIDESOLUTION; INJECTION
SODIUM CHLORIDE 0.9%

AP		NEXUS	90MG/10ML (9MG/ML)	A217535	001	Aug 23, 2023	Mar CAHN
AP			180MG/20ML (9MG/ML)	A217535	002	Aug 23, 2023	Mar CAHN

SODIUM NITROPRUSSIDEINJECTABLE; INJECTION
SODIUM NITROPRUSSIDE

@		XIROMED	25MG/ML	A211277	001	Oct 29, 2020	Jan DISC
---	--	---------	---------	---------	-----	--------------	----------

SODIUM POLYSTYRENE SULFONATEPOWDER; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

AA		AJENAT PHARMS	454GM/BOT	A205727	001	Feb 23, 2016	Jan CAHN
----	--	---------------	-----------	---------	-----	--------------	----------

SOLIFENACIN SUCCINATETABLET; ORAL
SOLIFENACIN SUCCINATE

AB		TORRENT	5MG	A209424	001	Mar 04, 2025	Feb NEWA
AB			10MG	A209424	002	Mar 04, 2025	Feb NEWA

SORAFENIB TOSYLATETABLET; ORAL
SORAFENIB TOSYLATE

AB		@ APOTEX	EQ 200MG BASE	A212228	001	Jan 27, 2025	Mar DISC
			EQ 200MG BASE	A212228	001	Jan 27, 2025	Jan NEWA

SPIRONOLACTONESUSPENSION; ORAL
SPIRONOLACTONE

AB		HETERO LABS LTD III	25MG/5ML	A218085	001	Feb 21, 2025	Feb NEWA
----	--	---------------------	----------	---------	-----	--------------	----------

TABLET; ORAL
SPIRONOLACTONE

AB		GRAVITI PHARMS	25MG	A219494	001	Jan 23, 2025	Jan NEWA
AB			50MG	A219494	002	Jan 23, 2025	Jan NEWA
AB			100MG	A219494	003	Jan 23, 2025	Jan NEWA

STREPTOZOCININJECTABLE; INJECTION
ZANOSAR

+	@	TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982	Feb DISC
---	---	-----------------	----------	---------	-----	--------------	----------

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
SUCCINYLCHOLINE CHLORIDE

AP	FRESENIUS KABI USA	20MG/ML	A217885	001	Feb 21, 2025	Feb NEWA
	SOLUTION; INTRAMUSCULAR, INTRAVENOUS					
	SUCCINYLCHOLINE CHLORIDE					
AP	FRESENIUS KABI USA	100MG/5ML (20MG/ML)	A217884	001	Feb 11, 2025	Jan NEWA

SUCRALFATE

SUSPENSION; ORAL
SUCRALFATE

>A> AB	PADAGIS US	1GM/10ML	A211780	001	Apr 14, 2025	Apr NEWA
	TABLET; ORAL					
	SUCRALFATE					
>A> AB	CHARTWELL RX	1GM	A074415	001	Jun 08, 1998	Apr CAHN
>D> AB	NOSTRUM LABS INC	1GM	A074415	001	Jun 08, 1998	Apr CAHN

SULINDAC

TABLET; ORAL
SULINDAC

AB	EPIC PHARMA	150MG	A072711	002	Mar 25, 1991	Mar CMS1
----	-------------	-------	---------	-----	--------------	----------

SUNITINIB MALATE

CAPSULE; ORAL
SUNITINIB MALATE

AB	FOSUN WANBANG	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Jan CAHN
AB		EQ 25MG BASE	A218012	002	Aug 21, 2023	Jan CAHN
AB		EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Jan CAHN
AB		EQ 50MG BASE	A218012	004	Aug 21, 2023	Jan CAHN
AB	MSN	EQ 12.5MG BASE	A214824	001	Feb 14, 2025	Feb NEWA
AB		EQ 25MG BASE	A214824	002	Feb 14, 2025	Feb NEWA
AB		EQ 37.5MG BASE	A214824	003	Feb 14, 2025	Feb NEWA
AB		EQ 50MG BASE	A214824	004	Feb 14, 2025	Feb NEWA

SUZETRIGINE

TABLET; ORAL
JOURNAVX

+!	VERTEX PHARMS INC	50MG	N219209	001	Jan 30, 2025	Jan NEWA
----	-------------------	------	---------	-----	--------------	----------

TACROLIMUS

CAPSULE; ORAL
TACROLIMUS

AB	AJENAT PHARMS	EQ 0.5MG BASE	A206651	001	Nov 30, 2017	Jan CAHN
AB		EQ 1MG BASE	A206651	002	Nov 30, 2017	Jan CAHN
AB		EQ 5MG BASE	A206651	003	Nov 30, 2017	Jan CAHN

INJECTABLE; INJECTION
PROGRAF

AP	+! ATELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994	Jan CTEC
----	------------	----------------	---------	-----	--------------	----------

TACROLIMUS

AP	NEXUS	EQ 5MG BASE/ML	A217108	001	Feb 12, 2025	Jan NEWA
----	-------	----------------	---------	-----	--------------	----------

OINTMENT; TOPICAL
TACROLIMUS

BX	ENCUBE	0.1%	A212387	001	Oct 10, 2023	Mar CTEC
----	--------	------	---------	-----	--------------	----------

TALAZOPARIB TOSYLATE

CAPSULE; ORAL
TALZENNA

+ @	PFIZER	EQ 0.1MG BASE	N211651	005	Jun 20, 2023	Feb DISC
+ @		EQ 0.25MG BASE	N211651	001	Oct 16, 2018	Feb DISC
+ @		EQ 0.35MG BASE	N211651	006	Jun 20, 2023	Feb DISC
+ @		EQ 0.5MG BASE	N211651	003	Sep 20, 2021	Feb DISC
+ @		EQ 0.75MG BASE	N211651	004	Sep 20, 2021	Feb DISC
+ @		EQ 1MG BASE	N211651	002	Oct 16, 2018	Feb DISC

TAMOXIFEN CITRATE

TABLET; ORAL
TAMOXIFEN CITRATE

@	APOTEX	EQ 10MG BASE	A090878	001	Sep 23, 2011	Mar DISC
@		EQ 20MG BASE	A090878	002	Sep 23, 2011	Mar DISC

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

FLOMAX

+ @ SANOFI 0.4MG

N020579 001 Apr 15, 1997 Feb DISC

TAMSULOSIN HYDROCHLORIDE

AB ASCENT PHARMS INC 0.4MG

A214730 001 May 04, 2022 Feb CMFD

>A> AB GRAVITI PHARMS 0.4MG

A219767 001 May 01, 2025 Apr NEWA

AB ! ZYDUS PHARMS USA INC 0.4MG

A078225 001 Apr 27, 2010 Feb CHRS

TAZAROTENE

CREAM;TOPICAL

TAZAROTENE

AB COSETTE 0.05%

A208662 002 Mar 10, 2025 Feb NEWA

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION

OSTEOLITE

@ SUN PHARM INDS INC N/A

N017972 001 Feb CAHN

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE;INJECTION

DRAXIMAGE DTPA

AP +! JUBILANT N/A

N018511 001 Dec 29, 1989 Mar CFTG

TECHNETIUM TC-99M PENTETATE KIT

AP CURIUM N/A

A215146 001 Mar 26, 2025 Mar NFTG

TELMISARTAN

TABLET;ORAL

MICARDIS

AB + BOEHRINGER INGELHEIM 80MG

N020850 002 Nov 10, 1998 Feb CHRS

TELMISARTAN

AB ! INVENTIA 80MG

A205150 003 Oct 30, 2015 Feb CHRS

AB MACLEODS PHARMS LTD 20MG

A203986 001 Jan 15, 2025 Jan NEWA

AB 40MG

A203986 002 Jan 15, 2025 Jan NEWA

AB 80MG

A203986 003 Jan 15, 2025 Jan NEWA

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

@ SUN PHARM INDUSTRIES 7.5MG

A078581 001 Sep 08, 2009 Mar DISC

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

>D> @ NEXTSOURCE 5MG

A203898 001 Feb 10, 2016 Apr CAHN

@ 5MG

A203898 001 Feb 10, 2016 Mar CAHN

>D> @ 20MG

A203898 002 Feb 10, 2016 Apr CAHN

@ 20MG

A203898 002 Feb 10, 2016 Mar CAHN

>D> AB 100MG

A203898 003 Feb 10, 2016 Apr CAHN

@ 100MG

A203898 003 Feb 10, 2016 Mar CAHN

AB 100MG

A203898 003 Feb 10, 2016 Mar CMFD

>D> AB 140MG

A203898 004 Feb 10, 2016 Apr CAHN

@ 140MG

A203898 004 Feb 10, 2016 Mar CAHN

AB 140MG

A203898 004 Feb 10, 2016 Mar CMFD

>D> AB 180MG

A203898 005 Feb 10, 2016 Apr CAHN

@ 180MG

A203898 005 Feb 10, 2016 Mar CAHN

AB 180MG

A203898 005 Feb 10, 2016 Mar CMFD

>D> AB 250MG

A203898 006 Feb 10, 2016 Apr CAHN

@ 250MG

A203898 006 Feb 10, 2016 Mar CAHN

AB 250MG

A203898 006 Feb 10, 2016 Mar CMFD

>A> @ TRI-SOURCE PHARMA 5MG

A203898 001 Feb 10, 2016 Apr CAHN

>A> @ 20MG

A203898 002 Feb 10, 2016 Apr CAHN

>A> AB 100MG

A203898 003 Feb 10, 2016 Apr CAHN

>A> AB 140MG

A203898 004 Feb 10, 2016 Apr CAHN

>A> AB 180MG

A203898 005 Feb 10, 2016 Apr CAHN

>A> AB 250MG

A203898 006 Feb 10, 2016 Apr CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

@ BRECKENRIDGE PHARM EQ 250MG BASE

A077714 001 Jun 04, 2010 Mar DISC

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

@ APOTEX

7MG

A209601 001 Nov 02, 2018 Feb DISC

@

14MG

A209601 002 Nov 02, 2018 Feb DISC

AB CONCORD BIOTECH LTD

7MG

A218663 001 Apr 07, 2025 Mar NEWA

AB

14MG

A218663 002 Apr 07, 2025 Mar NEWA

TERIPARATIDE

SOLUTION; SUBCUTANEOUS

BONSITY

ALVOGEN

0.56MG/2.24ML (0.25MG/ML)

N211939 001 Oct 04, 2019 Feb CPOT

FORTEO

AP +! LILLY

0.56MG/2.24ML (0.25MG/ML)

N021318 002 Jun 25, 2008 Feb CPOT

TERIPARATIDE

AP +! ALMAJECT

0.56MG/2.24ML (0.25MG/ML)

N218771 001 Jun 04, 2024 Feb CPOT

AP +!

0.6MG/2.4ML (0.25MG/ML)

N218771 001 Jun 04, 2024 Feb CTEC

AP APOTEX

0.56MG/2.24ML (0.25MG/ML)

A211097 001 Nov 16, 2023 Feb CPOT

AP TEVA PHARMS USA

0.56MG/2.24ML (0.25MG/ML)

A208569 001 Nov 16, 2023 Feb CPOT

TESTOSTERONE

SOLUTION, METERED; TRANSDERMAL

TESTOSTERONE

@ ENCUBE

30MG/1.5ML ACTUATION

A212301 001 Jan 11, 2021 Jan DISC

THEOPHYLLINE

SOLUTION, ELIXIR; ORAL

ELIXOPHYLLIN

>D> AA +! NOSTRUM LABS INC

80MG/15ML

A085186 001

Apr CAHN

>A> AA +! SOLIS PHARMS

80MG/15ML

A085186 001

Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

AB AJANTA PHARMA LTD

300MG

A218401 002 Mar 26, 2025

Mar NEWA

AB

450MG

A218401 001 Jan 13, 2025

Jan NEWA

@ RHODES PHARMS

300MG

A214113 001 May 11, 2023

Jan DISC

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

AP GLAND

100MG/ML

A217800 001 Feb 24, 2025 Feb NEWA

THIOTEPA

SOLUTION; INTRAVENOUS

TEPYLUTE

+! SHORLA

100MG/10ML (10MG/ML)

N216984 002 Feb 26, 2025 Mar NEWA

TICAGRELOR

TABLET; ORAL

BRILINTA

AB + ASTRAZENECA

60MG

N022433 002 Sep 03, 2015 Mar CTEC

TICAGRELOR

>A> AB ALEMBIC

90MG

A208576 001 May 01, 2025 Apr NEWA

>A> AB APOTEX

90MG

A208584 001 May 01, 2025 Apr NEWA

>A> AB INVAGEN PHARMS

90MG

A208537 001 May 05, 2025 Apr NEWA

AB

MSN

90MG

A208596 001 Apr 07, 2020 Mar CMFD

@

90MG

A208596 001 Apr 07, 2020 Feb CAHN

AB SUNSHINE

90MG

A208508 001 Apr 06, 2020 Mar CMFD

AB

WATSON LABS INC

60MG

A208390 001 Sep 04, 2018 Mar CMFD

AB

90MG

A208390 002 Sep 04, 2018 Mar CMFD

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

@ APOTEX	250MG	A075089	001	Jul 01, 1999	Mar DISC
----------	-------	---------	-----	--------------	----------

TOBRAMYCIN

POWDER; INHALATION

TOBI PODHALER

+! VIATRIS	28MG	N201688	001	Mar 22, 2013	Feb CAHN
------------	------	---------	-----	--------------	----------

SOLUTION; INHALATION

TOBI

AN +! VIATRIS	300MG/5ML	N050753	001	Dec 22, 1997	Feb CAHN
---------------	-----------	---------	-----	--------------	----------

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE; ORAL

TOFACITINIB CITRATE

>D>					
>D> AB	DEXCEL	EQ 11MG BASE	A218668	001	Dec 16, 2024

>A>	@	EQ 11MG BASE	A218668	001	Dec 16, 2024
-----	---	--------------	---------	-----	--------------

XELJANZ XR

>D> AB	+	PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016
--------	---	--------	--------------	---------	-----	--------------

>A>	+		EQ 11MG BASE	N208246	001	Feb 23, 2016
-----	---	--	--------------	---------	-----	--------------

TOLTERODINE TARTRATE

TABLET; ORAL

TOLTERODINE TARTRATE

AB	PTS CONSULTING	1MG	A204721	001	Jan 24, 2020	Mar CAHN
----	----------------	-----	---------	-----	--------------	----------

AB		2MG	A204721	002	Jan 24, 2020	Mar CAHN
----	--	-----	---------	-----	--------------	----------

TOLVAPTAN

TABLET; ORAL

JYNARQUE

>D>	+	OTSUKA	15MG	N204441	001	Apr 23, 2018
-----	---	--------	------	---------	-----	--------------

>A> AB2	+		15MG	N204441	001	Apr 23, 2018
---------	---	--	------	---------	-----	--------------

>D>	+		30MG	N204441	002	Apr 23, 2018
-----	---	--	------	---------	-----	--------------

>A> AB2	+		30MG	N204441	002	Apr 23, 2018
---------	---	--	------	---------	-----	--------------

>D>	+		45MG	N204441	003	Apr 23, 2018
-----	---	--	------	---------	-----	--------------

>A> AB	+		45MG	N204441	003	Apr 23, 2018
--------	---	--	------	---------	-----	--------------

>D>	+		60MG	N204441	004	Apr 23, 2018
-----	---	--	------	---------	-----	--------------

>A> AB2	+		60MG	N204441	004	Apr 23, 2018
---------	---	--	------	---------	-----	--------------

>D>	+		90MG	N204441	005	Apr 23, 2018
-----	---	--	------	---------	-----	--------------

>A> AB	+		90MG	N204441	005	Apr 23, 2018
--------	---	--	------	---------	-----	--------------

SAMSCA

>D> AB	+	OTSUKA	15MG	N022275	001	May 19, 2009
--------	---	--------	------	---------	-----	--------------

>A> AB1	+		15MG	N022275	001	May 19, 2009
---------	---	--	------	---------	-----	--------------

>D> AB	+		30MG	N022275	002	May 19, 2009
--------	---	--	------	---------	-----	--------------

>A> AB1	+		30MG	N022275	002	May 19, 2009
---------	---	--	------	---------	-----	--------------

TOLVAPTAN

>D> AB	ALKEM LABS LTD	15MG	A211891	003	Sep 06, 2022	Apr CTEC
--------	----------------	------	---------	-----	--------------	----------

>A> AB1		15MG	A211891	003	Sep 06, 2022	Apr CTEC
---------	--	------	---------	-----	--------------	----------

>D> AB		30MG	A211891	001	May 19, 2020	Apr CTEC
--------	--	------	---------	-----	--------------	----------

>A> AB1		30MG	A211891	001	May 19, 2020	Apr CTEC
---------	--	------	---------	-----	--------------	----------

>D> AB	APOTEX	15MG	A207605	002	Sep 06, 2022	Apr CTEC
--------	--------	------	---------	-----	--------------	----------

>A> AB1		15MG	A207605	002	Sep 06, 2022	Apr CTEC
---------	--	------	---------	-----	--------------	----------

>D> AB		30MG	A207605	001	May 19, 2020	Apr CTEC
--------	--	------	---------	-----	--------------	----------

>A> AB1		30MG	A207605	001	May 19, 2020	Apr CTEC
---------	--	------	---------	-----	--------------	----------

>D> AB	ENDO OPERATIONS	15MG	A206119	001	Feb 15, 2022	Apr CTEC
--------	-----------------	------	---------	-----	--------------	----------

>A> AB1		15MG	A206119	001	Feb 15, 2022	Apr CTEC
---------	--	------	---------	-----	--------------	----------

>D> AB		30MG	A206119	002	Feb 15, 2022	Apr CTEC
--------	--	------	---------	-----	--------------	----------

>A> AB1		30MG	A206119	002	Feb 15, 2022	Apr CTEC
---------	--	------	---------	-----	--------------	----------

>D> AB	HETERO LABS LTD V	15MG	A205646	002	Sep 06, 2022	Apr CTEC
--------	-------------------	------	---------	-----	--------------	----------

>A> AB1		15MG	A205646	002	Sep 06, 2022	Apr CTEC
---------	--	------	---------	-----	--------------	----------

>D> AB		30MG	A205646	001	Jul 16, 2021	Apr CTEC
--------	--	------	---------	-----	--------------	----------

>A> AB1		30MG	A205646	001	Jul 16, 2021	Apr CTEC
---------	--	------	---------	-----	--------------	----------

>A> AB2	LUPIN LTD	15MG	A216063	001	Apr 23, 2025	Apr NFTG
---------	-----------	------	---------	-----	--------------	----------

>A> AB2		30MG	A216063	002	Apr 23, 2025	Apr NFTG
---------	--	------	---------	-----	--------------	----------

>A> AB		45MG	A216063	003	Apr 23, 2025	Apr NFTG
--------	--	------	---------	-----	--------------	----------

>A> AB2		60MG	A216063	004	Apr 23, 2025	Apr NFTG
---------	--	------	---------	-----	--------------	----------

>A> AB		90MG	A216063	005	Apr 23, 2025	Apr NFTG
--------	--	------	---------	-----	--------------	----------

>D> AB	MSN	15MG	A216949	001	Jun 21, 2023	Apr CTEC
--------	-----	------	---------	-----	--------------	----------

>A> AB1		15MG	A216949	001	Jun 21, 2023	Apr CTEC
---------	--	------	---------	-----	--------------	----------

>D> AB		30MG	A216949	002	Jun 21, 2023	Apr CTEC
--------	--	------	---------	-----	--------------	----------

>A> AB1		30MG	A216949	002	Jun 21, 2023	Apr CTEC
---------	--	------	---------	-----	--------------	----------

TORSEMIDE

TABLET; ORAL

TORSEMIDE

>A>	AB	COREPHARMA	5MG	A076894	001	May 31, 2005	Apr CAHN
>A>	AB		10MG	A076894	002	May 31, 2005	Apr CAHN
>A>	AB		20MG	A076894	003	May 31, 2005	Apr CAHN
>A>	AB		100MG	A076894	004	May 31, 2005	Apr CAHN
>D>	AB	HERITAGE	5MG	A076894	001	May 31, 2005	Apr CAHN
>D>	AB		10MG	A076894	002	May 31, 2005	Apr CAHN
>D>	AB		20MG	A076894	003	May 31, 2005	Apr CAHN
>D>	AB		100MG	A076894	004	May 31, 2005	Apr CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB		APDM PHARMS	50MG	A090404	001	Jan 31, 2011	Feb CAHN
		@ APOTEX	50MG	A075981	001	Jul 10, 2002	Mar DISC
		@ MERRO PHARM USA	50MG	A206706	001	Jul 02, 2019	Feb DISC
		TABLET, EXTENDED RELEASE; ORAL					
		TRAMADOL HYDROCHLORIDE					
AB1	!	LUPIN LTD	100MG	A200503	001	Aug 29, 2011	Jan CTEC
AB1			200MG	A200503	002	Aug 29, 2011	Jan CTEC
AB1			300MG	A200503	003	Aug 29, 2011	Jan CTEC
AB1		MACLEODS PHARMS LTD	100MG	A209404	001	Jan 31, 2025	Jan NEWA
AB1			200MG	A209404	002	Jan 31, 2025	Jan NEWA
AB1			300MG	A209404	003	Jan 31, 2025	Jan NEWA

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL

TRAMETINIB DIMETHYL SULFOXIDE

		@ HIKMA	EQ 0.5MG	A219002	001	Aug 06, 2024	Feb CAHN
		@	EQ 2MG	A219002	002	Aug 06, 2024	Feb CAHN

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

		@ FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Jan DISC
--	--	----------------------	----------	---------	-----	--------------	----------

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN Z

AT2	+	SANDOZ	0.004%	N021994	001	Sep 21, 2006	Feb CTEC
		TRAVOPROST					
		@ ALEMBIC	0.004%	A210458	001	Dec 20, 2019	Feb DISC
AT2		APOTEX	0.004%	A203431	001	Jul 10, 2015	Feb CTEC
	!	CHARTWELL RX	0.004%	A091340	001	Mar 01, 2013	Feb CTEC
AT2		GLAND	0.004%	A218159	001	Jul 12, 2024	Feb CTEC
AT2		MICRO LABS	0.004%	A203767	001	Mar 19, 2021	Feb CTEC
AT2		MYLAN	0.004%	A205050	001	Jul 07, 2017	Feb CTEC
AT2		SOMERSET THERAPS LLC	0.004%	A217228	001	Sep 23, 2024	Feb CTEC

TREOSULFAN

POWDER; INTRAVENOUS

GRAFAPEX

+	!	MEDEXUS	1GM/VIAL	N214759	001	Jan 21, 2025	Jan CAHN
+	!		5GM/VIAL	N214759	002	Jan 21, 2025	Jan CAHN
+	!	MGFKSMB	1GM/VIAL	N214759	001	Jan 21, 2025	Jan NEWA
+	!		5GM/VIAL	N214759	002	Jan 21, 2025	Jan NEWA

TREPROSTINIL

POWDER; INHALATION

TYVASO DPI

+	!	UNITED THERAP	0.032MG/INH	N214324	002	May 23, 2022	Jan CHRS
+	!		0.048MG/INH	N214324	003	May 23, 2022	Jan CHRS
+	!		0.08MG/INH	N214324	005	Oct 24, 2024	Jan CHRS

TRETINOIN

CAPSULE;ORAL							
TRETINOIN							
	@ BARR LABS INC	10MG	A077684	001	Jun 22, 2007	Feb	DISC
AB	! ENDO OPERATIONS	10MG	A201687	001	Oct 24, 2012	Feb	CHRS
GEL;TOPICAL							
RETIN-A							
AB	+! BAUSCH	0.01%	N017955	001		Jan	CAHN
TRETINOIN							
AB	AUROBINDO PHARMA LTD	0.01%	A218246	001	Jan 13, 2025	Jan	NEWA
AB		0.025%	A218245	001	Feb 27, 2025	Feb	NEWA
AB	ENCUBE	0.01%	A217588	001	Mar 03, 2025	Feb	NEWA
AB		0.025%	A217587	001	Mar 03, 2025	Feb	NEWA

TRIAMCINOLONE ACETONIDE

GEL;TOPICAL							
ARISTOGEL							
	+ @ ASTELLAS	0.1%	A083380	001		Feb	CRLD
INJECTABLE;INJECTION							
KENALOG-10							
AB	+ APOTHECON	10MG/ML	N012041	001		Feb	CTEC
TRIAMCINOLONE ACETONIDE							
AB	DR REDDYS	10MG/ML	A218773	001	Mar 12, 2025	Feb	NEWA
>A> AB		40MG/ML	A218421	001	Apr 11, 2025	Apr	NEWA
LOTION;TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT	! XTTRIUM LABS INC	0.025%	A088450	001	Apr 01, 1985	Feb	CAHN
AT	!	0.1%	A088451	001	Apr 03, 1985	Feb	CAHN

TROSPIMUM CHLORIDE

TABLET;ORAL							
TROSPIMUM CHLORIDE							
AB	ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Feb	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL							
VALACYCLOVIR HYDROCHLORIDE							
	@ APOTEX	EQ 500MG BASE	A090500	001	Apr 04, 2014	Mar	DISC

VALBENAZINE TOSYLATE

CAPSULE;ORAL							
INGREZZA							
	+ NEUROCRINE	EQ 60MG BASE	N209241	003	Apr 23, 2021	Feb	CTEC
VALBENAZINE TOSYLATE							
	@ ZYDUS LIFESCIENCES	EQ 40MG BASE	A216137	001	Aug 07, 2024	Feb	DISC
	@	EQ 60MG BASE	A216137	002	Aug 07, 2024	Feb	DISC
	@	EQ 80MG BASE	A216137	003	Aug 07, 2024	Feb	DISC

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL							
VALGANCICLOVIR HYDROCHLORIDE							
>A> AB	SPH ZHONGXI PHARM	EQ 450MG BASE	A218027	001	Apr 16, 2025	Apr	NEWA

VALPROIC ACID

SYRUP;ORAL							
VALPROIC ACID							
>D>	@ NOSTRUM LABS INC	250MG/5ML	A077105	001	Jul 29, 2005	Apr	CAHN
>A>	@ PAI HOLDINGS	250MG/5ML	A077105	001	Jul 29, 2005	Apr	CAHN

VALSARTAN

TABLET;ORAL							
VALSARTAN							
	@ RENATA	40MG	A218169	001	Aug 05, 2024	Feb	DISC
AB		40MG	A218169	001	Aug 05, 2024	Jan	CAHN
	@	80MG	A218169	002	Aug 05, 2024	Feb	DISC
AB		80MG	A218169	002	Aug 05, 2024	Jan	CAHN
	@	160MG	A218169	003	Aug 05, 2024	Feb	DISC
AB		160MG	A218169	003	Aug 05, 2024	Jan	CAHN
	@	320MG	A218169	004	Aug 05, 2024	Feb	DISC
AB		320MG	A218169	004	Aug 05, 2024	Jan	CAHN

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOCIN HYDROCHLORIDE

>A>	@	STERISCIENCE	EQ 500MG BASE/VIAL	A060180	001		Apr	CAHN
>A>	@		EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984	Apr	CAHN
>A>	@		EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987	Apr	CAHN
>A>	@		EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987	Apr	CAHN
>A>	@		EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986	Apr	CAHN
>A>	@		EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986	Apr	CAHN
>A>	@		EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987	Apr	CAHN
>A>	@		EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987	Apr	CAHN
>A>	@		EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987	Apr	CAHN
>D>	@	STERISCIENCE SPECCLTS	EQ 500MG BASE/VIAL	A060180	001		Apr	CAHN
>D>	@		EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984	Apr	CAHN
>D>	@		EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987	Apr	CAHN
>D>	@		EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987	Apr	CAHN
>D>	@		EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986	Apr	CAHN
>D>	@		EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986	Apr	CAHN
>D>	@		EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987	Apr	CAHN
>D>	@		EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987	Apr	CAHN
>D>	@		EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987	Apr	CAHN

VANCOMYCIN HYDROCHLORIDE

AP		MEDIMETRIKS PHARMS	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Jan	CMFD
AP			EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Jan	CMFD
	@	PLANO PHARMS	EQ 500MG BASE/VIAL	A090250	001	Apr 27, 2010	Mar	CAHN
	@		EQ 1GM BASE/VIAL	A090250	002	Apr 27, 2010	Mar	CAHN
	@		EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Mar	CAHN
	@		EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Mar	CAHN

POWDER; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

AP		GLAND	EQ 750MG BASE/VIAL	A218140	001	Mar 21, 2025	Mar	NEWA
AP			EQ 1.25GM BASE/VIAL	A218140	002	Mar 21, 2025	Mar	NEWA
AP			EQ 1.5GM BASE/VIAL	A218140	003	Mar 21, 2025	Mar	NEWA
AP	+	MYLAN LABS LTD	EQ 750MG BASE/VIAL	N209481	002	Jul 10, 2018	Mar	CTFG

VARENICLINE TARTRATE

TABLET; ORAL

VARENICLINE TARTRATE

>A>	AB	AUROBINDO PHARMA	EQ 0.5MG BASE	A214595	001	May 02, 2025	Apr	NEWA
>A>	AB		EQ 1MG BASE	A214595	002	May 02, 2025	Apr	NEWA
	@	PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Feb	DISC
	@		EQ 1MG BASE	A217115	002	Jul 23, 2024	Feb	DISC
	AB	SHILPA	EQ 0.5MG BASE	A216615	001	Apr 08, 2025	Mar	NEWA
	AB		EQ 1MG BASE	A216615	002	Apr 08, 2025	Mar	NEWA
>A>	AB	VIWIT PHARM	EQ 0.5MG BASE	A212879	001	May 06, 2025	Apr	NEWA
>A>	AB		EQ 1MG BASE	A212879	002	May 06, 2025	Apr	NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB		MEDICAP LABS	EQ 37.5MG BASE	A201272	001	Nov 23, 2018	Feb	CAHN
AB			EQ 75MG BASE	A201272	002	Nov 23, 2018	Feb	CAHN
AB			EQ 150MG BASE	A201272	003	Nov 23, 2018	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB		ABON PHARMS LLC	EQ 150MG BASE	A217841	001	Feb 07, 2025	Jan	NEWA
AB			EQ 225MG BASE	A217841	002	Feb 07, 2025	Jan	NEWA
AB		TORRENT	EQ 37.5MG BASE	A218180	001	Jan 28, 2025	Jan	NEWA
AB			EQ 75MG BASE	A218180	002	Jan 28, 2025	Jan	NEWA
AB			EQ 150MG BASE	A218180	003	Jan 28, 2025	Jan	NEWA
AB			EQ 225MG BASE	A218180	004	Jan 28, 2025	Jan	NEWA

VIGABATRIN

TABLET; ORAL

VIGABATRIN

	@	AMNEAL PHARMS	500MG	A210042	001	Jun 22, 2022	Feb	DISC
	@	RYAN LABS	500MG	A215519	001	Apr 28, 2023	Jan	DISC

VIMSELTINIBCAPSULE;ORAL
ROMVIMZA

+	DECIPHERA PHARMS	14MG	N219304	001	Feb 14, 2025	Feb NEWA
+		20MG	N219304	002	Feb 14, 2025	Feb NEWA
+	!	30MG	N219304	003	Feb 14, 2025	Feb NEWA

VORICONAZOLEFOR SUSPENSION;ORAL
VORICONAZOLE

AB	ZHEJIANG POLY PHARM	200MG/5ML	A216805	001	Jan 02, 2024	Mar CAHN
----	---------------------	-----------	---------	-----	--------------	----------

ZANUBRUTINIBCAPSULE;ORAL
BRUKINSA

>D>	+	BEIGENE	80MG	N213217	001	Nov 14, 2019	Apr CAHN
>A>	+	BEONE MEDICINES USA	80MG	N213217	001	Nov 14, 2019	Apr CAHN

ZINC ACETATECAPSULE;ORAL
GALZIN

+	ETON	EQ 25MG ZINC	N020458	001	Jan 28, 1997	Jan CAHN
+	!	EQ 50MG ZINC	N020458	002	Jan 28, 1997	Jan CAHN

ZINC CHLORIDEINJECTABLE;INJECTION
ZINC CHLORIDE

>A>	AP	STIRA	EQ 1MG ZINC/ML	A217625	001	Apr 14, 2025	Apr NEWA
-----	----	-------	----------------	---------	-----	--------------	----------

ZINC SULFATESOLUTION;INTRAVENOUS
ZINC SULFATE

>A>	AP	ASPIRO	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A219585	001	May 01, 2025	Apr NEWA
>A>	AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A219585	002	May 01, 2025	Apr NEWA
>A>	AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A219585	003	May 01, 2025	Apr NEWA

ZOLEDRONIC ACIDINJECTABLE;INTRAVENOUS
ZOLEDRONIC ACID
@ APOTEX

EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Mar DISC
-------------------	---------	-----	--------------	----------

ZOLMITRIPTANSPRAY;NASAL
ZOLMITRIPTAN

>D>	AB	!	PADAGIS ISRAEL	5MG/SPRAY	A212469	002	Sep 30, 2021	Apr CHRS
>A>	AB			5MG/SPRAY	A212469	002	Sep 30, 2021	Apr CHRS

ZOMIG

>D>	AB	+	AMNEAL	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Apr CHRS
>A>	AB	+	!	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Apr CHRS

ZOLPIDEM TARTRATETABLET;ORAL
AMBIEN

AB	+	COSETTE	5MG	N019908	001	Dec 16, 1992	Jan CAHN
AB	+	!	10MG	N019908	002	Dec 16, 1992	Jan CAHN

ZOLPIDEM TARTRATE

@ APOTEX INC 5MG
@ 10MG

A077884	001	Apr 23, 2007	Mar DISC
A077884	002	Apr 23, 2007	Mar DISC

TABLET;SUBLINGUAL
EDLUAR

AB	+	VIATRIS	5MG	N021997	001	Mar 13, 2009	Feb CAHN
AB	+	!	10MG	N021997	002	Mar 13, 2009	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL
AMBIEN CR

AB	+	COSETTE	6.25MG	N021774	002	Sep 02, 2005	Jan CAHN
AB	+	!	12.5MG	N021774	001	Sep 02, 2005	Jan CAHN

ZOLPIDEM TARTRATE

@ APOTEX 6.25MG
@ 12.5MG

A200266	001	Sep 10, 2013	Mar DISC
A200266	002	Sep 10, 2013	Mar DISC

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

@ APOTEX	25MG	A077642	001	Dec 22, 2005	Mar DISC
@	50MG	A077642	002	Dec 22, 2005	Mar DISC
@	100MG	A077642	003	Dec 22, 2005	Mar DISC

ACETAMINOPHEN; IBUPROFEN

TABLET; ORAL

ACETAMINOPHEN AND IBUPROFEN

STRIDES PHARMA

250MG; 125MG

A217241 001

Jan 17, 2025

Jan NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA

0.2055MG/SPRAY

A216561 001

Jan 27, 2025

Jan NEWA

CETIRIZINE HYDROCHLORIDE

TABLET; ORAL

ZYRTEC ALLERGY

>D>

+ @ KENVUE BRANDS

5MG

N019835 003

Nov 16, 2007

Apr CMFD

>A>

+

5MG

N019835 003

Nov 16, 2007

Apr CMFD

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ APOTEX

100MG

A074948 001

Jun 19, 1998

Mar DISC

@

200MG

A074948 002

Jul 26, 2002

Mar DISC

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

CONTRACT PHARMACAL

60MG

A219032 001

Feb 28, 2025

Feb NEWA

180MG

A219032 002

Feb 28, 2025

Feb NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A>

AUROBINDO PHARMA LTD 180MG; 240MG

A215232 001

Apr 17, 2025

Apr NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>

DR REDDYS LABS LTD

200MG; 30MG

A077628 001

Aug 14, 2006

Apr CAHN

>A>

STRIDES PHARMA

200MG; 30MG

A077628 001

Aug 14, 2006

Apr CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

@ APOTEX

5MG

A211443 001

Apr 21, 2021

Jan DISC

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

IMODIUM A-D

>D>

+! KENVUE BRANDS

1MG/5ML

N019487 001

Mar 01, 1988

Apr DISC

>A>

+ @

1MG/5ML

N019487 001

Mar 01, 1988

Apr DISC

LOPERAMIDE HYDROCHLORIDE

@ PAI HOLDINGS

1MG/5ML

A074352 001

Nov 17, 1995

Feb CAHN

>D>

WOCKHARDT BIO AG

1MG/5ML

A074730 001

Aug 28, 1997

Apr DISC

>A>

@

1MG/5ML

A074730 001

Aug 28, 1997

Apr DISC

LORATADINE

CAPSULE; ORAL

LORATADINE

CATALENT PHARMA

10MG

A215127 001

Feb 28, 2025

Feb NEWA

TABLET, CHEWABLE; ORAL

LORATADINE

>A>

SUN PHARM

10MG

A210088 002

Apr 25, 2025

Apr NEWA

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

>D>

NOVELGENIX THERAPS

220MG

A207612 001

Nov 16, 2018

Apr DISC

>A>

@

220MG

A207612 001

Nov 16, 2018

Apr DISC

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

	BAUSCH AND LOMB INC	EQ 0.2% BASE	A206087	001	Dec 05, 2017	Feb	CMFD
	GLENMARK PHARMS INC	EQ 0.2% BASE	A219557	001	Feb 28, 2025	Feb	NEWA
>D>	@ RISING	EQ 0.2% BASE	A204620	001	Jun 16, 2020	Apr	CMFD
>A>		EQ 0.2% BASE	A204620	001	Jun 16, 2020	Apr	CMFD

OMEPRAZOLETABLET, DELAYED RELEASE;ORAL
OMEPRAZOLE

@ APOTEX	20MG	A210070	001	Feb 11, 2019	Jan	DISC
----------	------	---------	-----	--------------	-----	------

POTASSIUM IODIDETABLET;ORAL
THYROSAFE

BTG INTL	130MG	A076350	002	Apr 02, 2025	Mar	NFTG
----------	-------	---------	-----	--------------	-----	------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 4 APRIL 2025

NO APRIL 2025 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2025 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	10167291	Jul 01, 2036	DP U-2145		I-960	Jan 16, 2028
	10167291	Jul 01, 2036	DP U-2519			
	10167291	Jul 01, 2036	DP U-2666			
	10167291	Jul 01, 2036	DP U-2667			
	10167291	Jul 01, 2036	DP U-2668			
	10167291	Jul 01, 2036	DP U-2669			
	10167291	Jul 01, 2036	DP U-2670			
	10167291	Jul 01, 2036	DP U-2671			
	10167291	Jul 01, 2036	DP U-2682			
	10167291	Jul 01, 2036	DP U-2683			
	10167291	Jul 01, 2036	DP U-2684			
	10167291	Jul 01, 2036	DP U-2685			
	10167291	Jul 01, 2036	DP U-2686			
	10167291	Jul 01, 2036	DP U-2687			
	10167291	Jul 01, 2036	DP U-4109			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	10272083	Jan 21, 2035	U-4109			
	9758524	Jul 11, 2032	U-2145			
	9758524	Jul 11, 2032	U-4108			
	9796721	Jul 01, 2036	DS DP U-2145			
	9796721	Jul 01, 2036	DS DP U-2666			
	9796721	Jul 01, 2036	DS DP U-2667			
	9796721	Jul 01, 2036	DS DP U-2668			
	9796721	Jul 01, 2036	DS DP U-2669			
	9796721	Jul 01, 2036	DS DP U-2670			
	9796721	Jul 01, 2036	DS DP U-2671			
	9796721	Jul 01, 2036	DS DP U-4108			
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001	10272083	Jan 21, 2035	U-2519		I-960	Jan 16, 2028
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	10272083	Jan 21, 2035	U-4109			
	11059829	Jul 01, 2036	DS DP U-2145			
	11059829	Jul 01, 2036	DS DP U-2666			
	11059829	Jul 01, 2036	DS DP U-2667			
	11059829	Jul 01, 2036	DS DP U-2668			
	11059829	Jul 01, 2036	DS DP U-2669			
	11059829	Jul 01, 2036	DS DP U-2670			
	11059829	Jul 01, 2036	DS DP U-2671			
	11059829	Jul 01, 2036	DS DP U-4108			
	9758524	Jul 11, 2032	U-2145			
	9758524	Jul 11, 2032	U-4108			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 002 >A>	8748413	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 003 >A>	8748413	Jul 01, 2030	DS DP			
<u>ACORAMIDIS HYDROCHLORIDE - ATTRUBY</u>						
N 216540 001	9913826	May 05, 2031	U-4046		ODE-506	Nov 22, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	7396341	Oct 10, 2026	DP	Y		
	7837235	Mar 13, 2028	DP	Y		
	8733341	Oct 16, 2030	DP	Y		
	9027967	Mar 31, 2027	DP	Y		
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	12233033	Aug 23, 2038	U-2106			
	12233033	Aug 23, 2038	U-2224			
	12233033	Aug 23, 2038	U-3180			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	12233033	Aug 23, 2038	U-2106			
	12233033	Aug 23, 2038	U-2224			
	12233033	Aug 23, 2038	U-3180			
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	12168021	May 15, 2035	U-2414			
	12168022	May 15, 2035	U-2414			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 001	12005042	Feb 09, 2038	U-1744			
	12005042	Feb 09, 2038	U-2754			
	12005042	Feb 09, 2038	U-3467			
	12194022	Mar 10, 2031	U-1744			
	12194022	Mar 10, 2031	U-3467			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 002	12005042	Feb 09, 2038	U-1744			
	12005042	Feb 09, 2038	U-2754			
	12005042	Feb 09, 2038	U-3467			
	12194022	Mar 10, 2031	U-1744			
	12194022	Mar 10, 2031	U-3467			
<u>AMLODIPINE BESYLATE - NORLIQVA</u>						
N 214439 001	12005141	Feb 24, 2041	DP U-3309			
	12005141	Feb 24, 2041	DP U-3310			
	12005141	Feb 24, 2041	DP U-3311			
	12226528	Feb 24, 2041	DP U-3309			
	12226528	Feb 24, 2041	DP U-3310			
	12226528	Feb 24, 2041	DP U-3311			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	>A> 6967208	Nov 21, 2026	DS DP U-1167			
	>A> 6967208	Nov 21, 2026	DS DP U-1200			
	>A> 6967208	Nov 21, 2026	DS DP U-1301			
	>A> 6967208	Nov 21, 2026	DS DP U-1302			
	>A> 6967208	Nov 21, 2026	DS DP U-1323			
	>A> 6967208	Nov 21, 2026	DS DP U-1501			
	>A> 6967208	Nov 21, 2026	DS DP U-1502			
	>A> 6967208	Nov 21, 2026	DS DP U-1729			
	>A> 6967208	Nov 21, 2026	DS DP U-1730			
	>A> 6967208*PED	May 21, 2027				
	>A> 9326945	Feb 24, 2031	DP			
	>A> 9326945*PED	Aug 24, 2031				
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	>A> 6967208	Nov 21, 2026	DS DP U-1200			
	>A> 6967208	Nov 21, 2026	DS DP U-1301			
	>A> 6967208	Nov 21, 2026	DS DP U-1302			
	>A> 6967208	Nov 21, 2026	DS DP U-1323			
	>A> 6967208*PED	May 21, 2027				
	>A> 9326945	Feb 24, 2031	DP			
	>A> 9326945*PED	Aug 24, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APOMORPHINE HYDROCHLORIDE - ONAPGO</u>						
N 214056 001					>A> NP	Feb 03, 2028
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	12251381	Apr 09, 2039	U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	12251381	Apr 09, 2039	U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	12251381	Apr 09, 2039	U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	12251381	Apr 06, 2039	U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	12251381	Apr 06, 2039	U-543			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 001	12252478	May 14, 2040	DP			
	12252479	May 17, 2040	U-1374			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002	12252478	May 14, 2040	DP			
	12252479	May 17, 2040	U-1374			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 003	12252478	May 14, 2040	DP			
	12252479	May 17, 2040	U-1374			
<u>ATRASENTAN HYDROCHLORIDE - VANRAFIA</u>						
N 219208 001	>A> 10016393	Jul 07, 2034	DP		>A> NCE	Apr 02, 2030
	>A> 11491137	Dec 16, 2040	U-3980			
	>A> 11874283	Feb 18, 2032	U-3980			
	>A> 11998526	Dec 16, 2040	U-3980			
	>A> 12121509	Dec 16, 2040	U-3980			
	>A> 8623819	Aug 22, 2028	U-3980			
	>A> 9364458	Jul 07, 2034	DP U-3980			
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	7579456	Feb 14, 2026	DS			
	9617546	Feb 14, 2026	DS U-3673			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	>A> 12252494	Apr 10, 2040	U-3506			
<u>AVIBACTAM SODIUM; AZTREONAM - EMBLAVEO</u>						
N 217906 001	7112592	Jan 07, 2026	DS DP U-4147		NP	Feb 07, 2028
	7612087	Nov 12, 2026	DP		GAIN	Feb 07, 2033
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
	9284314	Jun 15, 2032	DS			
	9695122	Jun 15, 2032	DS DP			
<u>BACLOFEN - BACLOFEN</u>						
A 214445 001					PC	Jul 14, 2025
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001					M-187	Dec 19, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001					M-187	Dec 19, 2027
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	>A> 9463289	May 18, 2031	DP	Y		
	>A> 9808587	May 18, 2031	DP	Y		
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	>A> 9463289	May 18, 2031	DP	Y		
	>A> 9808587	May 18, 2031	DP	Y		
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	10561808	Jan 01, 2032	DP	Y		
	11395889	May 18, 2031	DP	Y		
	8132712	Sep 07, 2028	DP	Y		
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	10561808	Jan 01, 2032	DP	Y		
	11395889	May 18, 2031	DP	Y		
	8132712	Sep 07, 2028	DP	Y		
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002					>A> ODE*	Aug 09, 2026
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	12138248	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	12138248	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - VIVIMUSTA</u>						
N 212209 001	12208086	Jul 29, 2042	DP			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 001	>A> 12208167	Feb 26, 2044	DP U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 002	>A> 12208167	Feb 26, 2044	DP U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 003	>A> 12208167	Feb 26, 2044	DP U-713			
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	>A> 12257348	May 23, 2041	DP U-3947			
<u>BENZOYL PEROXIDE; TRETINOIN - TWYNEO</u>						
N 214902 001	>A> 12257348	May 23, 2041	DP U-3987			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2026	DS DP			
<u>BIRCH TRITERPENES - FILSUVEZ</u>						
N 215064 001 >A>	12268695	Jan 04, 2039	U-3811			
	8828444	Jun 21, 2026	DP			
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001	12171882	Jan 23, 2043	U-4085			
	12171882	Jan 23, 2043	U-4086			
	12171883	Jan 23, 2043	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	12226610	Feb 02, 2043	U-4148			
	12226610	Feb 02, 2043	U-4149			
	12226610	Feb 02, 2043	U-4150			
	12251468	Jul 02, 2044	DP U-4152			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	12226610	Feb 02, 2043	U-4148			
	12226610	Feb 02, 2043	U-4149			
	12226610	Feb 02, 2043	U-4150			
	12251468	Jul 02, 2044	DP U-4152			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001					M-314	Feb 21, 2028
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002					M-314	Feb 21, 2028
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 001	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 002	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 003	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 004	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 005	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 006	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 007	12161640	Jul 26, 2032	DP U-4100			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001 >A>	11389448	Apr 13, 2032	DP			
	12178815	Jul 18, 2038	U-3348			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002 >A>	11389448	Apr 13, 2032	DP			
	12178815	Jul 18, 2038	U-3348			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001 >A>	11098015	Jan 15, 2030	U-1220			
	>A> 11098015	Jan 15, 2030	U-1480			
	>A> 11098015	Jan 15, 2030	U-2488			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	>A> 11098015	Jan 15, 2030	U-3225			
	>A> 11098015	Jan 15, 2030	U-4131			
	>A> 11098015	Jan 15, 2030	U-4156			
	>A> 12128039	Feb 10, 2032	DP U-1220			
	>A> 12128039	Feb 10, 2032	DP U-1480			
	>A> 12128039	Feb 10, 2032	DP U-2488			
	>A> 12128039	Feb 10, 2032	DP U-3225			
	>A> 12128039	Feb 10, 2032	DP U-4131			
	>A> 12128039	Feb 10, 2032	DP U-4156			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	>A> 11098015	Jan 15, 2030	U-1220			
	>A> 11098015	Jan 15, 2030	U-1480			
	>A> 11098015	Jan 15, 2030	U-2488			
	>A> 11098015	Jan 15, 2030	U-3225			
	>A> 11098015	Jan 15, 2030	U-4131			
	>A> 11098015	Jan 15, 2030	U-4156			
	>A> 12128039	Feb 10, 2032	DP U-1220			
	>A> 12128039	Feb 10, 2032	DP U-1480			
	>A> 12128039	Feb 10, 2032	DP U-2488			
	>A> 12128039	Feb 10, 2032	DP U-3225			
	>A> 12128039	Feb 10, 2032	DP U-4131			
	>A> 12128039	Feb 10, 2032	DP U-4156			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	>A> 11098015	Jan 15, 2030	U-1220			
	>A> 11098015	Jan 15, 2030	U-1480			
	>A> 11098015	Jan 15, 2030	U-2488			
	>A> 11098015	Jan 15, 2030	U-3225			
	>A> 11098015	Jan 15, 2030	U-4131			
	>A> 11098015	Jan 15, 2030	U-4156			
	>A> 12128039	Feb 10, 2032	DP U-1220			
	>A> 12128039	Feb 10, 2032	DP U-1480			
	>A> 12128039	Feb 10, 2032	DP U-2488			
	>A> 12128039	Feb 10, 2032	DP U-3225			
	>A> 12128039	Feb 10, 2032	DP U-4131			
	>A> 12128039	Feb 10, 2032	DP U-4156			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					NPP PED	Dec 18, 2027 Jun 18, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANTHARIDIN - YCANTH</u>						
N 212905 001	12233042	Aug 22, 2038	DP U-3663			
<u>CAPIVASERTIB - TRUOAP</u>						
N 218197 001	12252495	Oct 10, 2028	U-3762			
<u>CAPIVASERTIB - TRUOAP</u>						
N 218197 002	12252495	Oct 10, 2028	U-3762			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 001	10596178	Jul 22, 2035	DP			
	12208101	Jul 22, 2035	DP			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 002	10596178	Jul 22, 2035	DP			
	12208101	Jul 22, 2035	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 001	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
>A>	12263148	Dec 21, 2041	U-1649			
>A>	12263148	Dec 21, 2041	U-219			
>A>	12263148	Dec 21, 2041	U-4004			
>A>	12263148	Dec 21, 2041	U-4005			
>A>	12263149	Dec 21, 2041	U-1649			
>A>	12263149	Dec 21, 2041	U-219			
>A>	12263149	Dec 21, 2041	U-4004			
>A>	12263149	Dec 21, 2041	U-4005			
>A>	12274793	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 002	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
>A>	12263148	Dec 21, 2041	U-1649			
>A>	12263148	Dec 21, 2041	U-219			
>A>	12263148	Dec 21, 2041	U-4004			
>A>	12263148	Dec 21, 2041	U-4005			
>A>	12263149	Dec 21, 2041	U-1649			
>A>	12263149	Dec 21, 2041	U-219			
>A>	12263149	Dec 21, 2041	U-4004			
>A>	12263149	Dec 21, 2041	U-4005			
>A>	12274793	Oct 07, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 003	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
>A>	12263148	Dec 21, 2041	U-1649			
>A>	12263148	Dec 21, 2041	U-219			
>A>	12263148	Dec 21, 2041	U-4004			
>A>	12263148	Dec 21, 2041	U-4005			
>A>	12263149	Dec 21, 2041	U-1649			
>A>	12263149	Dec 21, 2041	U-219			
>A>	12263149	Dec 21, 2041	U-4004			
>A>	12263149	Dec 21, 2041	U-4005			
>A>	12274793	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 004	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
>A>	12263148	Dec 21, 2041	U-1649			
>A>	12263148	Dec 21, 2041	U-219			
>A>	12263148	Dec 21, 2041	U-4004			
>A>	12263148	Dec 21, 2041	U-4005			
>A>	12263149	Dec 21, 2041	U-1649			
>A>	12263149	Dec 21, 2041	U-219			
>A>	12263149	Dec 21, 2041	U-4004			
>A>	12263149	Dec 21, 2041	U-4005			
>A>	12274793	Oct 07, 2034	DP			
<u>CEDAZURIDINE; DECITABINE - INOOVI</u>						
N 212576 001	12195496	Oct 07, 2040	DP			
	12239653	Feb 24, 2041	U-2865			
	12239653	Feb 24, 2041	U-2866			
<u>CHENODIOL - CTEXLI</u>						
N 219488 001					NP	Feb 21, 2028
<u>CHLOROPROCAINE HYDROCHLORIDE - IHEEZO</u>						
N 216227 001	11969403	May 14, 2039	DP			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	>A> 8148374	Sep 03, 2029	DS DP U-1279			
	>A> 8148374	Sep 03, 2029	DS DP U-2939			
	>A> 8148374	Sep 03, 2029	DS DP U-4162			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 002	>A> 10039718	Oct 06, 2032	DP			
	>A> 7700645	Dec 26, 2026	DS DP			
	>A> 7700645*PED	Jun 26, 2027				
	>A> 8148374	Sep 03, 2029	DS DP U-4162			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	>A> 12274751	Nov 22, 2036	U-2814			
<u>COLCHICINE - LODOCO</u>						
N 215727 001	12233035	Nov 01, 2033	U-4132			
	>A> 12280025	Nov 01, 2033	U-4168			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COPPER - MIUDELLA</u>						
N 218201 001	10022264	Mar 22, 2034	DP		NP	Feb 24, 2028
	10159596	Aug 14, 2032	DP			
	10166141	Jun 13, 2034	DP			
	10188546	Aug 14, 2032	DP			
	10398588	Feb 24, 2034	DP U-4155			
	10918516	Jan 23, 2037	DP			
	11207209	Aug 16, 2034	DP			
	11850181	Aug 14, 2032	DP			
	12138199	Oct 18, 2033	DP			
	9089418	Apr 09, 2033	DP			
	9265652	Apr 28, 2034	U-4155			
	9427351	Aug 14, 2032	DP			
	9610191	Feb 24, 2034	U-4155			
<u>COPPER CU-64 DOTATATE - DETECTNET</u>						
N 213227 001	10383961	Jul 02, 2033	U-2951			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 003	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 004	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL</u>						
N 008372 008	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	12233105	Oct 27, 2043	U-3904			
	12233105	Oct 27, 2043	U-3905			
	12233105	Oct 27, 2043	U-3906			
	12233105	Oct 27, 2043	U-3907			
	12233105	Oct 27, 2043	U-3908			
	12233105	Oct 27, 2043	U-3909			
	12233105	Oct 27, 2043	U-3910			
	12233105	Oct 27, 2043	U-3911			
	12233105	Oct 27, 2043	U-3912			
	12233105	Oct 27, 2043	U-3913			
	12233105	Oct 27, 2043	U-3914			
	12233105	Oct 27, 2043	U-3915			
	12233105	Oct 27, 2043	U-3916			
	12233105	Oct 27, 2043	U-3917			
	12233105	Oct 27, 2043	U-3918			
	12233105	Oct 27, 2043	U-3919			
	12233105	Oct 27, 2043	U-3920			
	12233105	Oct 27, 2043	U-3921			
	12233105	Oct 27, 2043	U-3922			
	12233105	Oct 27, 2043	U-3923			
	12233105	Oct 27, 2043	U-3924			
	12233105	Oct 27, 2043	U-3925			
	12233105	Oct 27, 2043	U-3926			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 001	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 002	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 003	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CRINECERFONT - CRENESSITY</u>						
N 218820 001	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	>A> 8292129	Feb 25, 2031	DP	Y		
	>A> 8561859	Apr 16, 2032	DP	Y		
	>A> 9669974	May 11, 2034	DP	Y		
	>A> 9676525	Feb 07, 2034	DP	Y		
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 001	7772243	May 05, 2028	DS DP			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 002	7772243	May 05, 2028	DS DP			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 003	7772243	May 05, 2028	DS DP			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	12213988	Apr 01, 2041	U-4140			
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 001					M-200	Sep 30, 2027
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 002					M-200	Sep 30, 2027
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	12161653	Feb 17, 2032	U-1940			
<u>DEURUXOLITINIB PHOSPHATE - LEQSELVI</u>						
N 217900 001	12247034	May 10, 2044	DS DP			
<u>DEUTIVACAFITOR; TEZACAFITOR; VANZACAFITOR CALCIUM - ALYFTREK</u>						
N 218730 001	10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
	10047053	May 17, 2032	DS			
	10081621	Mar 25, 2031	DP U-4087			
	10239867	Apr 09, 2027	DS DP U-4090			
	10646481	Aug 13, 2029	DP			
	11066417	Feb 14, 2039	DS DP			
	11564916	Aug 13, 2029	U-4095			
	11578062	Mar 25, 2031	DP U-4096			
	11639347	Apr 09, 2027	DS DP U-4090			
	11866450	Feb 14, 2039	U-4082			
	11873300	Aug 13, 2040	DS DP U-4083			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-4090			
	8354427	Jul 06, 2026	U-4091			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 001	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-4082			
	8598181	May 01, 2027	U-4090			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-4084			
	8754224	Dec 28, 2026	DS DP			
	8865902	May 17, 2032	DS DP			
	9181192	May 17, 2032	DS DP	U-4094		
	9512079	May 17, 2032	DS DP	U-4098		
	9670163	Dec 28, 2026	DP	U-4080		
	9931334	Dec 28, 2026	DP	U-4080		
	9974781	Apr 09, 2027	DP	U-4082		
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 002	10022352	Apr 09, 2027	DP	U-4081	NCE	Dec 20, 2029
	10047053	May 17, 2032	DS			
	10058546	Jul 15, 2033	U-4093			
	10081621	Mar 25, 2031	DP	U-4087		
	10206877	Apr 14, 2035	DP	U-4092		
	10239867	Apr 09, 2027	DS DP	U-4090		
	10646481	Aug 13, 2029	DP			
	11066417	Feb 14, 2039	DS DP			
	11564916	Aug 13, 2029	U-4095			
	11578062	Mar 25, 2031	DP	U-4096		
	11639347	Apr 09, 2027	DS DP	U-4090		
	11866450	Feb 14, 2039	U-4082			
	11873300	Aug 13, 2040	DS DP	U-4083		
	11951212	Apr 14, 2035	DP	U-4089		
	12186306	Jan 10, 2043	U-4088			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-4090			
	8354427	Jul 06, 2026	U-4091			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-4082			
	8598181	May 01, 2027	U-4090			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-4084			
	8754224	Dec 28, 2026	DS DP			
	8865902	May 17, 2032	DS DP			
	9012496	Jul 15, 2033	U-4097			
	9181192	May 17, 2032	DS DP	U-4094		
	9512079	May 17, 2032	DS DP	U-4098		
	9670163	Dec 28, 2026	DP	U-4080		
	9931334	Dec 28, 2026	DP	U-4080		
	9974781	Apr 09, 2027	DP	U-4082		
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	>A> 12268664	Mar 27, 2029	DP		>A> NPP	Apr 15, 2028
	>A> 8927497	Jul 21, 2025	DP	U-2727		
	>A> 8927497	Jul 21, 2025	DP	U-4173		
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	>A> 12268664	Mar 27, 2029	DP		>A> NPP	Apr 15, 2028
	>A> 8927497	Jul 21, 2025	DP	U-2727		
	>A> 8927497	Jul 21, 2025	DP	U-4173		
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	>A> 12268664	Mar 27, 2029	DP		>A> NPP	Apr 15, 2028
	>A> 8927497	Jul 21, 2025	DP	U-2727		
	>A> 8927497	Jul 21, 2025	DP	U-4173		
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 001	>A> 12178823	Nov 12, 2035	U-4167			
	>A> 7572789	Dec 20, 2026	DS DP			
	>A> 7799777	Mar 05, 2029	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 001	>A> 9757384	Nov 12, 2035	U-4167			
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 002	>A> 12178823	Nov 12, 2035	U-4167			
	>A> 7572789	Dec 20, 2026	DS DP			
	>A> 7799777	Mar 05, 2029	DS			
	>A> 9757384	Nov 12, 2035	U-4167			
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 003	>A> 12178823	Nov 12, 2035	U-4167			
	>A> 7572789	Dec 20, 2026	DS DP			
	>A> 7799777	Mar 05, 2029	DS			
	>A> 9757384	Nov 12, 2035	U-4167			
<u>DIROXIMEL FUMARATE - VUMERITY</u>						
N 211855 001	8669281	Oct 29, 2033	DS DP			
<u>DONEPEZIL HYDROCHLORIDE - ADLARTY</u>						
N 212304 001	12161767	Dec 30, 2036	DS DP	U-3334		
	12168075	Dec 30, 2036		U-3334		
<u>DONEPEZIL HYDROCHLORIDE - ADLARTY</u>						
N 212304 002	12161767	Dec 30, 2036	DS DP	U-3334		
	12168075	Dec 30, 2036		U-3334		
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE</u>						
A 208328 001					PC	Jul 15, 2025
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE</u>						
A 208328 002					PC	Jul 15, 2025
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	12233074	Feb 09, 2043	DP	U-3152		
	>A> 7732430	Jan 15, 2028	DP	U-3152		
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	12171742	Apr 13, 2037	DP			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 001	12213983	Apr 26, 2035	U-2412			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 002	12213983	Apr 26, 2035	U-2412			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	12194025	Nov 12, 2041	U-4111			
	>A> 12285409	Nov 01, 2039	DP			
<u>ELAFIBRANOR - IOIRVO</u>						
N 218860 001	12233038	Mar 30, 2037	U-1854			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10081621	Mar 25, 2031	DP U-3032		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-3157		>A> ODE-512	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4075			
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10239867	Apr 09, 2027	DS DP U-4056			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4067			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	8629162	Jun 24, 2025	U-4079			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	10081621	Mar 25, 2031	DP U-3157		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-4075		>A> ODE*	Oct 21, 2026
	10239867	Apr 09, 2027	DS DP U-3158		>A> ODE*	Dec 21, 2027
	10239867	Apr 09, 2027	DS DP U-4056		>A> ODE-512	Dec 20, 2031
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4069			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	8324242	Aug 05, 2027	U-3144			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	8324242	Aug 05, 2027	U-4073			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8629162	Jun 24, 2025	U-3146			
	8629162	Jun 24, 2025	U-4079			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	10081621	Mar 25, 2031	DP U-3600		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-4065		>A> ODE-512	Dec 20, 2031
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8629162	Jun 24, 2025	U-3592			
	8629162	Jun 24, 2025	U-4072			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	10081621	Mar 25, 2031	DP U-3600		>A> ODE-512	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4065			
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8629162	Jun 24, 2025	U-3592			
	8629162	Jun 24, 2025	U-4072			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001 >A>	12263153	Apr 03, 2034	U-4171			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002 >A>	12263153	Apr 03, 2034	U-4171			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	12178819	May 04, 2027	DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	12178819	May 04, 2027	DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	11666590	Apr 03, 2034	U-4154			
>A>	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	11666590	Apr 03, 2034	U-4154			
>A>	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	11666590	Apr 03, 2034	U-4154			
>A>	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	11666590	Apr 03, 2034	U-4154			
>A>	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	11666590	Apr 03, 2034	U-4154			
>A>	12263153	Apr 03, 2034	U-4154			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	11666590	Apr 03, 2034	U-4154			
	>A> 12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	11666590	Apr 03, 2034	U-4154			
	>A> 12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	11666590	Apr 03, 2034	U-4154			
	>A> 12263153	Apr 03, 2034	U-4154			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCovy</u>						
N 208215 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCovy</u>						
N 208215 002	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001					I-957	Dec 20, 2027
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335		I-957	Dec 20, 2027
	10005761	Aug 27, 2030	U-2802			
	10005761	Aug 27, 2030	U-2803			
	10005761	Aug 27, 2030	U-3738			
	10005761	Aug 27, 2030	U-4051			
	10258622	Nov 21, 2032	U-2802			
	10258622	Nov 21, 2032	U-4051			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	8541575	Feb 26, 2030	DS DP U-3738			
	8541575	Feb 26, 2030	DS DP U-4051			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9314464	Jul 04, 2031	U-3738			
	9314464	Jul 04, 2031	U-4051			
	9474754	Aug 05, 2033	U-2802			
	9474754	Aug 05, 2033	U-4051			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
	9850230	Aug 27, 2030	U-3738			
	9850230	Aug 27, 2030	U-4051			
<u>ENSARTINIB HYDROCHLORIDE - ENSACOVE</u>						
N 218171 001	10899744	Jun 01, 2037	DS	U-4099	NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS	U-4099		
<u>ENSARTINIB HYDROCHLORIDE - ENSACOVE</u>						
N 218171 002	10899744	Jun 01, 2037	DS	U-4099	NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS	U-4099		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENSIFENTRINE - OHTUVAYRE</u>						
N 217389 001	12251384	Jun 25, 2044	DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 218550 001					ODE*	Aug 15, 2026
					ODE*	Aug 15, 2026
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 001	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 002	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
<u>EPINEPHRINE - EPINEPHRINE</u>						
A 213708 001					PC	Jun 03, 2025
<u>EPINEPHRINE - EPINEPHRINE</u>						
A 219239 001					CGT	Sep 03, 2025
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001 >A>	12280024	Mar 13, 2035	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001 >A>	12280024	Mar 13, 2035	DP			
<u>EPINEPHRINE - NEFFY</u>						
N 214697 002	10576156	Feb 06, 2038	DP			
	10682414	Feb 06, 2039	U-3979			
	11173209	Feb 06, 2038	U-3979			
	11191838	Feb 06, 2039	DP U-3979			
	11717571	Feb 06, 2039	U-3979			
	11744895	Feb 06, 2039	U-3979			
	11918655	Feb 06, 2039	U-3979			
<u>EPLONTENSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388 001	8101743	Apr 01, 2026	DS DP			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	10869844	Sep 10, 2035	U-3034		I-959	Jan 17, 2028
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
	10869844	Sep 10, 2035	U-4113			
	10869844	Sep 10, 2035	U-4114			
	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
	11173134	Sep 10, 2035	U-4115			
	11311500	Sep 10, 2035	U-3034			
	11311500	Sep 10, 2035	U-3035			
	11311500	Sep 10, 2035	U-3036			
	11311500	Sep 10, 2035	U-4116			
	11311500	Sep 10, 2035	U-4117			
	11446260	Mar 14, 2034	U-3444			
	11446260	Mar 14, 2034	U-3445			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11446260	Mar 14, 2034	U-3446			
	11446260	Mar 14, 2034	U-4118			
	11446260	Mar 14, 2034	U-4119			
	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
	11883526	Feb 18, 2040	U-4120			
	8785500	Mar 05, 2033	U-2502			
	8785500	Mar 05, 2033	U-4112			
	9592207	Mar 20, 2027	U-2502			
	9592207	Mar 20, 2027	U-4112			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - FEMLYV</u>						
N 218718 001	12178824	Jun 24, 2041	DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2026	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2026	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2026	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2026	DS DP			
<u>FITUSIRAN SODIUM - QFITLIA</u>						
N 219019 001	>A> 11091759	Dec 07, 2036	U-4165		>A> NCE	Mar 28, 2030
	>A> 9127274	Mar 22, 2033	DS DP U-4165		>A> ODE-510	Mar 28, 2032
	>A> 9376680	Mar 15, 2033	DS DP U-4165		>A> ODE-511	Mar 28, 2032
<u>FITUSIRAN SODIUM - QFITLIA</u>						
N 219019 002	>A> 11091759	Dec 07, 2036	U-4165		>A> NCE	Mar 28, 2030
	>A> 9127274	Mar 22, 2033	DS DP U-4165		>A> ODE-510	Mar 28, 2032
	>A> 9376680	Mar 15, 2033	DS DP U-4165		>A> ODE-511	Mar 28, 2032
<u>FLUOCINOLONE ACETONIDE - ILUVIEN</u>						
N 201923 001	9849027	Nov 07, 2028	DP U-4157			
	9849027	Nov 07, 2028	DP U-708			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	>A> 8201556	Feb 05, 2029	DP		Y	
	>A> 8746242	Oct 11, 2030	DP		Y	
	>A> 8746242*PED	Apr 11, 2031				
	>A> 9333310	Oct 02, 2027	DP		Y	
	>A> 9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	>A> 8201556	Feb 05, 2029	DP		Y	
	>A> 8746242	Oct 11, 2030	DP		Y	
	>A> 8746242*PED	Apr 11, 2031				
	>A> 9333310	Oct 02, 2027	DP		Y	
	>A> 9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 003	>A> 8201556	Feb 05, 2029	DP		Y	
	>A> 8746242	Oct 11, 2030	DP		Y	
	>A> 8746242*PED	Apr 11, 2031				
	>A> 9333310	Oct 02, 2027	DP		Y	
	>A> 9333310*PED	Apr 02, 2028				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001	>A> 8161968	Feb 05, 2028	DP	Y		
	>A> 8161968*PED	Aug 05, 2028				
	>A> 8511304	Jun 14, 2027	DP U-2954	Y		
	>A> 8511304*PED	Dec 14, 2027				
	>A> 9333310	Oct 02, 2027	DP	Y		
	>A> 9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 002	>A> 8161968	Feb 05, 2028	DP	Y		
	>A> 8161968*PED	Aug 05, 2028				
	>A> 8511304	Jun 14, 2027	DP U-2954	Y		
	>A> 8511304*PED	Dec 14, 2027				
	>A> 9333310	Oct 02, 2027	DP	Y		
	>A> 9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	8161968	Feb 05, 2028	DP	Y		
	8161968*PED	Aug 05, 2028				
	>A> 9333310	Oct 02, 2027	DP	Y		
	>A> 9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	>A> 8161968	Feb 05, 2028	DP	Y		
	>A> 8161968*PED	Aug 05, 2028				
	>A> 9333310	Oct 02, 2027	DP	Y		
	>A> 9333310*PED	Apr 02, 2028				
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 003	>A> 8161968	Feb 05, 2028	DP	Y		
	>A> 8161968*PED	Aug 05, 2028				
	>A> 9333310	Oct 02, 2027	DP	Y		
	>A> 9333310*PED	Apr 02, 2028				
<u>FOSCARBIDOPA; FOSLEVODOPA - VYALEV</u>						
N 216962 001	>A> 12251365	Jun 11, 2040	U-4030		NP	Oct 16, 2027
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	12208109	Jun 02, 2037	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	12208109	Jun 02, 2037	DP			
<u>GALLIUM GA-68 GOZETOTIDE - GOZELLIX</u>						
N 219592 001	11027031	Jul 28, 2035	U-3317			
<u>GEPOTIDACIN MESYLATE - BLUJEPÄ</u>						
N 218230 001	>A> 8389524	Feb 12, 2029	DS DP U-4166		>A> NCE >A> GAIN	Mar 25, 2030 Mar 25, 2035
<u>HYDROCHLOROTHIAZIDE - INZIROO</u>						
N 219141 001	11878022	Jan 23, 2044	DP U-4138			
	11878022	Jan 23, 2044	DP U-4139			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	12201690	Jun 14, 2039	DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	12171738	Feb 09, 2030	U-4105			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	12171738	Feb 09, 2030	U-4105			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 001	12171778	Jun 16, 2039	U-3956			
	9388415	Sep 09, 2025	U-3956			
	9388416	Sep 09, 2025	U-3956			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 002	12171778	Jun 16, 2039	U-3956			
	9388415	Sep 09, 2025	U-3956			
	9388416	Sep 09, 2025	U-3956			
<u>IOMEPROL - IOMERVU</u>						
N 216016 001					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 002					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 003					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 004					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 005					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 006					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 007					NCE	Nov 27, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IOMEPROL - IOMERVU</u> N 216016 008					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 009					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 010					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 011					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 012					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 013					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 001					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 002					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 003					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 004					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 005					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 006					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 007					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 008					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 009					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 010					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 011					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 012					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 013					NCE	Nov 27, 2029
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u> N 021527 001	8474447	Jan 17, 2030	DP	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276 001	>A> 10093663	Jul 14, 2034	U-3980		>A> I-963	Mar 20, 2028
	>A> 10093663	Jul 14, 2034	U-4161			
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051 001					PC	Jan 11, 2025
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051 002					PC	Jan 11, 2025
<u>IVACAFITOR - KALYDECO</u>						
N 203188 001	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11564916	Aug 13, 2029	U-3530			
	11564916*PED	Feb 13, 2030				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	9670163	Dec 28, 2026	DP U-1311			
	9670163*PED	Jun 28, 2027				
<u>IVACAFITOR - KALYDECO</u>						
N 207925 001	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11564916	Aug 13, 2029	U-3528			
	11564916*PED	Feb 13, 2030				
	12214083	Feb 27, 2033	DP U-4126			
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
	9670163*PED	Jun 28, 2027				
<u>IVACAFITOR - KALYDECO</u>						
N 207925 002	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11564916	Aug 13, 2029	U-3528			
	11564916*PED	Feb 13, 2030				
	12214083	Feb 27, 2033	DP U-4126			
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
	9670163*PED	Jun 28, 2027				
<u>IVACAFITOR - KALYDECO</u>						
N 207925 003	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11564916	Aug 13, 2029	U-3528			
	11564916*PED	Feb 13, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	12214083	Feb 27, 2033	DP U-4128			
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027			U-1311	
	8324242	Aug 05, 2027			U-1906	
	8324242	Aug 05, 2027			U-2963	
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2966			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR - KALYDECO</u>						
N 207925 004	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11564916	Aug 13, 2029			U-3603	
	11564916*PED	Feb 13, 2030				
	12214083	Feb 27, 2033	DP U-4127			
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027			U-3609	
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR - KALYDECO</u>						
N 207925 005	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11564916	Aug 13, 2029			U-3603	
	11564916*PED	Feb 13, 2030				
	12214083	Feb 27, 2033	DP U-4127			
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027			U-3609	
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	10076513	Dec 04, 2028	DP U-2411			
	10076513*PED	Jun 04, 2029				
	10597384	Dec 04, 2028	DS DP U-2777			
	10597384*PED	Jun 04, 2029				
	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11052075	Dec 04, 2028	DP U-3181			
	11052075*PED	Jun 04, 2029				
	11564916	Aug 13, 2029			U-3529	
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028			U-3984	
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026			U-1973	
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027			U-1311	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	8324242	Aug 05, 2027	U-1911			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-1718			
	8716338	Sep 20, 2030	DP U-1910			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-1717			
	8741933	Nov 08, 2026	U-1909			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-1717			
	8846718	Jul 02, 2029	U-1908			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-1908			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-1912			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DS DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-1911			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2276			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	10597384	Dec 04, 2028	DS DP U-2777			
	10597384*PED	Jun 04, 2029				
	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11052075	Dec 04, 2028	DP U-3181			
	11052075*PED	Jun 04, 2029				
	11564916	Aug 13, 2029	U-3529			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3984			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-1973			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-1911			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-1910			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-1909			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-1908			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-1908			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-1912			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-1911			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2276			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-2374			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-2375			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-2375			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-2374			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-2375			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-2375			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	10597384	Dec 04, 2028	DS DP U-3430		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-3424			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-3424			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-3426			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-3424			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-3427			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-3427			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-3428			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-3429			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-3429			
	9931334*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVERMECTIN - IVERMECTIN</u>						
A 215922	002				>A> CGT	Oct 01, 2025
<u>LACTULOSE - LACTULOSE</u>						
A 217914	001				CGT	Sep 13, 2025
<u>LACTULOSE - LACTULOSE</u>						
A 217914	002				CGT	Sep 13, 2025
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861	001	11337967	May 16, 2037	U-4123		
		11974998	May 16, 2037	U-4124		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861	002	11337967	May 16, 2037	U-4123		
		11974998	May 16, 2037	U-4124		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710	001	11337967	May 16, 2037	U-4123		
		11974998	May 16, 2037	U-4124		
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280	001	>A> 12257246	Jul 07, 2030	U-2718		
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280	002	>A> 12257246	Jul 07, 2030	U-2718		
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280	003	>A> 12257246	Jul 07, 2030	U-2718		
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008	001	12138351	Apr 13, 2041	DP		
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008	002	12138351	Apr 13, 2041	DP		
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947	001	>A> 12083112	Mar 03, 2036	U-3996		
		>A> 12083112	Mar 03, 2036	U-3997		
		>A> 12083112*PED	Sep 03, 2036			
		>A> 12226409	May 15, 2038	U-4146		
		>A> 12226409*PED	Nov 15, 2038			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947	002	>A> 12083112	Mar 03, 2036	U-3996		
		>A> 12083112	Mar 03, 2036	U-3997		
		>A> 12083112*PED	Sep 03, 2036			
		>A> 12226409	May 15, 2038	U-4146		
		>A> 12226409*PED	Nov 15, 2038			
<u>LEVACETYLLLEUCINE - AONEURSA</u>						
N 219132	001	>A> 11400067	Aug 11, 2037	U-4170		
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133	001				NCE*	Dec 30, 2026
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280	001	12178819	May 04, 2027	DP		
<u>LISINOPRIL - OBRELIS</u>						
N 208401	001	12186360	Nov 06, 2035	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOSARTAN POTASSIUM - ARBLI</u>						
N 218772 001	11890273	Oct 07, 2041	DP			
	12156869	Oct 07, 2041	DP U-4158			
	12156869	Oct 07, 2041	DP U-4159			
	12156869	Oct 07, 2041	DP U-4160			
<u>LOTILANER - XDEMVY</u>						
N 217603 001	12171750	Dec 14, 2038	U-3674			
	12213964	Dec 14, 2038	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002 >A>	RE48825	Mar 12, 2029	DS			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003 >A>	RE48825	Mar 12, 2029	DS			
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - PLUVICTO</u>						
N 215833 001 >A>	10406240	Aug 15, 2028	DS DP U-4169		>A> I-965	Mar 28, 2028
	>A> 11318121	Aug 15, 2028	DS DP U-4169			
	>A> 11951190	Nov 12, 2035	U-4169			
	>A> 12208102	Sep 18, 2041	U-4169			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001					M-187	Feb 28, 2028
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE</u>						
N 215344 001	12239659	Jun 14, 2044	U-4143			
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001	12213989	Nov 18, 2042	U-4137			
<u>MELOXICAM - QAMZOVA</u>						
N 217593 001 >A>	12059423	Jul 19, 2040	DS DP			
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	10029010	Apr 11, 2036	U-4133		NP	Jan 30, 2028
	10058614	Apr 11, 2036	DP			
	10137131	Apr 11, 2036	DP U-1719			
	10195278	Apr 11, 2036	U-1719			
	10265324	Apr 11, 2036	U-1719			
	10363312	Apr 11, 2036	U-1719			
	10369224	Apr 11, 2036	U-4134			
	10426839	Apr 11, 2036	U-4135			
	10463736	Apr 11, 2036	DP			
	10471014	Apr 11, 2036	U-1719			
	10471069	Apr 11, 2036	U-1719			
	10512692	Apr 11, 2036	U-1719			
	10512693	Apr 11, 2036	U-1719			
	10517950	Apr 11, 2036	U-1719			
	10532101	Apr 11, 2036	U-1719			
	10537642	Apr 11, 2036	U-1719			
	10561664	Apr 11, 2036	U-1719			
	10583144	Apr 11, 2036	U-1719			
	10653777	Apr 11, 2036	U-1719			
	10688102	Apr 11, 2036	U-1719			
	10688185	Apr 11, 2036	U-1719			
	10695429	Apr 11, 2036	U-1719			
	10695430	Apr 11, 2036	U-1719			
	10702535	Apr 11, 2036	U-4136			
	10702602	Apr 11, 2036	U-1719			
	10722583	Apr 11, 2036	U-1719			
	10729696	Apr 11, 2036	U-1719			
	10729697	Apr 11, 2036	U-1719			
	10729773	Apr 11, 2036	U-1719			
	10758617	Apr 11, 2036	U-1719			
	10758618	Apr 11, 2036	U-1719			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	10780165	Apr 11, 2036	U-1719			
	10780166	Apr 11, 2036	U-1719			
	10799588	Apr 11, 2036	U-1719			
	10821181	Apr 11, 2036	U-1719			
	10821182	Apr 11, 2036	U-1719			
	10894053	Apr 11, 2036	U-1719			
	10905693	Apr 11, 2036	U-1719			
	10918722	Apr 11, 2036	U-1719			
	10933136	Apr 11, 2036	U-1719			
	10933137	Apr 11, 2036	U-1719			
	10940153	Apr 11, 2036	U-1719			
	10987358	Apr 11, 2036	U-1719			
	11013805	Apr 11, 2036	U-1719			
	11013806	Apr 11, 2036	U-1719			
	11020483	Apr 11, 2036	U-1719			
	11045549	Apr 11, 2036	U-1719			
	11135295	Apr 11, 2036	U-1719			
	11207328	Apr 11, 2036	U-1719			
	11219626	Apr 11, 2036	U-1719			
	11285213	Apr 11, 2036	U-1719			
	11331323	Apr 11, 2036	U-1719			
	11369684	Apr 11, 2036	U-1719			
	11426414	Apr 11, 2036	U-1719			
	11471464	Apr 11, 2036	U-1719			
	11471465	Apr 11, 2036	U-1719			
	11504429	Apr 11, 2036	U-1719			
	11510927	Apr 11, 2036	U-1719			
	11571428	Apr 11, 2036	U-1719			
	11602563	Apr 11, 2036	U-1719			
	11607456	Apr 11, 2036	U-1719			
	11617755	Apr 11, 2036	U-1719			
	11617756	Apr 11, 2036	U-1719			
	11617791	Apr 11, 2036	U-1719			
	11628173	Apr 11, 2036	U-1719			
	11712441	Apr 11, 2036	U-1719			
	11738085	Apr 11, 2036	U-1719			
	11759522	Apr 11, 2036	U-1719			
	11801250	Apr 11, 2036	U-1719			
	11806354	Apr 11, 2036	U-1719			
	11826370	Apr 11, 2036	U-1719			
	11865117	Apr 11, 2036	U-1719			
	12128052	May 28, 2040	U-1719			
	9821075	Apr 11, 2036	DP U-1719			
<u>MERCAPTOPURINE - MERCAPTOPURINE</u>						
A 216418 001					CGT	Aug 25, 2025
<u>MESNA - MESNA</u>						
A 218871 001					CGT	Jul 13, 2025
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	12194008	Dec 22, 2029	U-2843			
	12194009	Dec 22, 2029	U-2843			
<u>METRONIDAZOLE - LIKMEZ</u>						
N 216755 001	>A> 12257236	Jan 16, 2039	DP U-3169			
	>A> 12257236	Jan 16, 2039	DP U-4163			
	>A> 12257236	Jan 16, 2039	DP U-4164			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	>A> 12280042	May 30, 2038	DS U-2371			
<u>MIGLUSTAT - OPFOLDA</u>						
N 215211 001	12246062	Sep 16, 2038	U-3726			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219379 001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041		U-4130		
	11571402	Feb 17, 2041	DP			
	11806321	Feb 17, 2041		U-4130		
	11806322	Mar 16, 2043		U-4130		
	11819487	Feb 17, 2041		U-4130		
	11839595	Mar 16, 2043		U-4130		
	11883375	Mar 16, 2043		U-4130		
	12011424	Feb 17, 2041		U-4130		
	12029711	Mar 15, 2044	DP	U-4130		
	12037306	Feb 17, 2041		U-4130		
	12090128	Feb 17, 2041	DP	U-4130		
	12220390	Mar 16, 2043		U-4130		
	12257215	Mar 16, 2043		U-4130		
	12263146	Feb 17, 2041		U-4130		
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219389 001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041		U-4130		
	11806321	Feb 17, 2041		U-4130		
	11806322	Mar 16, 2043		U-4130		
	11819487	Feb 17, 2041		U-4130		
	11839595	Mar 16, 2043		U-4130		
>A>	11883375	Mar 16, 2043		U-4130		
	12011424	Feb 17, 2041		U-4130		
	12029711	Mar 15, 2044	DP	U-4130		
	12037306	Feb 17, 2041		U-4130		
	12220390	Mar 16, 2043		U-4130		
	12257215	Mar 16, 2043		U-4130		
	12263146	Feb 17, 2041		U-4130		
>A>	12275688	Feb 17, 2041	DP	U-4130		
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219389 002	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041		U-4130		
	11806321	Feb 17, 2041		U-4130		
	11806322	Mar 16, 2043		U-4130		
	11819487	Feb 17, 2041		U-4130		
	11839595	Mar 16, 2043		U-4130		
>A>	11883375	Mar 16, 2043		U-4130		
	12029711	Mar 15, 2044	DP	U-4130		
	12037306	Feb 17, 2041		U-4130		
	12220390	Mar 16, 2043		U-4130		
	12257215	Mar 16, 2043		U-4130		
	12263146	Feb 17, 2041		U-4130		
>A>	12275688	Feb 17, 2041	DP	U-4130		
<u>MITOMYCIN - JELMYTO</u>						
N 211728 001 >A>	12268745	Jan 20, 2031		U-4172		
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001 >A>	10918615	Feb 27, 2035	DP	U-1384		
>A>	10918616	Feb 27, 2035		U-1384		
>A>	10918617	Feb 27, 2035	DP			
>A>	10945985	Feb 27, 2035	DP			
>A>	11590095	Feb 27, 2035		U-1384		
<u>MOTIXAFORTIDE ACETATE - APHEXDA</u>						
N 217159 001 >A>	12257285	Dec 29, 2041	DP			
>A>	12268725	Dec 29, 2041	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MOXIDECTIN - MOXIDECTIN</u>						
N 210867 001					NPP	Feb 07, 2028
<u>MYCOPHENOLATE MOFETIL - MYHIBBIN</u>						
N 216482 001	12194143	Aug 16, 2039	DP U-1752			
	12226526	Aug 16, 2039	DP U-1752			
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	12186308	Apr 16, 2038	DP U-2804			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 001	11730725	Jan 25, 2039	DP			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 002	11730725	Jan 25, 2039	DP			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 003	11730725	Jan 25, 2039	DP			
<u>NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)</u>						
N 217188 001					D-195	Jan 31, 2028
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	12234210	Jul 08, 2042	DP			
	12247012	Jul 08, 2042	DP			
	7951958	Mar 11, 2026	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	12234210	Jul 08, 2042	DP			
	12247012	Jul 08, 2042	DP			
	7951958	Mar 11, 2026	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	12234210	Jul 08, 2042	DP			
	12247012	Jul 08, 2042	DP			
	7951958	Mar 11, 2026	DS			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 001	12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 002	12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 003	12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 001	RE49422	Feb 26, 2035	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 002	RE49422	Feb 26, 2035	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 003	10251848	Feb 26, 2035	DP			
	RE49422	Feb 26, 2035	DP			
	RE49443	Feb 26, 2035	DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	12246054	Feb 03, 2036	U-2857			
	12251418	Feb 03, 2036	U-2857			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	12194035	Aug 23, 2031	U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	12194035	Aug 23, 2031	U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	12194035	Aug 23, 2031	U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	12194035	Aug 23, 2031	U-3141			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	12178816	Oct 07, 2029	DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	12178816	Oct 07, 2029	DP			
<u>OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)</u>						
N 218614 001	9127276	May 01, 2034	DS			
	9157082	Apr 27, 2032	U-4050			
	9163239	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
	9593333	Feb 14, 2034	U-4050			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	7396341	Oct 10, 2026	DP	Y		
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP	Y		
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP	Y		
	9027967	Mar 31, 2027	DP	Y		
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001	>A> 12275715	Sep 18, 2035	DS DP	U-3684		
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	9265740	Oct 24, 2030	DP	U-1569		
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	9265740	Oct 24, 2030	DP			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001					M-270	Dec 20, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	12246094	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	12246094	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	12246094	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	12246094	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	12246094	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	12246094	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	12246094	Aug 24, 2027	DP			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	8481573	Mar 24, 2033	DS DP U-2774			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	8481573	Mar 24, 2033	DS DP U-2774			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	8481573	Mar 24, 2033	DS DP U-2774			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005	12208100	May 07, 2041	U-3359			
	12208100	May 07, 2041	U-4110			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006	12208100	May 07, 2041	U-3359			
	12208100	May 07, 2041	U-4110			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 001					NCE	Aug 09, 2029
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 002					NCE	Aug 09, 2029
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 003					NCE	Aug 09, 2029
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 001	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 002	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 003	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 004	12201614	Jun 08, 2037	U-4031			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 005	12201614	Jun 08, 2037	U-4031			
<u>PATISIRAN SODIUM - ONPATRO</u>						
N 210922 001	8168775	Aug 10, 2032	DS DP U-2378			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	>A> 12290566	Dec 14, 2038	DP U-4174			
	>A> 12290566	Dec 14, 2038	DP U-4175			
<u>PEGULICIANINE ACETATE - LUMISIGHT</u>						
N 214511 001	11592396	Sep 01, 2030	DS			
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	12201615	Dec 25, 2039	U-3804			
	12201616	Oct 25, 2039	U-3804			
<u>PHENYLEPHRINE HYDROCHLORIDE - IMPHENTIV</u>						
N 203826 004	>A> 12257342	Sep 26, 2036	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - IMPHENTIV</u>						
N 203826 005	>A> 12257342	Sep 26, 2036	DP			
<u>PHYTONADIONE - PHYTONADIONE</u>						
A 214966 001					CGT	Sep 06, 2025
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001	12220401	Dec 16, 2036	DS DP U-3518			
	12220401	Dec 16, 2036	DS DP U-4144			
	>A> 12268666	Jul 29, 2039	DP			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002	12220401	Dec 16, 2036	DS DP U-3518			
	12220401	Dec 16, 2036	DS DP U-4144			
	>A> 12268666	Jul 29, 2039	DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 001	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 002	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 003	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 008	RE43728	Nov 16, 2029	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498 009	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 010	RE43728	Nov 16, 2029	DS DP			
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
N 217604 001	12233166	Jun 18, 2038	DP			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001	12187739	Jul 05, 2036	DP		ODE-483	Jun 13, 2031
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 002	12187739	Jul 05, 2036	DP		ODE-483	Jun 13, 2031
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001 >A>	12285417	Aug 29, 2039	U-2440			
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 001					ODE-504 ODE-505	Nov 15, 2031 Nov 15, 2031
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 002					ODE-504 ODE-505	Nov 15, 2031 Nov 15, 2031
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 003					ODE-504 ODE-505	Nov 15, 2031 Nov 15, 2031
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	8309569	Jul 18, 2029	U-1707	Y		
	8309569	Jul 18, 2029	U-1708	Y		
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	12213967	Dec 30, 2040	DP			
	12213968	Dec 30, 2040	DP			
	12226406	Dec 30, 2040	DP			
<u>RISDIPLAM - EVRYSDI</u>						
N 219285 001	11534444	Oct 04, 2038	U-1943		M-270	Oct 03, 2026
	11827646	Jan 25, 2036	U-1943		NCE	Aug 07, 2025
	12122789	Apr 15, 2041	DS DP			
	9586955	Feb 08, 2033	DS DP			
	9969754	May 11, 2035	DS DP U-1943			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	12220409	Jun 07, 2037	DP			
>A>	12257242	Jun 07, 2037	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 002	12220409	Jun 07, 2037	DP			
>A>	12257242	Jun 07, 2037	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001	12220409	Jun 07, 2037	DP			
>A>	12257242	Jun 07, 2037	DP			
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	12226419	May 20, 2031	DP			
	12233067	Jul 28, 2040	U-4151			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELINEXOR - XPOVIO</u>						
N 212306 005	10519139	Aug 14, 2035	DS DP U-2584			
	10519139	Aug 14, 2035	DS DP U-2855			
	10519139	Aug 14, 2035	DS DP U-3018			
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS			
	8999996	Jul 03, 2033	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001					M-311 M-312	Sep 27, 2027 Sep 27, 2027
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 002					M-311 M-312	Sep 27, 2027 Sep 27, 2027
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 001					M-311 M-312	Sep 27, 2027 Sep 27, 2027
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 002					M-311 M-312	Sep 27, 2027 Sep 27, 2027
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 003					M-311 M-312	Sep 27, 2027 Sep 27, 2027
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 004					M-311 M-312	Sep 27, 2027 Sep 27, 2027
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	12220403	Mar 26, 2029	DP			
	7425637	Mar 13, 2026	DS			
	8178693	Mar 13, 2026	DS DP			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	12220403	Mar 26, 2029	DP			
	7425637	Mar 13, 2026	DS			
	8178693	Mar 13, 2026	DS DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	>A> 10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	>A> 10357616	Jan 20, 2026	DP	Y		
	>A> 10376652	Jan 20, 2026	DP	Y		
	>A> 11097063	Jul 17, 2026	DP	Y		
	>A> 8684969	Oct 20, 2025	DP	Y		
	>A> 8920383	Jul 17, 2026	DP	Y		
	>A> 9108002	Jan 20, 2026	DP	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	>A> 9132239	Feb 01, 2032	DP	Y		
	>A> 9457154	Sep 27, 2027	DP	Y		
	>A> 9616180	Jan 20, 2026	DP	Y		
	>A> 9687611	Feb 27, 2027	DP	Y		
	>A> 9775953	Jul 17, 2026	DP	Y		
	>A> 9861757	Jan 20, 2026	DP	Y		
	>A> RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002	>A> 10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	>A> 10357616	Jan 20, 2026	DP	Y		
	>A> 10376652	Jan 20, 2026	DP	Y		
	>A> 11097063	Jul 17, 2026	DP	Y		
	>A> 8684969	Oct 20, 2025	DP	Y		
	>A> 8920383	Jul 17, 2026	DP	Y		
	>A> 9108002	Jan 20, 2026	DP	Y		
	>A> 9132239	Feb 01, 2032	DP	Y		
	>A> 9457154	Sep 29, 2027	DP	Y		
	>A> 9616180	Jan 20, 2026	DP	Y		
	>A> 9687611	Feb 27, 2027	DP	Y		
	>A> 9775953	Jul 17, 2026	DP	Y		
	>A> 9861757	Jan 20, 2026	DP	Y		
	>A> RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 003	>A> 10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	>A> 10357616	Jan 20, 2026	DP	Y		
	>A> 10376652	Jan 20, 2026	DP	Y		
	>A> 11097063	Jul 17, 2026	DP	Y		
	>A> 8684969	Oct 20, 2025	DP	Y		
	>A> 8920383	Jul 17, 2026	DP	Y		
	>A> 9108002	Jan 20, 2026	DP	Y		
	>A> 9132239	Feb 01, 2032	DP	Y		
	>A> 9457154	Sep 29, 2027	DP	Y		
	>A> 9616180	Jan 20, 2026	DP	Y		
	>A> 9687611	Feb 27, 2027	DP	Y		
	>A> 9775953	Jul 17, 2026	DP	Y		
	>A> 9861757	Jan 20, 2026	DP	Y		
	>A> RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 004	>A> 10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	>A> 10357616	Jan 20, 2026	DP	Y		
	>A> 10376652	Jan 20, 2026	DP	Y		
	>A> 11097063	Jul 17, 2026	DP	Y		
	>A> 8684969	Oct 20, 2025	DP	Y		
	>A> 8920383	Jul 17, 2026	DP	Y		
	>A> 9108002	Jan 20, 2026	DP	Y		
	>A> 9132239	Feb 01, 2032	DP	Y		
	>A> 9457154	Sep 29, 2027	DP	Y		
	>A> 9616180	Jan 20, 2026	DP	Y		
	>A> 9687611	Feb 27, 2027	DP	Y		
	>A> 9775953	Jul 17, 2026	DP	Y		
	>A> 9861757	Jan 20, 2026	DP	Y		
	>A> RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10278923	May 02, 2034	U-2628			
	>A> 12239739	May 02, 2034	DS DP U-2628			
	>A> 8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10278923	May 02, 2034	U-2628			
	>A> 12239739	May 02, 2034	DS DP U-2628			
	>A> 8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10278923	May 02, 2034	U-2628			
	>A> 12239739	May 02, 2034	DS DP U-2628			
	>A> 8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10278923	May 02, 2034	U-2628			
	>A> 12239739	May 02, 2034	DS DP U-2628			
	>A> 8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 004	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
	>A> 12239739	May 02, 2034	DS DP U-2628			
	>A> 8129343	Dec 05, 2031	DS DP U-2628			
	>A> 8536122	Mar 20, 2026	DS DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 005	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
	>A> 12239739	May 02, 2034	DS DP U-2628			
	>A> 8129343	Dec 05, 2031	DS DP U-2628			
	>A> 8536122	Mar 20, 2026	DS DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 006	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
	>A> 12239739	May 02, 2034	DS DP U-2628			
	>A> 8129343	Dec 05, 2031	DS DP U-2628			
	>A> 8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DS DP U-2628			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	12214017	Aug 24, 2038	DP U-3162			
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001	8039435	Aug 21, 2032	DS DP		NPP ODE-508 ODE-509	Dec 20, 2027 Dec 20, 2031 Dec 20, 2031
<u>SILDENAFIL CITRATE - LIOREV</u>						
N 214952 001	12186321	Dec 24, 2038	DP U-3582			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	11944602	Apr 23, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	11944602	Apr 23, 2036	U-3889			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	11944602	Apr 23, 2036	U-3889			
<u>SITAGLIPTIN HYDROCHLORIDE - BRYNOVIN</u>						
N 219122 001	11944621	Oct 23, 2040	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	12226377	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	12226377	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	12226377	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	12226377	Jul 21, 2037	DP			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 002					>A> ODE*	Mar 19, 2027
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	12194016	Mar 19, 2040	U-4106			
	12209059	Jun 07, 2026	U-2548			
	>A> 12263145	Dec 30, 2042	U-3693			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	12194016	Mar 19, 2040	U-4106			
	12209059	Jun 07, 2026	U-2548			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 002	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 003	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001					NPP PED	Dec 12, 2027 Jun 12, 2028
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002					NPP PED	Dec 12, 2027 Jun 12, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUZETRIGINE - JOURNAVX</u>						
N 219209 001	11834441	Dec 04, 2040	DS DP U-4125		NCE	Jan 30, 2030
<u>TADALAFIL - TADLIO</u>						
N 214522 001	12186322	Dec 24, 2038	DP U-3397			
<u>TAPINAROF - VTAMA</u>						
N 215272 001	10426743	May 19, 2036	U-2625		I-956	Dec 12, 2027
	10426743	May 19, 2036	U-4048			
	11497718	Nov 13, 2039	U-4048			
	11612573	May 19, 2036	U-2625			
	11612573	May 19, 2036	U-4048			
	11938099	Nov 13, 2039	U-4048			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	12201604	Jan 25, 2033	U-3003			
	12201604	Jan 25, 2033	U-3865			
<u>TASIMELTEON - HETLIOZ LQ</u>						
N 214517 001	12201604	Jan 25, 2033	U-3003			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	12161645	Sep 12, 2031	U-2853			
	12162865	May 21, 2034	U-2736			
	12168014	May 03, 2038	U-2736			
	12168014	May 03, 2038	U-2852			
	12168014	May 03, 2038	U-2853			
	12168015	Sep 12, 2031	DS DP			
	12168016	Sep 12, 2031	U-2736			
	12168016	Sep 12, 2031	U-2853			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001					>A> NPP	Apr 04, 2028
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001					>A> NPP	Apr 04, 2028
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>TETRACAINE HYDROCHLORIDE - TETRACAINE HYDROCHLORIDE</u>						
A 217227 001					CGT	Jun 25, 2025
<u>THIOTEPA - TEPLYLUTE</u>						
N 216984 002	11975013	Aug 16, 2041	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	>A> 7396341	Oct 10, 2026	DP		Y	
	>A> 7396341*PED	Apr 10, 2027				
	>A> 7837235	Mar 13, 2028	DP		Y	
	>A> 7837235*PED	Sep 13, 2028				
	>A> 8733341	Oct 16, 2030	DP		Y	
	>A> 8733341*PED	Apr 16, 2031				
	>A> 9027967	Mar 31, 2027	DP		Y	
	>A> 9027967*PED	Sep 30, 2027				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	>A> 7396341	Oct 10, 2026	DP		Y	
	>A> 7396341*PED	Apr 10, 2027				
	>A> 7837235	Mar 13, 2028	DP		Y	
	>A> 7837235*PED	Sep 13, 2028				
	>A> 8733341	Oct 16, 2030	DP		Y	
	>A> 8733341*PED	Apr 16, 2031				
	>A> 9027967	Mar 31, 2027	DP		Y	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	>A> 9027967*PED	Sep 30, 2027				
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012					I-958	Dec 20, 2027
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	7166722	Nov 16, 2028	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	7166722	Nov 16, 2028	DS DP			
<u>TIZANIDINE HYDROCHLORIDE - ONTRALFY</u>						
N 216190 001	>A> 12263158	May 07, 2042		DP U-2779		
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	RE41783	Dec 08, 2025	DS		M-14	Feb 21, 2028
	RE41783*PED	Jun 08, 2026			PED	Aug 21, 2028
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	11253523	Mar 14, 2034		U-3326		
	11253523	Mar 14, 2034		U-3327		
	11253523	Mar 14, 2034		U-3328		
	11253523	Mar 14, 2034		U-3329		
	11253523*PED	Sep 14, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	9937181	Mar 14, 2034	DP			
	9937181*PED	Sep 14, 2034				
	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	10639309	Mar 14, 2034	DP			
	10639309*PED	Sep 14, 2034				
	11253523	Mar 14, 2034	U-3326			
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
	11253523*PED	Sep 14, 2034				
	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 213082 001	RE41783	Dec 08, 2025	DS		M-14	Feb 21, 2028
	RE41783*PED	Jun 08, 2026			PED	Aug 21, 2028
<u>TRAVOPROST - IDOSE TR</u>						
N 218010 001	12201555	Feb 14, 2031	DS DP			
	12201557	Jun 18, 2030	DS DP U-4129			
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 001 >A>	7199162	Mar 21, 2026	U-4142		NCE	Jan 21, 2030
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 002 >A>	7199162	Mar 21, 2026	U-4142		NCE	Jan 21, 2030
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001 >A>	11357782	May 14, 2027	U-1849			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002 >A>	11357782	May 14, 2027	U-1849			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003 >A>	11357782	May 14, 2027	U-1849			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004 >A>	11357782	May 14, 2027	U-1849			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 005 >A>	11357782	May 14, 2027	U-1849			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	12168666	Nov 13, 2040	DS DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	7452895	Nov 16, 2025	DS DP U-2788			
	7452895	Nov 16, 2025	DS DP U-4153			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	7452895	Nov 16, 2025	DS DP U-2788			
	7452895	Nov 16, 2025	DS DP U-4153			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	12168004	Jan 30, 2035	DP			
	12194030	Dec 22, 2041	U-4121			
	12194030	Dec 22, 2041	U-4122			
	12220408	Jan 30, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	12168004	Jan 30, 2035	DP			
	12220408	Jan 30, 2035	DP			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	>A> 8201556	Feb 05, 2029	DP	Y		
	>A> 8746242	Oct 11, 2030	DP	Y		
	>A> 9333310	Oct 02, 2027	DP	Y		
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	>A> 8161968	Feb 05, 2028	DP	Y		
	>A> 8161968*PED	Aug 05, 2028				
	>A> 8534281	Mar 08, 2030	DP	Y		
	>A> 8534281*PED	Sep 08, 2030				
	>A> 8746242	Oct 11, 2030	DP	Y		
	>A> 8746242*PED	Apr 11, 2031				
	>A> 9333310	Oct 02, 2027	DP	Y		
	>A> 9333310*PED	Apr 02, 2028				
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	12201639	Mar 17, 2040	DS DP U-3747			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 005	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 006	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 007	12161690	Nov 06, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 005	12186362	Jan 30, 2035	DP			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	12180219	Mar 12, 2034	DS DP		I-955	Dec 18, 2027
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	9662338	Apr 02, 2035	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	9662338	Apr 02, 2035	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	9662338	Apr 02, 2035	DP			
<u>VIMSEL TINIB - ROMVIMZA</u>						
N 219304 001	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
	>A> 12285430	Dec 23, 2039	U-4145			
	9181223	Mar 14, 2034	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 001	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
>A>	12285430	Dec 23, 2039	U-4145			
	9181223	Mar 14, 2034	DS DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 002	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
>A>	12285430	Dec 23, 2039	U-4145			
	9181223	Mar 14, 2034	DS DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 003	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
>A>	12285430	Dec 23, 2039	U-4145			
	9181223	Mar 14, 2034	DS DP			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	12233106	Jul 11, 2042	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	12233106	Jul 11, 2042	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	12233106	Jul 11, 2042	U-3927			
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001					>A> I-964	Mar 20, 2028
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	11884696	Aug 23, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	11884696	Aug 23, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	11884696	Aug 23, 2037	U-2552			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 45TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm